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BUTYROPHENONES IN NARCOTIC WITHDRAWAL 
ABSTRACT 
Narcotic dependence was established by continuous in-
travenous infusion of gradually increasing doses of morphine. 
Several days at the terminal concentration of morphine (100 
mg/kg/day) was allowed prior to withdrawal. Morphine with-
drawal body shakes were reliably observed upon the termina-
tion of continuous morphine infusion. The administration of 
morphine, methadone or _fentanyl, potent narcotic drugs, re-
liably abolished the occurrence of withdrawal body shakes 8 
hours after the terf!lination of morphine infusion. The nar-
cotic antagonist naloxone or pentazocine ~ad no significant 
effect on the rate of occurrence of withdrawal body shakes; 
however, there was a slight trend towards an increase in the 
frequency of this withdrawal index. A wide variety of neuro-
leptics were investigated for their ability to reduce with-
drawal. The order of potency for reduction of withdrawal 
body shakes on a mg/kg basis for those neuroleptics tested 
was spiperone, benperidol, +butaclarriol, loxapine, oxiperomide, 
haloperidol, spiramide, chlorpromazine, trifluoperazine, 
pimozide and pipamperone. The dopaminergic agonists amphet-
amine, apomorphine and L-IX>PA were also found to dose de-
pendently reduce withdrawal · body shakes. Azaperone, a 
butyrophenone possessing high alpha noradrenergic blocking 
potency, reduces withdrawal body shakes in a dose related 
manner, while the alpha adrenergic blocker phenoxybenzamine 
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and the beta adrenergic blocker propronalol failed to reduce 
withdrawal shakes to any significant extent. Dose dependent 
decreases in morphine withdrawal body shakes were produced 
by clonidine and desmethylimipramine, adrenergic agonists. 
Reserpine and alpha-methyl-p-tyrosine also reduced withdrawal 
shakes, but the effect was dose dependent for only reserpine. 
The serotoninergic agents fluoxetine, 5-HTP and methysergide 
were without effect on the occurrence of withdrawal body 
shakes at the doses tested. A slight but non-significant in-
crease in the rate of withdrawal shakes was observed after 
the administration of the anticholinergic drugs atropine, 
benztropine, dexetimide and scopolamine. Conversely, the 
cholinergic agonists physostigmine and pilocarpine, reduced 
withdrawal body shakes in a dose related fashion. Modifica-
tion of gabaminergic system by the administration of bi-
cuculline, depakene and picrotoxin had no significant effect. 
Chlordiazepoxide, flurazepam and pentobarbital, sedative-
hypnotic agents, did not produce dose dependent effects on 
the occurrence of withdrawal shakes. However, the highest 
dose of each sedative hypnotic employed did reduce withdrawal 
body shakes. The exact mechanism by which neuroleptics re-
duce withdrawal is not known. Manipulation of each of the 
transmitters effect by neuroleptics indicates that dopamine 
and acetylcholine are involved in mediating the reduction in 
withdrawal body shakes. The fact that the antiwithdrawal 
activity of certain neuroleptics is reversed by the narcotic 
antagonist naloxone _implicates opiate receptor mechanisms. 
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However, not all neuroleptics were antagonized by naloxone, 
suggesting that neuroleptics may be working at more than one 
site to reduce withdrawal. Thus neuroleptics may be reduc-
ing withdrawal body shakes by several different mechanisms. 
The data gathered from these studies suggest a role for cho-
linergic, dopaminergic and narcotic mechanisms in the anti-
wi thdrawal activity of neuroleptic drugs . 
. iv 
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INTRODUCTION 
Treatment of narcotic dependence invariably requires 
the discontinuation of the abused narcotic . Discontinuation 
of narcotic drugs results in an abstinence syndrome which 
is so aversive that patients hesitate undergoing treatment 
and continue using illicit narcotics. Presently, methadone 
is employed to prevent the narcotic abstinence syndrome. Al-
though methadone is an effective agent in blocking with-
drawal, it is a narcotic drug (Jaffe and Martin, 1975) and 
is therefore likely to perpetuate the underlying cause of 
narcotic dependence. Thus chemotherapeutic approaches to 
the treatment of narcotic addiction require the development 
of non-addicting drugs which are able to successfully re-
lieve the withdrawal syndrome. This research was undertaken 
to investigate the effectiveness of butyrophenone neurolep-
tics and related compounds in relieving norphine withdrawal 
body shakes in the rat. The mechanism by which these drugs 
inhibit the narcotic withdrawal syndrome was also explored. 
Interest in the use of butyrophenones in narcotic 
withdrawal was stimulated by their known effectiveness in 
blocking brain dopamine receptors. Several lines of evi-
dence have suggested that supersensitivity of dopamine re-
ceptors is int imately involved in the development of 
1 
2 
narcotic dependence. This evidence has been in part gener-
ated by studies of morphine withdrawal aggression. Withdrawal 
from morphine elicits intense aggression upon grouping of de-
pendent rats. Pretreatment with L-dihydroxyphenylalanine 
(L-DOPA), amphetamine or apomorphine enhanced that aggression 
severalfold. These agents are known to stimulate brain dop-
amine receptors. Haloperidol, a potent dopaminergic blocking 
agent, inhibits this aggression (Puri and Lal, 1973). Sever-
al other studies have suggested a role for brain dopamine in 
narcotic dependence. Lesions placed stereotaxically in mon-
keys at the origin of the nigrostriatal system and the 
tegmenti ventralus, known to be mainly dopaminergic pathways 
(Anden et al., 1964) abolish craving for morphine and the 
signs of withdrawal (Pozuelo and Kerr, 1972). Spontaneous 
aggression is reliably seen when morphine dependent rats are 
grouped after 30 days of abstinence. Electrolytic lesions of 
the nigrostriatal nerve tract abolished this morphine with-
drawal aggression. A low dose of the dopaminergic stimulant 
apomorphine was effective in reinstating the withdrawal ag-
gression in these lesioned animals (Gianutsos et al., 1973; 
1974). For a detailed review of narcotic dependence and 
brain dopamine see Lal (1975). 
More recently, another line of evidence became avail-
able to suggest that butyrophenones may serve as nonaddicting 
substitutes for narcotic drugs in the treatment of withdrawal. 
Clay and Brougham (1975) reported a competition for binding 
at selective brain sites between the butyrophenone, haloperidol 
and the narcotic antagonist, naloxone, suggesting that halo-
peridol binds with narcotic-specific receptors. Creese et 
3 
al. (1976) and Leysen et al. (1976) have shown marked affin-
ity between several neuroleptics and opiate binding sites to 
suggest that the binding was due to a structural feature 
common to both narcotics and butyrophenone type neuroleptics. 
Their conclusions are supported by a number of pharmacological 
similarities between neuroleptics and narcotics (Lal et al., 
1975; Lal et al., 1976). It therefore became apparent that 
butyrophenones and related drugs are likely to block with-
drawal signs. Results from preliminary experiments with 
haloperidol in laboratory animals (Lal et al., 1971; Lal and 
Numan, 1976; Martin et al., 1974) and human patients (Karkalas 
and Lal, 1973) were encouraging. 
The present study was undertaken to investigate buty-
rophenones and related drugs in reducing morphine withdrawal 
body shakes, an important sign of narcotic withdrawal in rats. 
Morphine withdrawal body shakes are employed as an index of 
withdrawal since they are a consistent and objective sign of 
narcotic withdrawal (Gianutsos et al., 1975, Martin et al., 
1963). The anti-withdrawal mechanism of butyrophenones were 
explored in detail. The specific hypothesis to be tested 
with respect to the anti-withdrawal mechanisms of neurolep-
tic drugs are that these drugs interfere with transmitter 
substances in the brain thereby reducing withdrawal intensity 
or alternatively these drugs bind to narcotic receptors to 
suppress withdrawal. 
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Neuroleptics have many important and well deroonstrated 
effects on neurotransmitters such as dopamine, norepinephrine, 
serotonin,r-aminobutyric acid, and acetylcholine. It is 
conceivable that the anti-withdrawal actions of neuroleptic 
agents are mediated by their effects on the aforementioned 
neurotransmitters. Alternatively, in view of the fact that 
neuroleptic drugs have been shown to bind to opiate receptor 
sites within the central nervous system it is possible that 
this binding is responsible for the anti-withdrawal activity 
of neuroleptics. 
In order to test the hypothesis that the anti-with-
drawal mechanism of neuroleptics are related to effects on 
neurotransmitters it was necessary to roodify the activity of 
each transmitter individually. This was accomplished by 
studying the effects of specific neurotransmitter agonist and 
antagonist on morphine withdrawal body shakes. To determine 
if anti-withdrawal activity is due to antagonism of dopamine 
receptor, a number of anti-dopamine drugs were adrninstered. 
The dopaminergic antagonists employed were haloperidol, ben-
peridol, spiroimide, oxiperimide, spiperone, loxapine, chlo r -
promazine, trifluoperazine, pimozide, butaclamol and pipam-
perone. Stimulation of dopamine receptors was accomplished 
by the administration of apomorphine, L-DOPA and amphetamine. 
Norepinephrine receptors were antagonized by the use of 
propranolol, phenoxybenzarnine and azaperone. Clonidine, imi-
pramine, tranylcypromine and amitripty line were the noradren-
ergic agaonists employed. Synthesis and storage of the 
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catecholamines was inhibited by the administration of alpha-
methy-p-tyrosine and reserpine, respectively. Serotonin 
activity was mimicked by 5-hydroxytryptophan (5-HTP) and 
fluoxetine. Antagonism of serotonergic receptors was achieved 
by administration of methysergide. Acetylcholine was also 
systematically explored. The following anticholinergic drugs 
were investigated - scopolamine, atropine, benztropine and 
dexetimide while the cholinomimetics employed were pilocar-
pine, deanol, choline chloride, oxotremorine and physostig-
mine. Additionally, the effect of the gabaminergic agents 
bicuculline, depakene and picrotoxin were investigated for 
their effects on morphine withdrawal body shakes. Chlordi-
azepoxide, flurazepam and pentobarbital, sedative-hypnotic 
agents, were administered to investigate the possibility 
that neuroleptics induce these anti-withdrawal effects by 
their ability to produce sedation. A dose response curve 
was established for all drugs employed in 100difying neuro-
transmitter activity. These experiments will determine if 
reduction of withdrawal intensity is due to modification of 
dopamine, norepinephrine, serotonin, acetylcholine, or K' 
-aminobutyric acid activity. A series of saline injections 
were interspersed with drug trials to control for a spon-
taneous decrease in withdrawal intensity, the effect of hand-
ling and the injection procedure. 
The hypothesis that the anti-withdrawal activity of 
neuroleptics is mediated by an interaction with narcotic 
binding sites or release of endorphins was tested with the 
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aid of naloxone a specific narcotic antagonist. Neuroleptics 
which were found t o reduce morphine withdrawal body shakes were 
interacted with naloxone. Theoretically, if neuroleptic bind-
ing to opiate receptors mediates the anti-withdrawal activity 
then this effect should be reversed by the narcotic antago-
nist, naloxone. The maximum effective dose of each neurolep-
tic was administered in conjunction with naloxone to determine 
if the effect was reversible by this narcotic antagonist. 
This research has significance in that evidence for 
the role of various neurotransmitters in the expression of 
morphine withdrawal body shakes will be gathered. It will 
give expanded insight into the role of dopamine systems in 
narcotic dependence and withdrawal. Drugs which have poten-
tial for use in reducing the narcotic withdrawal syndrome in 
humans will hopefully be found. Additionally, further in-
formation on the pharmacological mode of action of narcotics 
and neuroleptics will be achieved. 
II 
LITERATURE SURVEY 
A. The Narcotic Withdrawal Syndrome in the Rat 
The study of the pathophysiology of narcotic depend-
ence requires an appropriate animal model • The rat has proven 
to be a useful subject for the study of the mechanism of nar-
cotic addiction since it is easily made dependent on narcotics. 
Dependence in the rat has been produced by chronic intraperi-
toneal injections of morphine sulfate (Martin et al., 1963), 
intravenous injections (Numan et al., 1975), subcutaneous im-
plantation of morphine alkaloid pellets (Collier et al., 1972; 
Wei and Way, 1975), administration of narcotics in the drink-
ing water (Gianutsos et al., 1975a) or continuous intraperi-
toneal infusion (Teiger, 1974; Harris, 1976). 
The withdrawal syndrome exhibited by the rat is con-
sistent, reliable and can be objectively measured (for review 
see Gianutsos et al., 1975a). This syndrome may be brought 
about either by administration of a narcotic antagonist or 
by the abrupt termination of chronic morphine administration. 
The withdrawal precipitated by an antagonist is immediate, 
shortlived and quantifiable. However, except for special 
circumstances, it is never clinically encountered in man. In 
contrast, the spontaneous withdrawal caused by cessation of 
narcotic drug administration has wider application to re-
search and the screening of antiabstinence drugs (Gianutsos 
et al., 1975a). 
7 
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1. Withdrawal Signs, Acute and Protracted 
The withdrawal syndrome can be divided into two phases, 
primary abstinence and protracted abstinence (Martin and 
Sloan, 1971; Martin, 1972). The primary abstinence syndrome 
begins to appear 12-24 hours after discontinuing chronic mor-
phine. It consists of the following symptoms: "wet shakes," 
loss of body weight, decreased metabolic rate, increased uri-
nation and defecation, decreased fluid consumption, hypo-
thermia, sleeplessness, irritability on handling, enhanced 
excretion of norepinephrine and epinephrine. In addition, 
there is a decline in the voltage output of the EEG (Khazan 
et al., 1967), writhing (Buckett, 1964), social aggression 
(Lal et al., 197la), ptosis and piloerection (Wikler et al., 
1960). This syndrome lasts for approximately 72 hours after 
which the syndrome begins to change (Gianutsos et al., 1975a). 
During the protracted phase, food and water intake, body 
weight, temperature and locomotor activity increase above 
normal levels and may persist for several months (Martin et 
al., 1963). Additionally, there is a continuation of wet 
shakes (Martin et al., 1974) and EEG abnormalities (Khazan 
and Colasanti, 1971) during the protracted phase. Many of 
the other symptoms . begin to return to normal levels during 
this time (Gianutsos et al., 1975a). 
2. Morphine Withdrawal Body Shakes 
Body shakes constitute a widely used and reliable 
criterion of narcotic withdrawal (Martin et al., 1963; 
Gianutsos et al., 1975a). They are defined as violent shaking 
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movements of the head and/or body of the rat which resemble 
the action of an animal that has been drenched with water and 
are readily distinguishable from tremors or jerky movements 
(Gianutsos et al., 1975a). The frequency at which wet shakes 
occur is greatest shortly after handling the rat or after 
changing its place of residence and decreases with time 
(Gianutsos et al., 1975a). Withdrawal body shakes are most 
intense 24 hours after the last morphine injection and begin 
to decrease by 72 hours of withdrawal (Gianutsos et al., 
1975a). 
Withdrawal body shakes have been shown to occur upon 
abrupt termination of morphine treatment (Martin et al., 1963; 
Gianutsos et al., 1975a), the administration of narcotic an-
tagonist (Wei et al., 1973c) and to a lesser extent in drug 
naive rats (Martin et al., 1963; Gianutsos et al., 1975a). 
Rats rendered chronically epileptic by the implantation o f 
cobalt in the right parietal cortex exhibited a significant 
number of wet dog shakes (Colasanti et al., 1975). Wet dog 
shakes have also been elicited in non-addicted rats without 
concomitant symptoms by the administration of [(4-chloro-
benzylidene-amino)-oxy)] isobutyric acid (Jahn and Mixich, 
1976). Additionally, repetitive shaking movements can be 
elicited in pentobarbital anesthetized rats after immersion 
in water. The frequency of shakes is inversely related to 
the temperature of the water and is a function of the drop 
in body temperature (Wei et al., 1973b). However, hypo-
thermia per se was not found to be a necessary condition for 
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eliciting shaking behavior (Wei et al., 1973b). This wet shake 
response was facilitated by stimuli to the ear (Wei et al., 
1973b). The endogenous morphinomemetic brain peptides meten-
kephalin and~, B and /j' endorphins have been found to produce 
acute episodes of wet-dog-like shaking behavior in animals 
not previously treated with drugs. This response began with-
in 90 seconds after lateral ventricular injection (Bloom et 
al., 1976). These shaking episodes were found to be more in-
tense and prolonged with the~ and d' -endorphins. The ad-
ministration of naloxone completely abolished these wet-dog-
shaking episodes from lateral ventricular peptide injections 
(Bloom et al., 1976). Intraperitoneal administration of 
n-dipropylacetate (DPA) to naive rats produced abstinence 
behavior which included shaking (de Boer et al., 1977). This 
behavioral effect of DPA, which increases GABA concentrations 
in the brain, is suppressed by bicuculline and morphine 
(de Boer et al., 1977). 
Several investigations have been undertaken to study 
the neuroanatomical pathways related to morphine abstinence, 
in particular the effects of brain lesions on the wet shake 
behavior of morphine abstinence. Wei et al. (1973a) have 
explored the brains of morphine-dependent rats for areas 
sensitive to naloxone-precipitated withdrawal. Wet shakes 
were most frequently elicited after application of naloxone 
to the medial thalamus and in medial areas of the dience-
phalic-mesencepholic junctures. Neocortical, hippocampal, 
hypothalamoic, tegmental, lateral thalamic and striatal 
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areas of the brain were found less sensitive to naloxone-
precipitated withdrawal body shakes (Wei et al., 1972; 1973a). 
Transverse brain lesions made at the mid-collicular level 
completely inhibit the wet shake response to ice water in non-
tolerant rats, while lesions at the mid-thalamic level did 
not significantly affect the wet shake response (Wei et al., 
1973a). The areas in the rat brain where knife cuts alternate 
the wet shake response to ice water and where naloxone pre-
cipitates the shaking behavior of the morphine abstinence 
syndrome (Wei et al., 1973a) bears considerable resemblance 
to the primary motor center for shivering in the cat and brain 
areas thought to be intimately related to subcortical mecha-
nism for arousal and emotional behavior (Wei et al., 1973a). 
In addition to those studies employing lesions of 
various brain regions to study the neuroanatomical pathways 
related to morphine abstinence, there are studies which have 
employed intraventricular injections of morphine antagonist 
into dependent animals. Withdrawal signs have been precipi-
tated by injection of morphine antagonist into the ventricular 
system of dependent rats (Watanabe, 1971), rabbits (Herz et 
al., 1972) and monkeys (Eidelberg and Barstow, 1971). The 
withdrawal pattern precipitated by intraventricular injection 
generally resembles that observed after systemic administration 
of morphine antagonist (Laschka et al., 1976a). When antago-
nists were applied into restricted parts of the ventricular 
system of rabbits, severe withdrawal signs were e l icited after 
injection of antagonists into the 4th ventricle, whereas 
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only weak signs were observed when antagonists were adminis-
tered into restricted parts of the anterior ventricular system, 
consisting of the lateral ventricles and third ventricle 
(Herz et al., 1972). Similar studies in the rat show a weak 
withdrawal syndrome when the antagonists could spread only 
within the lateral ventricles and the 3rd ventricle; however, 
when antagonist administration was restricted to the 4th 
ventricle, strong withdrawal signs were elicited by small 
doses (Laschka et al., 1976b). Following intraventricular 
injection of antagonist wet dog shakes were readily obtained; 
this was most clearly dem:>nstrated by the fact that SH 254, 
a partial agonist, induces wet dog shakes at low doses follow-
ing intraventricular administration but which after systemic 
administration induces almost no wet dog shakes (Laschka 
et al., 1976). Similarly, naloxone which induced only a few 
wet dog shakes in rats made dependent by pellet implantation 
•• (Blasig et al., 1976), elicits this symptom reliably after 
intraventricular injection (Laschka et al., 1976a). These 
studies lead to the conclusion that brain structures located 
in the anterior parts of the floor of the 4th ventricle and 
caudal parts of the periaqueductal gray matter are important 
sites in the development of morphine physical dependence. 
B. The Effect of Drugs on the Morphine Withdrawal Syndrome 
1. Narcotic Drugs 
During abstinence from morphine, the rat exhibits a 
large variety of measurable signs (Martin et al., 1963; 
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Gianutsos et al., 1975a) which may be prevented by both mor-
phine and methadone (Gianutsos et al., 1975a) . Withdrawal 
wet shakes, writhing, piloerection, ptosis and aggression are 
blocked by the administration of morphine and methadone. 
Weight loss during withdrawal is not immediately reversed by 
narcotic administration; however, if morphine is continually 
administered, the occurrence of weight loss is prevented. 
Methadone initially prevents weight loss in morphine with-
drawn rats, but a tolerance rapidly develops to this effect 
(Gianutsos et al., 1975a). Withdrawal hypothermia is re-
versed by morphine administration; however, methadone is only 
partially able to reverse this withdrawal sign (Gianutsos 
et al., 1975a). It should be noted that the effectiveness 
of morphine and methadone is short-lived, lasting less than 
24 hours, after which the syndrome again emerges. The ef-
fectiveness of methadone on certain parameters, body weight 
loss and wet shakes, disappears during repeated treatment, 
indicating the rapid development of tolerance (Gianutsos 
et al., 1975a). In contrast to the spontaneous withdrawal 
syndrome, the withdrawal precipitated by an antagonist is 
very difficult, if not impossible, to suppress by drugs, in-
cluding opiates (Gianutsos et al., 1975a). Morphine has 
been found to suppress the withdrawal abstinence syndrome in 
the dog in a dose-related manner. However, morphine was less 
effective in suppressing abstinence in dogs with a high level 
of dependence (Martin et al., 1974). A wide variety of com-
pounds with diverse chemical structures which possess very 
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potent morphine-like activity have been tested for their 
ability to suppress abstinence in the morphine-dependent mon-
key. Some of the chemical families test include the phenyl-
piperidines, benzimidazoles, benzomorphans, morphinans, 
methadones and diazabicyclo-octanes. These compounds have 
been found to suppress abstinence in the morphine-dependent 
monkey with varying degrees of potency (Villarreal, 1973). 
Studies done at the Addiction Research Center at Lexington, 
Kentucky also show these compounds to suppress morphine ab-
stinence in man (Villarreal, 1973). 
2. Non-Narcotics Drugs 
a. Dopaminergic Agonist and Antagonist 
Narcotic dependent rats undergoing withdrawal are 
hyper-irritable and when placed together show vigorous fight-
ing (Boshka et al., 1966; Lal, et al., 197la). This aggres-
sion is blocked by continued treatment with morphine, but 
emerges when drug administration is discontinued. Aggression 
in the rat consists of vocalizations, aggressive posture, 
biting and other forms of attack which often leads to severe 
injury or death (Lal, 1975a). Haloperidol, a potent anti-
psychotic drug (Janssen, 1966), is very effective in block-
ing morphine withdrawal aggression (Puri et al., 1973; Lal, 
1975b). This aggression is also reduced by chlorpromazine, 
a pentothiazine neuroleptic (Lal, 1975a}. 
Wet-dog-like body shakes are a characteristic sign of 
morphine withdrawal in rats (Martin et al., 1963; Gianutsos 
et al., 1975a}. Haloperidol has been found to produce a dose 
dependent decrease in withdrawal shakes (Lal and Numan, 1976}. 
15 
During morphine-withdrawal, animals learn to self-
administer narcotic drugs directly into the bloodstream at 
high rates (Weeks and Collins, 1968; Schuster, 1970; Numan 
et al., 1975). Intraperitoneal administration of haloperidol 
given in small doses was shown to significantly decrease 
morphine self-administration in addicted rats (Cimini-Venoma 
and Hanson, 1972). This observation was later replicated in 
the monkey by Pouzolo and Kerr (1972). Spiramide, a buty-
rophenone neuroleptic, reduces the rate of self-administra-
tion of fentanyl, a potent narcotic (Lal and Hynes, 1977). 
Haloperidol has also been found to decrease morphine rein-
forcement and inhibit relapse in post-addict rats (Schwartz 
and Marchok, 1974). 
Haloperidol (Lal et al., 197lb) and pimozide (Cox et 
al., 1975) prevent as well as reverse withdrawal hypothermia 
in the morphine dependent rat. Recently, Martin et al. 
(1974) reported that haloperidol depressed certain aspects 
of the morphine abstinence syndrome in the dog but not others. 
Haloperidol proved to be more effective than morphine in 
suppressing mydriasis and panting while it was relatively 
less effective in reducing whining, gnawing and hindlimb 
stepping movement (Martin et al., 1974). Morphine withdrawal 
jumping in the mouse is blocked by the administration of 
haloperidol (Takemori et al., 1976). 
Several years ago it was reported (Lal et al., 197lb) 
that haloperidol reduced several withdrawal symptoms in 
heroin addicts. This initial study was replicated by Karkalas 
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and Lal (1973) who compared haloperidol with methadone in 18 
patients. Haloperidol was found effective in completely block-
ing the withdrawal symptoms in half of the patients and com-
pared well with methadone in this respect. The failure of 
several patients to respond to therapy was ascribed to the 
use of too low a dose of haloperidol. Those patients respond-
ing to haloperidol reported a reduction in their craving for 
heroin (Karkalas and Lal, 1973). These findings have been 
replicated by a number of physicians (Lal and Hynes, 1977). 
Haloperidol in conjunction with psychological and social 
counseling, has been found useful in getting patients to give 
up heroin for a six-month period or longer (Le Compte and 
Friedman, 1974). 
Chlorpromazine, a phenothiazine neuroleptic, has been 
reported to reduce wet-dog shakes characteristic of precipi-
tated withdrawal in the rat (Cicero et al., 1974). Narcotic 
withdrawal symptoms in newborn infants of drug dependent 
mothers have been successfully controlled with chlorpromazine 
(Glass, 1974; Kandall, 1976). However, adult patients who 
were being treated with both methadone and chlorpromazine re-
quested the discontinuation of chlorpromazine because of ad-
verse effects (Dufficy, 1973). 
Morphine-withdrawal aggression is seen after the with-
drawal of narcotic drugs (Lal, 1975; Puri and Lal, 1973). 
This aggression is enhanced by directly and indirectly acting 
dopamine-receptor stimulants such as amphetamine, L-DOPA or 
apomorphine (Puri and Lal, 1973). DOPA has also been found 
to exacerbate withdrawal jumping, diarrhea, tremors, writh-
ing and convulsions (Gunne, 1965). Herz (1975) found L-DOPA 
administered shortly before precipitating withdrawal induced 
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a dose-dependent increase in withdrawal jumping and a decrease 
in wet-dog shakes. Other signs such as diarrhea and ptosis 
decreased, whereas rhinorrhea, lacrimation and salivation in-
creased (Herz, 1975). Apomorphine, administered at doses 
between 1 and 2.5 mg/kg, increased jumping, teeth chattering 
and eye twitches but only the increase in jumping was statis-
tically significant (Herz, 1975). Ptosis and diarrhea were 
both significantly decreased, with wet-dog shakes, writhing 
and rhinorrhea yielding only equivocal results (Herz, 1975). 
Apomorphine has been found to reduce morphine withdrawal body 
shakes in rats after the termination of morphine injections 
(Hynes, 1975). 
b. Adrenergic Agonist and Antagonist 
The alpha adrenergic stimulant clonidine has been 
found effective in reducing body shakes, weight loss, ptosis, 
urination, diarrhea, teeth chattering, salivation and ejacu-
lation in dependent animals injected with naloxone (Meyer 
and Sparber, 1976; Tseng et al., 1 9 75). Clonidine has been 
found to potentiate escape attempts induced by naloxone in 
dependent rats (Tseng et al., 1975). 
Inhibition of brain monoarnine oxidase by pargyline re-
sults in a potentiation of jumping behavior during naloxone-
precipitated withdrawal in mice (Iwamoto et al., 1971). The 
potentiation of jumping has been attributed to the elevation 
of biogenic amines in the central nervous system resulting 
from monoamine oxidase inhibition. Similarly, it has been 
reported that imipramine, a drug which inhibits the reuptake 
of norepinephrine potentiates morphine withdrawal activity 
in mice (Chiesa et al., 1968) and rats (Herz, 1975). Low 
doses of d - amphetamine and cocaine given shortly before pre-
cipitating withdrawal induced a dose-dependent increase in 
jumping and a decrease in wet-dog shakes (Herz, 1975). Signs 
such as diarrhea and ptosis decreased, whereas rhinorrhea, 
lacrimation and salivation increased after amphetamine or 
cocaine treatment (Herz, 1975). 
Alpha adrenergic blockers such as phenoxybenzamine 
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have been found to produce a dose-related suppression of 
diarrhea and wet-dog shakes in precipitated narcotic withdraw-
al (Cicero et al., 1974). Propranolol, the beta adrenergic 
blocker, has been the subject of numerous and conflicting in-
vestigations. Propranolol has been reported to prevent heroin 
induced euphoria, cause the use of heroin to precipitate pro-
tracted withdrawal symptoms and reduce the craving for nar-
cotics in ex-addicts (Grosz, 1972; Black and Grosz, 1974). 
Other investigators have failed to find that propranolol 
aggravated the opiate withdra wal syndrome and on the contrary 
reported that it provided some relief (Jacob et al., 1975). 
Furthermore, no blockade by propranolol of the morphine-
induced euphoria was found in man (Jacob et al., 1975). Re-
sults obtained in the chronic spina l dog indicate that pro-
pranolol neither antagonized nor mimics the effects of morphine 
{Martin et al., 1974). Similarly, the morphine Lo50 in mice 
is not altered by pretreatment with propranolol {Navarro et 
al., 1976). 
c. Cholinergic Agonist and Antagonists 
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There is considerable evidence suggesting that 
acetylcholine (ACh) may be involved in some of the acute 
manifestations of morphine action and in the expression of 
certain withdrawal signs. Several investigators have indi-
cated a possible role for cholinergic mechanisms in the with-
drawal syndrome precipi tated by narcotic antagonists. The 
changes in the jumping response appear to be related to brain 
levels of acetylcholine. It has been demonstrated the mor-
phine dependent animals which jump after a naloxone injection 
exhibited a decrease in brain acetylcholine, whereas those 
that did not jump exhibited no change in brain acetylcholine 
(Bhargava and Way, 1975). Elevation of brain acetylcholine 
by the cholinesterase inhibitor physosti gmine greatly inhibit 
naloxone-precipitated withdrawal jumping in mice (Bhargava 
and Way, 1972; 1976; Brase et al., 1974). Conversely, injec-
tion of hemicholinium intracerebrally to inhibit central 
nervous system acetylcholine synthesis, enhanced naloxone-
precipitated withdrawal jumping (Bhargava and Way, 1976). 
The centrally active cholinergic agonist nicotine, tremorine, 
oxotremorine and arecoline have been found to significantly 
inhibit naloxone induced jumping behavior i n mice (Brase et 
al., 1974). Whereas the cholinergic antagonist atropine, 
benztropine, pempidine and mecamylamine significantly 
potentiate this jumping (Brase et al., 1974). However the 
effects elicited by the cholinergic antagonist atropine on 
precipitated withdrawal conflict since both an enhancement 
and an inhibition of naloxone-precipitated withdrawal jump-
ing have been found. The critical factors in whether a 
stimulatory or inhibitory response is to be elicited by 
atropine appears to be the time of atropine administration 
and the brain level of acetylcholine. When naloxone is ad-
ministered 10 min after atropine there is enhanced jumping 
response (Brase et al., 1974; Bhargava and Way, 1976). How-
ever, if naloxone is administered 30 min after atropine the 
jumping response is inhibited and after 2 hours no effect 
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of atropine is apparent (Jhamandas and Dickinson, 1973; 
Iwamoto et al., 1973). During peak naloxone-precipitated 
withdrawal jumping there is a lowering of brain acetylcholine 
(Bhargava and Way, 1975). When atropine enhances naloxone 
precipitated withdrawal jumping, brain acetylcholine levels 
are also decreased. At those time intervals when the poten-
tiating action of atropine is absent, brain acetylcholine 
levels are normal {Bhargava and Way, 1976). 
Several studies exist which have examined the effects 
of cholinergic and anticholinergic agents on the expression 
of morphine dependence in rats {Frederickson and Pinsky, 
1975; Hynes et al., 1976). The anticholinergic drugs atro-
pine and mecomylamine were found to have a biphasic effect 
on the narcotic withdrawal syndrome by Frederickson and 
Pinsky {1975). Mecamylamine by itself potentiated the peak 
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severity and accelerated the subsequent decline in severity 
of the signs. Atropine by itself was found to have a simi-
lar tendency but none of its effects proved significant 
(Frederickson and Pinsky, 1975). However, when the two 
treatments were combined, there was no significant effect on 
the severity of withdrawal (Frederickson and Pinsky, 1975). 
Apparently the action of atropine antagonized the actions of 
mecamylamine. Atropine methylnitrate, a peripherally active 
anticholinergic, reduced the withdrawal severity (Frederick-
son and Pinsky, 1975). The anticholinergic atropine and 
dexetimide produced no significant effect on withdrawal wet 
shakes, weight loss, piloerection and diarrhea; however, 
there was a slight increase in the number of withdrawal body 
shakes (Hynes et al., 1976). Eserine sulfate, a tertiary 
anticholinesterase agent, when administered during the ab-
stinence period was found to have little effect on the sever-
ity of the total withdrawal syndrome but decreased weight 
loss (Frederickson and Pinsky, 1975). Choline chloride was 
found to effectively reduce the overall withdrawal severity 
and weight loss throughout the withdrawal period (Frederick-
son and Pinsky, 1975). Hynes et al. (1976) found that pilo-
carpine, a drug which stimulates cholinergic receptors, was 
effective in reducing both wet dog-like body shakes and with-
drawal aggression but increased diarrhea and body weight 
loss. Pretreatment with atropine blocked all of the effects 
of pilocarpine on withdrawal signs. While methylscopolamine, 
an anticholinergic drug unable to penetrate into the central 
nervous system failed to block the pilocarpine-induced inhi-
bition of withdrawal wet shakes but protected the animal 
against pilocarpine-induced diarrhea, suggesting that pilo-
carpine 's reduction of withdrawal body shakes was centrally 
mediated (Hynes et al., 1976). The hyperinitabil i ty charac-
teristics of the abstinence syndrome have been attenuated by 
the administration of the physostigmine (Grumbach, 1969). 
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Atropine and methylatropine have been also tested in 
rats for their ability to alter the reinforcing action of 
intravenous morphine sulfate. Morphine self-administration 
was blocked by atropine but not by methylatropine (Davis and 
Smith, 1975). Similarly, atropine but not methylatropine 
prevented the establishment of a conditioned reinforcer based 
on passive intravenous infusions of morphine (Davis and 
Smith, 1975). These results indicate that a central cholin-
ergic system exerts an influence on the brain mechanisms 
which are affected by morphine to produce positive reinforce-
ment (Davis and Smith, 1975). 
d. 5-Hydroxytryptamine Agonist and Antagonist 
Evidence suggesting that morphine and 5-hydroxy-
tryptomine (5-HT) may interact in the peripheral and central 
nervous systems is mostly circumstantial. Molecular models 
of morphine exhibit some degree of complementariness to 5-HT 
and arguments can be made indicating that certain actions of 
morphine may be mediated by endogenous 5-HT. The compound, 
p-chlorophenylalanine (PCPA), which selectively inhibits the 
synthesis of 5-HT (Koe and Weissman, 1966) has been reported 
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to modify morphine effects on analgesia (Tenen, 1968; Fennessy 
and Lee, 1970) and on motor activity (Eidelberg and Schwartz, 
1970; Cheney and Goldstein, 1971) . Attempts have been made 
to modify the morphine abstinence syndrome with agents that 
might alter brain 5-HT, but no clear picture has emerged. 
Cyproheptadine, a 5-HT antagonist, when given in large doses 
prior to levallorphan precipitated withdrawal abolished teeth 
chattering, ej a culations, wet dog shakes, loose stools and 
reduced body weight loss (Opitz and Reimann, 1973). Huidobro 
et al., (1963) reported that the administration of 5-HT or its 
metabolic precursors attenuated the abstinence syndrome. 
Collier (1965) in the development of his receptor theory of 
tolerance and depe ndence, pointed out that the abstinence 
signs in the dog a nd rat are very similar to those produced 
by the administration of the 5-HT precursor, 5-hydroxytrypto-
phan. 
Several attempts to link morphine with 5-HT in the 
tolerant and dependent state have been made by studying the 
effects of morphine on brain concentrations of 5-HT after 
repeated morphine administra tion and during the withdrawal 
state. The evidence indicates that steady state levels of 
5-HT are affected only slightly, or not at all, by acute or 
chronic morphine administration or by morphine withdrawal 
(Way, 1971; Way and Shen, 1971). A comparison of the turn-
over of brain 5-HT in tolerant and non-tolerant mice re-
vealed a mean increase in tolerant animals more than double 
24 
that in non-tolerant ones (Way, Loh and Shen, 1968; Loh, Shen 
and Way, 1969; Shen, Loh and Way, 1970). The increased rate 
of 5-HT synthesis resulting from chronic morphine administra-
tion was blocked by cycloheximide, an inhibitor of protein 
synthesis and this was accompanied by an inhibition of toler-
ance and development of physical dependence to morphine 
(Way et al., 1968; Loh et al., 1969). When the development of 
tolerance and physical dependence to morphine was prevented 
by concomitant administration of the narcotic antagonist, 
naloxone, the increased brain 5-HT levels was also prevented. 
The elevated turnover rate which existed during the tolerant 
state reverted to normal two -weeks after withdrawal (Loh 
et al., 1969). When brain 5-HT synthesis was inhibited by 
PCPA, tolerance and physical dependence development to mor-
phine was in part prevented (Way et al., 1968; Shen et al., 
1970). On the basis of these findings it has been suggested 
that 5-HT turnover may be associated with morphine tolerance 
and physical dependence . 
e. Endorphins 
Intracerebroventricular administration of meth-
ionine-enkephalin or morphine sulfate prior to naloxone ad-
ministration has been shown to inhibit the precipitated with-
drawal jumping response in mice dependent on morphine by 
the pellet implantation method (Bhargava, 1977). Howevever, 
both methionine-enkephalin and morphine sulfate failed to 
inhibit withdrawal defecation and rearing behavior. Morphine 
sulfate was found to be 4 times as potent as methionine-
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enkephalin, on molar basis, in inhibiting the abstinence syn-
drome (Bhargava, 1977). 
f. Miscellaneous Drugs 
Tetrahydroconnabinol when administered prior to 
naloxone precipitated abstinence in rats, blocked the appear-
ance of wet shakes and escapes (Hine et al., 1975), and re-
duced withdrawal jumping, defecation and rearing in mice 
(Bhargava, 1976). 
C. The Pharmacology of Naloxone 
Naloxone or N-allylnoroxymorphone was synthesized by 
Lewenstein and Fishman in the early part of 1960 from oxy-
morphone, a potent analgesic (Blumberg and Dayton, 1973). 
Initial investigations demonstrated that naloxone was a po-
tent narcotic antagonist in animals being about 10-20 times 
more active than nalorphine (Blumberg et al., 1961). Fol-
lowing the animal studies, Foldes et al. (1963) reported 
that naloxone was also a potent narcotic antagonist in man. 
1. Narcotic Antagonism 
Naloxone is at least 10-20 times more active than 
nalorphine and about 3-6 times more active than levallorphan 
when tested by prevention of the Straub tail erection in 
mice, by counteraction of narcosis in rats, and by counter 
action of narcotic depression of respiration in rabbits 
(Blumberg et al., 1965). In precipitating the withdrawal 
syndrome in morphine-dependent monkeys, naloxone is about 7 
times more active than nalorphine (Deneau and Seevers, 1963). 
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Nalorphine is a narcotic antagonist that has several unde-
sirable side effects, such as respiratory depression and psy-
chotomimetic reactions (Blumberg and Dayton, 1973). Similar-
ly, naloxone is 5-8 times m:>re potent than nalorphine in 
precipitating the abstinence syndrome in morphine-dependent 
humans and is itself non-addicting (Jasinski et al., 1967). 
Naloxone acts very rapidly and counteracts narcotic 
depression within 1-2 min when given intravenously (Blumberg 
and Dayton, 1973). Peak brain levels of naloxone occur with-
in 15 min of injection and decline by 50 percent within 1 
hour (Berkowitz et al., 1975). It is effective in counter-
acting various different narcotics, but is ineffective 
against non-narcotic depressants such as barbiturates 
(Blumberg and Dayton, 1973). 
2. Counteraction of Narcotic Antagonist Analgesics 
Unlike nalorphine and levallorphan, naloxone not 
only counteracts narcotics but also counteracts agonist ef-
fects of narcotic antagonist analgesics. Thus naloxone 
counteracts the depressant effects of cyclazocine on the 
flexor reflex of the spinal dog (Mcclane and Martin, 1967), 
the antinoriceptive activity of cyclazocine, cyclorphan, 
levallorphan, nalorphine and pentazocine in writhing test 
in mice and rats (Blumberg et al., 1966). The depressant 
action of pentazocine in rats and the respiratory depression 
caused by pentazocine in anaesthetized dogs are also re-
versed by naloxone (Blumberg and Dayton, 1973). In man, 
naloxone also counteracts undesirable side effects of 
cycloazocine (Jasinski et al., 1968) and the respiratory 
depressent action of pentazocine (Kallos and Smith, 1968). 
3. Other Pharmacological Properties of Naloxone 
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Naloxone is not a 'pure' antagonist for at high doses 
it does exhibit some agonist actions . For example, in rats 
a dose of 50 mg/kg, which is about 200 times the narcotic 
antagonist dose, will produce restlessness and salivation. 
At higher toxic doses clonic-tonic convulsions appear 
(Blumberg and Dayton, 1973). At doses well above the nar-
cotic antagonist dose naloxone appears to manifest few or 
no side effects or agonist action in man or mammalian labor-
atory animals (Blumberg and Dayton, 1973). However, there 
is some evidence of agon ist activity at non-toxic doses in 
behavior experiments in pigeons (McMillan et al., 1970). 
Naloxone, although a very potent narcotic antagonist, 
appears to show no anti-nociceptive activity in animals 
(Blumberg et al., 1961; Blumberg et al., 1965) and little or 
no analgesic activity in man (Blumberg and Dayton, 1973). 
There is essentially no effect on respiration at therapeutic 
doses of naloxone in narcotic-free animals. However, at 
about 100 times the antagonist dose in rabbits the respira-
tory rate and minute volume begin to show a slight increase 
(Blumberg and Dayton, 1973). Naloxone by itself has essen-
tially no effect on respiration in man (Foldes et al., 1963; 
Jasinski et al., 1967). Heart rate and blood pressure are 
not significantly affected by naloxone (Blumberg and Dayton, 
1973). Naloxone likewise has little or no cardiovascular 
effect in man (Jasinski et al., 1967). Naloxone causes no 
significant change in the body temperature of rabbits or 
dogs (Blumberg and Dayton, 1973). 
Naloxone has been shown to modify the effects of 
a-amphetamine on continuous avoidance behavior in the ra t 
(Holtzman and Jewett, 1973; Holtzman, 1974). The dose re-
sponse curves for a-amphetamine stimulation of continuous 
avoidance and locomotor activity were shifted downward by 
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the administration of naloxone (Holtzman, 1974). Addition-
ally, naloxone has proven to be almost as effective as 
a-amphetamine in suppressing food intake in food-deprived 
rats (Holtzman, 1974). However, naloxone failed to affect 
food intake in the mous e, indicating that some e ffects of 
naloxone may be species dependent (Holtzman, 1974). Nalox-
one has also been shown to block apomorphine induced stero-
typed behaviors in male guinea pigs (Moon and Margolin, 1977). 
Haloperidol and morphine sulfate completely suppress 
bar-pressing for brain self-stimulation in rats implanted 
with electrodes in the lateral hypothalamus (Wauquier et 
al., 1974). Naloxone at a dose (5 mg/kg) which was inef-
fective when given alone, differentially reversed the mor-
phine effects but was without any reversing influence on the 
actions of haloperidol (Wauquier et al., 1974). When the 
self-stimulating electrodes are in or just lateral to the 
pontine central gray the rate of self-stimulation was dose-
relatedly decreased by naloxone administration (Belluzzi 
and Stein, 1977). Electrical stimulation of the periaque-
ductal grey matter in rats and humans has been found to pro-
duce a strong analgesia (Mayer and Liebeskind, 1974; Akil 
et al., 1976) which is antagonized by naloxone (Aki l et al., 
1976; Adams, 1976). 
Several experiments have demonstrated that naloxone 
can restore normal peristaltic reflex activity in fatigued 
guinea pig preparations or after inhibition by adenine 
nucleotides (Van Neuten et al., 1976). Distention of the 
guinea pig ileum segment elicits peristaltic activity, how-
ever maintenance of this distended condition results in the 
gradual disappearance of peristaltic activity (Van Neuten 
et al., 1976). Naloxone has been found by Van Neuten et 
al. (1976) to restore normal activity in such preparations. 
Adenosine, adenosine monophosphate, adenosine diphosphate 
and adenosine triphosphate inhibit the perestaltic reflex 
activity of guinea pig ileum and this inhibitory effect is 
also reversed by naloxone (Van Neuten et al., 1976). In 
the guinea pig ileum segment, met-enkephalin, an endogenous 
ligand for the opiate receptor, causes a dose-dependent in-
hibition of the rhythmic peristaltic reflex activity induced 
by increasing the distending pressure (Van Neuten et al., 
1977). This inhibitory effect of met-enkephalin is reversed 
by naloxone (Van Neuten et al., 1977). 
Recent studies have revealed the existence of endoge-
nous morphine-like compounds in the central nervous system 
(Teschemacher et al., 1975; Hughes et al., 1975). These 
endogenous morphine-like compounds have been reported to 
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produce analgesia when injected intraventricularly in rats 
and cats (Belluzzi et al., 1976) which is antagonized by nal-
oxone. A morphine-like peptide obtained from the pituitary 
gland, endorphin, and two brain peptides, enkephalins, have 
been shown to have a high affinity for the opiate receptor 
demonstrated by displacement of naloxone from these receptors 
(Terenius and Wahlstrom, 1975; Pasternak et al., 1975; 
Bradbury et al., 1976). These findings have led to the hypo-
thesis that these morphine-like compounds are partially re-
sponsible for pain thresholds. If this is true then an an-
tagonism of the effects of the endogenous compounds by nalox-
one should affect pain perception. However, naloxone has 
been found not to alter the perception of experimentally in-
duced pain in normal human subjects (El-Sobky et al., 1976). 
Rats treated with doses of naloxone sufficient to block mor-
phine analgesia have been found to show no change in the 
threshold for escape from foot shock (Goldstein et al., 1976). 
However, naloxone has been shown to lower pain threshold in 
mice (Jacob et al., 1974), to block analgesia produced by 
electrical stimulation of the periaqueductal grey in rats 
(Akil et al., 1976), to antagonize acupuncture analgesia in 
man (Mayer and Price, 1976), and to antagonize nitrous oxide 
analgesia in mice (Berkowitz et al., 1976). Bell and Martin 
(1977) recorded C-fiber reflexes from an S, ventral root in 
the acute decerabrate low spinal cat following stimulation of 
the ipsilateral superficial peroneal nerve or application of 
radiant heat to the metacarpel footpad. Naloxone was found 
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to increase the electrically evoked C-fiber reflex and the 
radiant heat evoked ventral root reflex (Bell and Martin, 
1977). The fact that naloxone facilitated these reflexes in 
doses too small to have non-specific excitatory effects is 
consistent with the hypothesis that these effects are due to 
antagonism of a naturally occurring opiate-like substance . . 
D. Opiate Receptors 
1. Stereospecific Binding Sites for Opiates 
It has been postulated for many years that opiates 
must bind to macromolecular sites or receptors located in, 
or on the surface of, nerve cells before they can produce 
their characteristic pharmacological responses. The reason 
for this receptor postulate was the high degree of structur-
al and steric specificity which characterizes opiate action. 
Among the many classes of natural and synthetic morphine-
like analgesics studied, it is usually the D-isomer that is 
active, while the L enantiomorph tends to have very low or 
no analgesic potency (Simon, 1976). Small structural alter-
ations in the opiate molecule can lead to dramatic changes 
in potency. The search for opiate receptors has been under-
way in a number of laboratories for many years. However, 
success was limited until Goldstein et al. (1971) suggested 
using stereospecificity as a criterion of receptor binding. 
They incubated mouse brain homogenate with H3-levorphanol. 
Stereospecif ic binding was defined as that portion of the 
binding that was prevented b y levorphanol but not by 
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dextrorphan. In their experiments stereospecific binding 
amounted to only 2% of total binding. Using modifications of 
the Goldstein procedure Pert and Snyder (1973), Simon and his 
co-workers (1973) and Terenius (1973a) independently identi-
fied binding to brain tissue that was highly stereospecif ic 
by using labeled opiates and opiate antagonist of high spe-
cific activity. 
Stereospecific binding sites have been found in the 
central nervous system of many species and the myenteric 
plexus of the guinea pig ileum. They are tightly bound to 
membranous elements of the cell and have been reported to 
be most concentrated in the synaptosomal fraction of brain 
and guinea pig ileum homogenates (Hitzeman et al., 1974; Pert 
et al., 1974; Terenius, 1973b) suggesting that they occur on 
membranes in the vicinity of synapses. Whether they are situ-
ated pre- or postsynaptically has not yet been established. 
Opiate binding sites have been found in the central nervous 
system of every vertebrate species so far examined, including 
man (Hiller et al., 1973) but not in that of any inverte-
brates (Pert et al., 1974). 
Biochemical studies have shown that stereospecific 
binding of opiates is highly sensitive to proteolytic enzymes 
(Simon et al., 1973; Pasternak and Snyder, 1973) and various 
sulfhydryl reagents (Simon et al., 1973; Terenius, 1973a) 
suggesting the participation of protein. The binding of 
agonist and antagonist drugs has a broad pH optimum between 
6.5 and 8, and is decreased by the presence of alkali, 
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alkaline earth, transition metal and organic cations. An ex-
ception is the sodium ion which at concentrations up to 200 
mM enhances antagonist binding while depressing agonist bind-
ing (Simon, 1976). 
Opiate binding sites have high affinity for narcotic 
analgesics and their antagonists. Dissociation constants 
range from 0.4 nM for etorphine to no detectable affinity for 
drugs which do not exhibit morphine-like narcotic analgesic 
effects (Simon, 1976). One of the most important convincing 
pieces of evidence regarding the pharmacological relevance 
of binding sites is the degree of correlation between bind-
ing affinity of a variety of ligands and their pharmacolog-
ical potency. Excellent correlation has been found between 
the in vivo potencies of opiates and antagonists and their 
affinities for the stereospecific binding sites in vitro 
(Simon et al., 1973; Pert and Snyder, 1973; Terenius, 1974). 
The ability of opiates to inhibit electrically stimulated 
contractions of the isolated guinea pig ileum has also been 
shown to be very well correlated with their binding affini-
ties for stereospecific sites in the myenteric plexus of 
the ileum (Creese and Snyder, 1975). Narcotic binding af-
finities, determined both in the presence and absence of 
sodium, showed excellent and closely similar correlation 
with the tail withdrawal analgesia test in rats after intra-
venous administration of drugs (Simon, 1976). Very high 
correlation was also obtained between binding affinities of 
drugs and their ability to inhibit the contractions of the 
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guinea pig ileum. These binding affinities show good correla-
tion with the cod-liver oil test for antidiarrheal potency 
(Simon, 1976). The stereospecificity, saturability and high 
affinity of the stereospecific opiate binding sites and the 
excellent correlation between pote ncy and binding affinity of 
opiates and their antagonist strongly support the hypothesis 
that these sites are pharmacologically relevant recognition 
and binding sites for opiates. 
a. Distribution of Opiate Receptors in Different 
Regions of the Brain 
The manner in which stereospecific binding sites 
are distributed throughout the brain is of considerable in-
terest as a clue to the sites of opiate action. Receptor 
binding has been determined in numerous regions of the monkey 
brain where receptor binding varies by a greater than 30-fold 
range (Kuhar et al., 1973). The amygdala shows the greatest 
amount of receptor binding, with its anterior portion display-
ing almost twice as much as the posterior. Binding in the 
periaqueductal area of the midbrain is about the same as in 
the posterior amygdala. The hypothalamus and medial thalamus, 
the next highest areas, display only about 40 percent as much 
binding as the anterior amygdala. In the head of the caudate, 
receptor binding has been found to be 80 percent of that in 
the hypothalamus and medial thalamus. Marked regional varia-
tions have also been found within the cerebral cortex. Frontal 
cortex is the highest cortical area with precentral gyrus, 
postcentral gyrus and occipital pole showing considerably 
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less binding. Receptor binding is very low or not detectable 
in various white matter areas. The cerebellum, lower brain 
stem and the spinal cord show only very low levels of recep-
tor binding (Kuhar et al., 1973). Stereospecific binding 
has also been demonstrated in human brain (Hiller et al., 
1973). There are large differences in binding within the hu-
man brain ranging from 0.4 pmol/mg protein in the olfactory 
trigone, amygdala and septal nuclei to virtually no binding 
in cerebral white matter, dentate nucleus of the cerebellum, 
tegmentum, pineal and pituitary gland (Simon, 1976; Hiller, 
1973). The most interesting conclusions reached from these 
studies is that most areas with high opiate binding are lo-
cated in, or associated with, the limbic system. 
The heterogenity of opiate receptor distribution is 
reminiscent of the large regional differences observed for 
concentrations of the neurotransmitters. There are similar-
ities of opiate receptor distribution to the distribution 
of several neurotransmitters, such as acetylcholine,d'l -amino-
butyric acid, serotonin and the catecholamines (Snyder and 
Pert, 1975). However, there are some differences as well. 
Acetylcholine and opiate receptor binding are both high in 
the caudate nucleus, the putamen is quite rich in acetyl-
choline but contains only a moderate degree of opiate bind-
ing. The periaqueductal areas of the midbrain, which pos-
sesses the second highest levels of opiate receptors, has 
only moderate acetylcholine-synthesizing capacity (Snyder and 
Pert, 1975). Whereas the hypothalamus is rich in both 
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d"aminobutyric acid and opiate receptors, the globus pallidus 
which contains one of the highest r -aminobutyric acid con-
centrations in the brain, is relatively low in opiate receptor 
binding (Snyder and Pert, 1975). The caudate nucleus is high 
in opiate receptor binding and tyrosine hydroxylase, the rate 
limiting enzyme in catecholamine synthesis. Additionally, 
the hypothalamus and periaqueductal gray are also rich in ty-
rosine hydroxylase and opiate receptor binding. However, while 
the medial thalamus contains much more opiate receptor binding 
than the lateral hypothalamus,the reverse is true for tyrosine 
hydroxylase (Snyder and Pert, 1975). Serotonin is found in 
the caudate, hypothalamus and amygdala just as the opiate re-
ceptor is. However the midbrain raphe area, which contains 
the cell bodies of serotonin neurons in the brain and one of 
the richest in serotonin content, is quite low in opiate re-
ceptor binding (Snyder and Pert, 1975). Lesions that selec-
tively destroy norepinephrine, serotonin, acetylcholine, or 
dopamine containing pathways have no effect on opiate recep-
tor binding in the areas of brain in which these pathways 
possess the greatest density of nerve terminals (Kuhar et 
al., 1973). These results indicate that the opiate receptors 
are not localized on or within the nerve terminals of the 
specific neurotransmitter pathways discussed here. 
b. Interaction of Opiate Receptors with Agonist and 
Antagonist 
Simon et al. (1973) reported that the presence 
of salt in the incubation mixture led to a dose-dependent 
decrease in etorphine binding while no such effect was ob-
served for naloxone binding by Pert and Snyder (1973). The 
effect of salt is a general one between the classes of ago-
nist and antagonist drugs resulting in an actual enhancement 
of antagonist binding which in the case of naloxone and nal-
trexone is at least two-fold (Pert and Snyder, 1974). They 
have further demonstrated that the effect is not a salt or 
ionic strength effect but a unique property of sodium ions, 
exhibited to a lesser extent by lithium but by none of the 
other alkali metal ions. None of a large variety of other 
cations studied including alkaline earth and transition 
metals (Pert and Snyder, 1974) nor a series of organic ca-
tions (Simon et al., 1975) could mimic the selective action 
of sodium and lithium. This effect is remarkable both for 
the ability of an inorganic cation to distinguish between 
such close related structures as opiate agonist and antago-
nists and for the uniqueness of sodium in this regard. 
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The question of whether the changes produced by sodium 
are due to changes in the number of binding sites or in bind-
ing affinities has been explored by both the Simon and Snyder 
groups. However, on this point there exists disagreement be-
tween the experiments performed in the two laboratories which 
has yet to be resolved. Pert and Snyder (1974) have reported 
an increase in the number of high affinity bindin g sites for 
naloxone in the presence of sodium with no change in affinity. 
On the other hand, Simon et al. (1975) reported that sodium 
causes an increase in the affinity of naltrexone without any 
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change in the number of binding sites. Similarly, for agonist 
binding Simon et al. (1975) reported a decrease in affinity 
while Pert and Snyder (1974) reported a decrease in number of 
binding sites. 
Unlabeled opiates have been allowed to compete with 
labeled antagonists in the presence and absence of sodium. 
When the unlabeled competitor was a relatively poor antago-
nist there was little or no change in the concentration able 
to displace 50 percent of the labeled antagonist (ED50 ) in 
the presence of sodium while the ED 50 of strong agonist was 
increased dramatically (Simon, 1976). Drugs with mixed 
agonist-antagonist properties acted in an intermediate fash-
ion, their ED 50 for displacement of 
3H-naloxone or 3H-nalt:r€x-
one. being increased 2 to 7 fold in sodium (Simon, 1976). 
Shifts in ED 50 are compatible with changes in affinity but 
not with changes in the number of binding sites (Simon, 1976). 
In spite of the disparity of results between the Simon 
and Snyder groups they view the mechanism of the sodium ef-
fect in a similar manner and have independently proposed 
similar models (Simon, 1975; Pert and Snyder, 1975). The 
essence of these models is that the sodium ion acts as an 
allosteric effector, the binding of which to an allosteric 
site on the receptor molecule results in a conformational 
change in the opiate binding site. The new conformer, so-
dium dependent, exhibits a higher affinity for antagonist 
and a lower affinity for agonist than the conformer that 
exists in sodium-free media. 
c. The Effect of Tolerance and Dependence on Opiate 
Receptors 
There has been great interest in the way the de-
velopment of tolerance and physical dependence may affect 
the number and properties of opiate receptors. It has been 
known for a long time that during chronic morphinization 
39 
there is not only an increase in the dose of morphine required 
to produce analgesia and other central effect (tolerance) but 
there is also a dramatic decrease in the amount of antagonist 
required to produce precipitated withdrawal. Thus it is 
attractive to postulate that these changes result from alter-
ations in the receptor which increase its affinity for antag-
onists and reduce its affinity for agonists (Simon, 1976). 
To date experiments in several laboratories have failed to 
provide direct evidence for either a qualitative or quantita-
tive change in opiate receptors during chronic treatment of 
animals with opiates. Klee and Streaty (1974) reported that 
the binding of 3H-dihydromorphine to particulate fractions 
derived from the brains of controls and morphine dependent 
rats is identical with respect to both number of sites and 
binding affinity. The displacement of bound dihydromorphine 
by either morphine or naloxone is unchanged in brain frac-
tions from dependent rats (Klee and Streaty, 1974). The 
latter results provides evidence against a significant in-
crease in the affinity of antagonist. Similar negative re-
sults have been obtained by Hitzeman et al. (1974) and Pert 
et al. (1973). 
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2. The Binding of Non-Narcotic Drugs to the Opiate 
Receptor Site 
a. Butyrophenone Influences and Related Neuroleptics 
The butyrophenones, neuroleptic drug useful in 
the treatment of schizophrenia, were developed as analogues 
of the opiate meperidine (Janssen, 1965). Recently, haloperi-
dol, the prototype of the butyrophenones, was found to bind 
to the opiate receptor and inhibit binding of labeled nalox-
one (Clay and Brougham, 1975). The haloperidol binding is 
+ greatly reduced in the presence of 100 nM Na (Clay and 
Brougham, 1975), and this finding is consistent with the data 
reported for other opiate agonists (Pert and Snyder, 1974). 
However, the affinity of haloperidol for the opiate receptor 
is markedly different from that of morphine. Clay and Brougham 
(1975) found that the concentration of morphine required t o 
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reduce the stereospecific binding of 8 nM [ H]-naloxone by 50 
percent was 12 nM while the concentration of haloperidol 
needed to achieve the same effect was 880 nM. Although both 
morphine and haloperidol are bound in a competitive manner to 
the opiate receptor, there is some indication that haloperi-
dol may be bound in a different manner than morphine. This 
indication is provided by an analysis of the log-probit plots 
for the binding affinity of these drugs. Morphine has a pro-
file that parallels that of a large number of opiate agonist 
and antagonists (Clay and Brougham, 1975; Pert and Sny der, 
1973). Haloperidol appears to have a binding profile differ-
ing from that reported for morphine o r other opiate agonist 
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and antagonists (Clay and Brougham, 1975). These results have 
been confirmed by Creese et al. (1976) who have also shown 
that several other butyrophenones also display substantial 
potency as inhibitors of 3H naloxone binding. They have found 
benperidol and pimozide to be almost as potent as the opiate 
fentanyl in inhibiting 3H-naloxone binding in the presence of 
sodium. The potency of these two drugs is decreased very 
little in the presence of sodium, suggesting that these phar-
macological actions may resemble those of opiate antagonist 
(Pert et al., 1973; Pert and Snyder, 1974). On the other 
hand, spiperone was found to lose a great deal of potency in 
the presence of sodium, consistent with opiate agonist activ-
ity. The other butyrophenones tested by Creese et al. (1976) 
respond to sodium in a fashion resembling that of mixed 
agonist-antagonists. 
The results achieved by Creese et al. (19 76) for pimo-
zide differ from those of Clay and Brougham (1975) who found 
pimozide to have no effect on opiate binding. Other studies 
have also shown pimozide to have no significant effect on 
the specific binding of the tritiated opiate antagonist, 
naloxone (Charalampous and Askew, 1974). Phenothiazine also 
have influences on the opiate receptor. Creese et al. (1976), 
have fo.und that a number of the phenothi az i ne neuroleptics 
also inhibit 3H-naloxone binding. Of the phenothiazines 
tested, thioridazine was the most potent wi th promethazine 
(a non-neuroleptic phenothiazine) and chlorpromazine being 
somewhat weaker. Fluphenazine, one of the most potent 
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neuroleptic phenothiazines, is one of the weakest in its in-
fluence on the opiate receptor binding of 3H-naloxone (Creese 
et al., 1976). However, other investigators have found 
chlorpromazine to not affect opiate binding at concentrations 
up to 10- 3 M (Clay and Brougham, 1975). Sodium decreases 
the potency of thioridozine by 1.5 fold, consistent with an 
opiate antagonist profile, while the sodium ratio for the 
other phenothiazines resemble opiate mixed agonist-antagonists 
(Creese et al., 1976). In light of the fact that these drugs 
have a very low affinity for the opiate receptor, this sug-
gests that the sodium influences for these drugs do not have 
major pharmacological relevance. 
b. Adrenergic Agents 
Phenoxybenzamine, an alpha receptor antagonist, 
has been found to have no significant effect on the binding 
of naloxone (Charalampous and Askew, 1974). However, the 
beta adrenergic receptor antagonist, propanolol and the 
beta adrenergic agonist, isoproterenol, were found to sig-
nificantly reduce the binding of naloxone to the opiate re-
ceptor (Charalampous and Askew, 1974). The inhibition of 
binding by propanolol was reconfirmed by in vivo administra-
tion of propanolol. Sodium was found not to affect binding 
of the beta antagonist and agonist as with specific opiate 
antagonists and agonists (Charalampous and Askew, 1974). 
c. Cholinergic Agents 
Atropine, a muscarinic cholinergic receptor an-
tagonist, was found to not significantly affect specific 
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binding of the triated opiate antagonist, naloxone (Charalam-
pous and Askew, 1974; Pert and Snyder, 1973). 
E. A Comparison of Narcotic Analgesics with Neuroleptics 
Narcotic analgesics bear certain behavioral and bio-
chemical similarities to neuroleptic drugs. 
1. Behavioral Similarities 
a. Acute Actions 
(1) Catalepsy 
Catalepsy is a state of behavioral immo-
bility accompanied by either muscular hypotonia as with neuro-
leptics, or by muscle rigidity as with narcotics. Both, halo-
peridol and morphine, cause catalepsy in zoost animal species 
and in human subjects, with the Eo50 in rats, 1.5 and 20 umol/ 
kg, respectively (Lal et al., 1975). The catalepsy induced 
either by haloperidol or by morphine has been effectively 
counteracted by apomorphine as benztropine (Lal et al., 1975). 
B-Endorphin, an endogenous peptide with morphine-like bio-
logical properties, has been found to also produce catalepsy 
when injected into the periaqueductal gray (Jacquet and 
Marks, 1976) and the cerebrospinal fluid (Bloom et al., 1976). 
(2) Jumping 
Dihydroxyphenylalanine (L-DOPA) injected 
in mice pretreated with amphetamine reliably elicits upward 
jumping (Lal, et al., 1975a). Haloperidol, pimozide, chlor-
promazine, thionidazine and clozapine block the mouse jump-
ing (Colpaer et al., 1975) suggesting that jumping behavior 
is a measure of dopaminergic stimulation. Morphine also 
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blocks mouse jumping in a dose related manner (Lal et al., 
1975a). Dexitimide, a centrally acting anticholinergic drug, 
reversed the pimozide induced blockade of jumping (Van Neuten, 
1962) without reversing the morphine induced blockade (Lal 
et al., 1975), suggesting that the narcotics block dopamine 
receptors but through a different brain site which does not 
involve a doparninergic cholinergic interaction (Lal et al., 
1975). 
(3) Stereotypy 
Drugs which directly or indirectly stimu-
late dopamine receptors cause stereotypy in rats. Morphine, 
methadone and demerol are potent antagonists of apomorphine 
and amphetamine in the stereotypy test. Amphetamine and apo-
morphine induced stereotypies are also antagonized by neuro-
leptic drugs (Lal et al., 1975). 
(4) Vomiting 
The narcotic drugs, morphine, methadone 
and demerol are potent antagonist of apomorphine induced 
vomiting in dogs (Lal et al., 1975). Neuroleptics also show 
marked activity in antagonizing apomorphine induced vomiting 
(Lal et al . , 19 7 5) • 
( 5) Aggression 
Aggression can be elicited in laboratory 
animals by a variety of treatments. Apomorphine produces 
aggression in a dose dependent manner and both haloperidol 
and morphine effectively block this aggression (Lal et al., 
1975). Additionally, haloperidol and morphine effectively 
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block the aggression elicited by amphetamine and L-DOPA treat-
ment (Lal et al., 1975). Electric shock delivered to the paw 
is known to elicit aggression in paired rats. Haloperidol 
and morphine block shock induced aggression in a dose-depend-
ent manner ·:(Lal et al., 1975). Withdrawal from narcotic drugs 
produces marked irritability and aggression (Lal, 1975). This 
withdrawal aggression is blocked by narcotics and neurolep-
tics in relatively low doses (Puri and Lal, 1973). 
(6) Neuroleptanalgesia 
Various combinations of narcotic analgesics 
and butyrophenones have been employed for neuroleptanalgesia 
as a total or partial alternative to surgical anesthesia (De 
Castro and Mundeleer, 1959; Nilson and Janssen, 1961; Deligene, 
1961; Edmonds-Seal and Prys-Roberts, 1970; Lewis and Jennings, 
1972). The term neuroleptanalgesia implies the use of a 
butyrophenone in combination with a short-acting, potent anal-
gesic (Edmonds-Seal and Prys-Roberts, 1970). Of the buty-
rophenones available those commonly used in neuroleptanalgesia 
are haloperidol and droperidol. The analgesics commonly used 
in neuroleptanalgesia are dextromorarnide (Palfiurn), pheno-
peridine (Operidine) and fentanyl (Sublimaze) in order of in-
creasing potency and decreasing duration of action (Edrnonds-
Seal and Prys-Roberts, 1970). 
The effects of mixtures of neuroleptics and analgesic 
drugs may be predicted from a knowledge of the pharmacology 
of the constituents. The pharmacology of the mixture of 
fentanyl citrate and droperidol (Innovan) will be examined 
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since it is the most common of the neuroleptanalgesics. Drop-
eridol is a butyrophenone type neuroleptic which produces 
sedation, tranquilization, adrenergic blockade and vasodila-
tion (Janssen et al., 1963; Yelnosky et al., 1964), whereas 
studies on the pharmacology of fentanyl citrate alone indicate 
its principal actions are analgesia, central nervrussystem 
depression, respiratory depression and bradycardia (Janssen, 
1962; Gardocki and Yelnosky, 1964). Each compound in the 
mixture exerts its own pharmacologic action without any well-
defined antagonistic or potentiating interactions with one 
exception. Droperidol enhances the analgesic activity of 
fentanyl citrate (Yelnosky and Gardocki, 1964). Since droper-
idol appears to be devoid of analgesic activity, the enhance-
ment of the analgesic action of fentanyl citrate is the re-
sult of a potentiating effect of droperidol, not an additive 
effect. The mechanism of potentiation is not known; however, 
it is doubtful that it is due to inference by droperidol 
with the catabolism of fentanyl citrate since the duration 
of analgesic action of the combination was no greater than 
that of fentanyl alone (Yelnosky and Gardocki, 1964). Other 
investigators have found no potentiation of the analgesic 
effect of fentanyl by droperidol (Corssen, Domino and Sweet, 
1964; Prys-Roberts and Kelnan, 1967). The neuroleptics do not 
appear to augment the ventilatory depressant effects of the 
analgesics (Corssen, Domino and Sweet, 1964; Yelnosky and 
Gardocki, 1964; Prys-Roberts and Kelman, 1967; Harper et al., 
1976). Nausea and vomiting have been found after the 
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administration of fentanyl (Harper et al., 1976). This is 
hardly surprising since this result occurs with most narcotics. 
However, the concomitant administration of droperidol reduced 
the incidence of nausea and vomiting (Harper et al., 1976). 
Fentanyl produces minimal circulatory changes as evidenced by 
the lack of orthostatic hypotension (Harper et al., 1976). 
This is in contrast to the combination of fentanyl plus dro-
peridol which appears to predispose some patients to ortho-
static hypotension (Harper et al., 1976). The hyperthermia 
normally seen after morphine administration in cats has been 
reported to be markedly potentiated by pimozide, a specific 
dopamine receptor blocker (French et al., 1976). 
In the state of neuroleptanalgesia the patient appears 
calm, detached from his surroundings and immobile. The face 
is without expression and the closed eyes give an impression 
of sleep, though the patient will respond immediately to 
quiet command (Hayward-Butt, 1957; Edmonds-Seal and Prys-
Roberts, 1970). The degree of analgesia is dose-dependent 
but limited by ventilatory depression although sufficient 
analgesia can be obtained with spontaneous vent i lation for 
minor surgery (Edmonds-Seal and Prys-Roberts, 1970). 
Neuroleptana lgesia has been mainly employed in minor 
surgical procedures, as an adjunct to local analgesics, as 
preanesthesia medication and in combination with light gener-
al anesthesia. Minor surgical procedures such as insertion 
of eyelid sutures, nerve blocking injections and dressing of 
burns have been performed under neuroleptanalgesia 
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(Edmonds-Seal and Prys-Roberts, 1970). Neuroleptanalgesia 
combinations have been found useful for supplementing local 
analgesic techniques such as retie-ocular block (Cameron, 
1967), endobronchial intubation (Coppen and Fox, 1968), and 
bronchoscopy procedures (Berenyi et al., 1966). Neurolepti-
analgesia is widely used as a preanesthetic medication. 
Fentanyl plus droperidol has been found to produce better 
pre-operative sedation than morphine, together with signifi-
cantly less post-operative nausea and vomiting (Norris and 
Telfer, 1968). The concept of combining neuroleptanalgesics 
with light general anesthesia has been employed for a number 
' 
of years. A mixture of fentanyl citrate and droperidol has 
been used successfully with nitrous oxide for general anes-
thesia in man (Holderness et al., 1963). In the field of 
cardiovascular surgery, the use of neuroleptanalgesic com-
bination during cardiopulmonary bypass has supplanted the 
use of volatile anesthetic agents which are known to depress 
myocardial function (Corssen et al., 1965). 
The combination of fentanyl plus droperidol has also 
been used with remarkable success in dogs (Yelnosky and 
William, 1964), guinea pigs (Lewis and Jennings, 1972), rats 
(Jones and Simmons, 1968; Garcia et al., 1975), mice (Lewis 
and Jennings, 1972), parakeets (Yelnosky and William, 1964), 
and rabbits (Lewis and Jennings, 1972) to produce analgesia, 
anesthesia, sediation and tranquilization for surgery. 
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b. Chronic Actions 
(1) Tolerance to Cataleptic Action 
Rats made tolerant to the effects of mor-
phine by chronic treatment show tolerance to the catalepsy-
inducing action of both morphine and haloperidol {Lal et al., 
1975). However, rats chronically treated with haloperidol 
show no tolerance to either morphine or haloperidol {Lal et 
al., 1975). 
(2) Withdrawal Signs 
Withdrawal from chronic morphine produces 
wet-dog-like body shakes, ptosis, weight loss, hyperactivity 
and aggression {Lal, 1975). Rats withdrawn from chronic halo-
peridol exhibit body shakes and increased locomotor activity 
{Lal et al., 1975). In both cases, the aggression eliciting 
effects of apomorphine are markedly increased. However, ad-
ministration of amphetamine to morphine-withdrawn rats elic-
its intense aggression {Lal et al., 1971) but fails to 
elicit aggression in haloperidol withdrawn rats {Lal et al., 
1975). 
2. Biochemical Similarities 
a. Acute Actions 
(1) Striatal Dopamine 
Steady state concentrations of dopamine in 
the rat striaturn have been found not to change after the in-
jection of morphine sulfate or haloperidol. However, both 
morphine and haloperidol increase the rate of dopamine de-
pletion after inhibition of its synthesis by alpha methyl-
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paratyrosine (Lal et al., 1976). In the absence of changes 
in dopamine steady state levels, an alteration in the deple-
tion rates of neurotransmitter can be considered as a measure 
of changes in the turnover rate of that transmitter (Co s ta 
and Neff, 1966). Both morphine and haloperidol produce a 
dose-dependent increase in striatal dopamine turnover, with 
haloperidol showing considerable more potency (Lal et al., 
1976). The fact that both of these drugs produce increases 
in striatal dopamine turnover is indicated by the fact that 
they also increase striatal homovanillic acid, a dopamine 
metabolite (Lal et al., 1976). Naloxone block the action 
of morphine on striatal dopamine turnover; however, it did 
not affect the similar action of haloperidol. 
The effects of morphine and haloperidol in causing 
stimulation of dopamine turnover coincides with their effect 
on catalepsy. Both morphine and haloperidol produce a dose-
related catalepsy (Lal et al., 1975), with the cataleptic ac-
tion of morphine being readily reversed by naloxone; however, 
naloxone treatment was ineffective in haloperidol catalepsy 
(Wauquier et al., 1974). 
An important interaction between haloperidol and mor-
phine in producing an elevation of dopamine turnover was 
noted when a subthreshold dose of haloperidol was combined 
with the ED 50 dose of morphine . The subthreshold dose of 
haloperidol caused a significant increase in the effect of 
morphine so that the morphine ED50 produce d as great an ef-
fect as was produced by the maximally-effective dose of 
morphine and haloperidol were combined there was an increase 
in striatal dopamine turnover equivalent to that which was 
obtained by haloperidol alone (Lal, et al., 1976). 
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Apomorphine is known to directly stimulate dopamine 
receptors (Anden et al., 1967, Ernst, 1967; Costall and Naylor, 
1973) and thereby reduce dopamine turnover. Lal et al., 
(1976) reasoned that if the actions of morphine and haloperi-
dol involved blockade of dopamine receptors, then apomorphine 
might reverse the actions of both drugs by stimulating the 
same receptor. Similarly, it has been known for some time 
that anticholinergic type anti-Parkinsonian drugs interact 
with dopamine containing neurons in the central nervous sys-
tem and thereby alter the activity of neuroleptics. There-
fore, if certain actions of morphine overlap with those of 
haloperidol then benztropine may interact with both drugs 
in a similar manner. Treatment with morphine or haloperidol 
produces a significant increase in striatal dopamine turn-
over while apomorphine or 
over (Lal, et al., 1975). 
benztropine reduce dopamine turn-
Apomorphine on benztropine re-
versed the elevation of dopamine turnover elicited by an 
injection of morphine or haloperidol (Lal et al., 1976). A 
similar interaction was also observed for catalepsy. While 
neither apomorphine or benztropine cause catalepsy on their 
own, either drug effectively antagonized the catalepsy in-
duced by haloperidol or morphine (Lal, et al., 1976). 
The haloperidol-induced elevation of striatal dopa-
mine turnover is markedly diminished after lesioning of the 
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nigrostriatal tract at the level of the lateral hypothalamus 
(Anden et al., 1973). For purposes of comparison the nigro-
striatal tract was lesioned before the administration of mor-
phine sulfate. Unilateral lesions of the nigrostriatal tract 
increased the dopamine content of the striaturn (Hynes et al., 
1975; Lal, et al., 1976). Following lesioning morphine still 
elevated dopamine turnover but the magnitude of this eleva-
tion was smaller than that on the intact side (Lal, et al., 
1976). The effect of morphine on striatal dopamine turnover 
was completely eliminated by bilateral lesioning of the nigro-
striatal tract (Lal et al., 1976). 
(2) Adenylate Cyclase and Phosphodiesterase 
Earlier studies have suggested that many 
actions of the catecholamines may be mediated by cyclic AMP 
(Greengard and Kebabian, 1974). An adenylate cyclase acti-
vated by low concentrations of dopamine have been found in 
homogenates of rat cuadate nucleus. This enzyme is stimulated 
by dopamine and 1-norepinephrine and in the presence of op-
timal amounts of either dopamine or norepinephrine no further 
increase in adenylate cyclase activity can be obtained by 
the addition of the other catecholamine (Krugger et al., 1975). 
Like dopamine and norepinephrine, morphine sulfate added to 
the homogenate of the rat striaturn also increased the forma-
tion of cyclic AMP (Lal et al., 1975; Puri et al., 1975). How-
ever, the m::>rphine stimulation of adenylate cyclase was not 
antagonized by naloxone. The maximal stimulation of adenyl-
ate cyclase by either morphine or dopamine was about the same 
(Puri et al., 1975). When submaximally effective concentra-
tions of dopamine were combined with morphine, there was an 
additive effect. However, in the presence of an optimal 
concentration of either dopamine or morphine, no further in-
crease in adenylate cyclase activity could be obtained by 
the addition of the other agent (Lal et al., 1976). 
The effect of morphine on striatal phosphodiesterase 
activity in crude striatal homogenates has also been mea-
sured. The in vitro addition of morphine inhibited phospho-
diesterase activity only when the highest concentrations of 
C AMP were employed. Similarly, the in vivo administration 
of morphine also inhibited phosphodiesterase activity when 
the three highest C AMP concentrations were employed as sub-
strate (Lal, et al., 1976). 
b. Chronic Actions 
(1) Striatal Dopamine 
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Unlike its effects in naive rats an acute 
injection of morphine failed to produce an increase in the 
striatal dopamine turnover in morphine-dependent rats. In 
these morphine dependent rats, dopamine turnover was marked-
ly lower in response to an acute morphine injection than the 
turnover rate obtained in naive or chronically haloperidol 
treated rats in response to morphine administration. Simi-
larly, an acute dose of haloperidol, which increased stri-
atal dopamine turnover in naive and chronically haloperidol 
treated rats was only marginally effective in morphine de-
pendent rats (Lal, et al., 1976). 
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It has been previously demonstrated that supersensi-
bility develops to the aggression-eliciting effects of apo-
morphine in rats withdrawn from chronic morphine or haloperi-
dol (Puri and Lal, 1973; Gianutsos et al., 1974; Lal et al., 
1975). After chronic morphine administration supersensitiv-
ity also develops to apomorphine's effect on striatal 
dopamine turnover (Lal, et al., 1976). Doses of apomorphine 
which were previously ineffective in naive rats cause a 
marked inhibition of striatal dopamine turnover in rats with-
drawn from chronic morphine or haloperidol. 
(2) Adenylate Cyclase Activity 
The relationship between opiates and the 
cyclic AMP-adenylate cyclase system has been examined in a 
number of ways. Peripheral administration of cyclic AMP an-
tagonized morphine analgesia and increased withdrawal signs 
in morphine-tolerant animals (Ho et al., 1972; 1973). The 
injection of cyclic AMP into the lateral ventricles of rats 
also increased withdrawal signs in tolerant animals (Collier 
and Francis, 1975). 
An acute injection of morphine (60 mg/kg) has been 
found to produce significant increases in cyclic AMP levels 
in midbrain, cerebellum, striatum and cortex 15 to 30 minutes 
after the injection (Clouet and Iwatsubo, 1976). While in 
the hypothalamus, medulla and cerebellum, the levels of 
cyclic AMP were significantly lower than control values two 
hours after the injection of morphine (Clouet, et al., 1975). 
In morphine tolerant rats sacrificed two hours after the last 
twice-daily injections for 10 days, the levels of cyclic AMP 
were at control levels or higher, indicating that tolerance 
to the decreased cyclic AMP had developed (Clouet et al., 
1975). 
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Adenylat e cyclase activity was increased in midbrain 
and striatum one hour after the injection of 60 mg/kg mor-
phine or 15 mg/kg levorphonal, but not after 15 mg/kg dextror-
phan (Clouet and Iwatsubo, 1976). The enzyme activity was, 
however, decreased by narcotic agonists in the cerebellum. 
In tolerant animals, cerebellar adenylate cyclase activity in-
creased by a morphine challenge, as it was in midbrain and 
cortex, again indicating a tolerance in cerebellar cyclase 
(Clouet et al., 1975). 
Dopamine-sensitive adenylate cyclase activity in 
shocked preparations of striatal synaptosomes was found to 
increase after acute morphine treatment above control dopa-
mine-stimulation (Clouet and Iwatsubo, 1976). Although the 
basal cyclase activity was found to increase above control 
levels from 15 to 60 minutes after morphine injection, the 
absolute stimulation by 100 JIM dopamine was significantly 
higher at 30 minutes to 2 hours after the injection of the 
opiate than stimulation by dopamine in preparations from 
untreated rats. The percent stimulation by dopamine was 
similar at each time point after acute morphine treatment 
(Iwatsubo and Clouet, 1975). The basal adenylate cyclase 
activity in striatal nerve endings was unchanged after rats 
were made tolerant by morphine pellet implantation. However, 
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when rats were made dependent by increasing doses of morphine 
a significant increase in the basal levels of adenylate cy-
clase was observed. The increase was seen from 1 to 72 hours 
after the last injection of 100rphine and was therefore not 
related to the acute effects of morphine. The elevated levels 
of adenylate cyclase activity could not be further stimulated 
by in vitro addition of dopamine {Lal et al., 1976). 
3. Endocrinological Similarities 
a. Adrenocorticotropin Hormone 
Current evidence indicates that adrenocortico-
tropin {ACTH) is under dual hypothalamic control {Fortier, 
1966) and neurochemical findings have in addition led to the 
proposal of adrenergic-inhibitory and cholinergic-stimulatory 
regulation of ACTH secretion {Ganong, 1972; de Wied and de Jong, 
1974, Marks et al., 1970). In considering the effects of nar-
cotics on pituitary function, it must be determined if mor-
phine interferes with the basal secretion of ACTH, the release 
of ACTH in response to stress and the circadian rhythm of 
ACTH secretion. 
Acute morphine administration in rats stimulates ACTH 
secretion {Briggs and Munson, 1955; George and Way, 1955; 
Nikidijevic and Maickel, 1967). Using the depletion of adren-
al ascorbic acid as a measure of ACTH release it has been re-
ported that a single injection of morphine enhances the 
secretion of ACTH in the unanesthetized rat {George and Way, 
1955; Nasmyth, 1954; Van Peenen and Way, 1957; Briggs and 
Munson, 1955; Nikodijevic and Maichel, 1967; Lotti et al., 
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1969). Similar findings have been reported following acute 
administration of (+) and (-) methadone (George and Way, 1955). 
Preadministration of nalorphine in small doses inhibits the 
adrenal ascorbic acid depletion effect of both morphine 
(George and Way, 1955; Burdette et al., 1961) and the isomers 
of methadone (George and Way, 1955). The effects of morphine 
on ACTH are also completely blocked by naloxone (Kakka and 
George, 1974). These results suggest that the ACTH releasing 
effects of these drugs are mediated via specific neural path-
ways and/or narcotic receptors. This ascorbic acid depleting 
effect of morphine and methadone is dependent upon an intact 
pituitary-adrenal axis since it is abolished by hypophysec-
tomy (George and Way, 1955). 
A more direct measure of pituitary-adrenal activity is 
reflected by changes in the plasma level of corticosteroids. 
The effect of acute morphine administration on adrenal corti-
cal hormone secretion appears to be species dependent (George 
and Lomax, 1972). Several reports have clearly shown that a 
single injection of morphine is capable of elevating plasma 
corticosterone levels in conscious rats (Nikodijevic and 
Maickel, 1967; Lotti et al., 1969; Oliver and Troop, 1963; 
Shusher and Browning, 1961) and plasma 17-hydroxycorticoster-
one levels in dogs (Suzuki et al., 1959). However, this has 
not been confirmed in studies on the guinea pig (Sobel, et 
al., 1958) and man (Eisenman et al., 1958). 
Although the mechanism by which morphine exerts these 
effects is not clear, it is however evident that it is 
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mediated by the central nervous system (George and Lomax, 
1972; Kokka and George, 1974; Zimmermann and Critchlow, 1973). 
The studies of George and Way (1959) in rats with hypothalamic 
lesions that were challenged with morphine and those of Lotti 
et al., (1969) in which rats were injected intrahypothalami-
cally with micro-quantities of morphine, have indicated that 
the integrity of the hypothalamic-pituitary axis is essential 
for these actions of morphine. It was found that hypothalam-
ic lesions, primarily in the anterior medial eminence blocked 
the ascorbic acid depleting effect of morphine. Conversely, 
injections of microgram amounts of morphine into this hypo-
thalamic region reduced adrenal ascorbic acid while elevating 
plasma corticosterone levels. Thus most of the available 
evidence indicates that morphine activation of ACTH secretion 
is mediated via a direct action on the rostral region of the 
hypothalamus and medial eminence (George and Way, 1959; Lotti 
et al., 1969; Zimmermann and Critchlow, 1973), although extra-
hypothalamic sites and peripheral mechanisms can not be ex-
cluded (Kokka and George, 1974). 
The chronic administration of morphine to rats pro-
duces a marked adrenal cortical hypertrophy. This observa-
tion was first made in 1926 by McKay and McKay and has been 
confirmed by others (George and Way, 1959; Tanabe and Cafruny, 
1958; Sloan et al., 1963; Sloan and Eisemann, 1968). Investi-
gations in which different parameters of pituitary-adrenal 
activity were studied seem to indicate an opposite effect, 
for example chronic administration of morphine depresses the 
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basal level of adrenal cortical secretion. The injection of 
morphine into guinea pigs for 12 days was found to reduce 
the basal level of urinary 17-hydroxysteroids (Sobel et al., 
1958). Similar findings have been observed in the rat and in 
man. Paroli and Melchiorri (1961) injected rats for periods 
ranging between 10 to 40 days and 40 to 100 days and noted a 
decrease in the urinary levels of hydroxysteroids. In a 
study on human addicts Eisenmann et al. (1961) found that two-
to-four month cycles of morphine addiction reduced both plasma 
and urinary 17-hydroxycorticosteroid levels. They showed 
that this reduction in the basal secretory rate of adrenal 
cortical hor:rrones was due chiefly to a decrease in the pro-
auction of 17-hydroxycorticosteroid. 
Chronic administration of morphine may also depress 
the pituitary adrenal response to a variety of stresses. In 
rats treated with morphine for a five-day period, the re-
sponse to several stresses was blocked (Munson and Briggs, 
1955). In other investigations on rats injected with mor-
phine for 25 days (Paroli and Melchiorri, 1961) and guinea 
pigs injected for 12 days (Sobel et al., 1958) it was re-
ported that the increase in urinary hydroxysteroids in re-
sponse to cold stress- was inhibited. On the basis of these 
findings it would appear that chronic morphine administra-
tion produces a depression in the basal secretion of adrenal 
cortical hormones and prevents pituitary-adrenal activation 
in response to numerous stresses. However, in a study with 
methadone-treated heroin addicts, Cushman et al. (1970) 
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found no differences in basal plasma 17-hydroxycorticoster-
oid levels of addicts from normal control valves, also chronic 
methadone treatment did not interfere with the metyrapone 
test, which produces an increase in urinary 17-ketogenic ster-
oids,or _to the stress of insulin hypoglycemia, as reflected 
by elevated plasma 17-hydroxycorticosteroid (17-0HCS) levels. 
The normal diurnal pattern of 17-0HCS also may be al-
tered by the chronic administration of morphine and methadone. 
Eisenmann et al. (1961) found that morphine interfered with 
the early morning rise of plasma 17-0HCS; they also noted the 
presence of a mid-day increase of plasma 17-0HCS during the 
period of morphine administration. The results of Cushman 
et al. (1970) in general, corroborate these findings. They 
were able to show that chronic methadone treatment in a group 
of 16 heroin addi cts altered the normal diurnal variations of 
plasma 17-0HCS in 10 of the 16 subjects. 
In both the rat and man, abrupt withdrawal of morphine 
res ulted in increased adrenal cortical activity (George and 
Lomax, 1972). Rats given morphine chronically and then 
abruptly withdrawn from the drug or administered nalorphine 
show an increase in levels of urinary 17-0HCS, 17-ketosteroids 
and aldosterone (Paroli and Melchiorri, 1961). In man, also, 
the abrupt withdrawal of morphine produces a marked increase 
in plasma and urinary 17-0HCS and an elevation in urinary 17-
ketosteroids (Eisenmann et al., 19 61) . The maximal rlse in 
adrenal cortical levels correlates well with the peak physic-
logical effects of the abstinence syndrome, approximately 48 
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hours after withdrawal. 
Although there are numerous reports regarding the ef-
feet of chlorpromazine on pituitary adrenal function, it is 
not clear whether chlorpromazine stimulates or inhibits ACTH 
secretion. The discrepancies could arise from a number of 
factors, the dose of chlorpromazine, the time chlorpromazine 
was administered prior to stress challenge, the cor e temper-
ature of the stressed animal and the parameter of pituitary 
adrenal activation employed. 
In general, numerous studies in rats have indicated 
that small doses of chlorpromazine do not alter adrenal as-
corbic levels to an appreciable degree, larger doses deplete 
ascorbic acid {de Wied, 1967; George and Lomax, 1972). Both 
small and large doses of chlorpromazine have been reported 
to have no effect; a partial blocking effect, or complete 
blocking effect on the ascorbic acid depletion response to 
several types of stress {de Wied, 1967; George and Lomax, 
1972). Marks et al. {1970) have shown that a single injec-
tion of chlorpromazine {25 mg/kg) was capable of lowering 
hypothalamic corticotropin-releasing factor, while simultane-
ously elevating plasma corticosterone levels. When the 
corticotropin-releasing factor content of the ventral hypo-
thalamus returned to control levels it was found to be closely 
related to the return to normal adrenal corticosterone levels. 
Marks et al. {1970) interpret the blockade of stresses fol-
lowing chlorpromazine-administration as being due to the 
possibility that corticotropin-releasing factor secretion has 
become maximal, which is the result of removal of inhibitory 
neural influences by chlorpromazine. 
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The results obtained from other species are more con-
sistent. Using plasma 17-0HCS as an index of pituitary 
adrenal activity, it has been shown that chlorpromazine in-
creases ACTH secretions in the guinea pig (Sasaki, 1963) dog 
(Egdahl and Richards, 1956; Betz and Ganong, 1963) and monkey 
(Harwood and Maon, 1957). This effect of chlorpromazine is 
abolished by hypophysectomy (Egdahl and Richards, 1956), 
thereby placing the site of action at the pituitary or hypo-
thalamus. 
Chronic administration of chlorpromazine like morphine 
produces adrenal cortical hypertrophy, but, unlike morphine, 
does not consistently prevent adrenal activation in response 
to stress (de Wied, 1967). In patients treated with chlor-
promazine, the ACTH response to the stresses of insulin 
(Christy et al., 1957) and typhoid vaccine (Fotherby et al., 
1959) is inhibited. 
b. Antidiuretic Hormone 
It is well established that morphine and its 
surrogates produce an antidiuretic effect in certain animals 
(Fujimoto, 1971; Hayward, 1974). The bulk of evidence 
(Fujimoto, 1971; Hayward, 1974) favors the concept first pro-
posed by de Bodo (1944) that the antidiuretic effect of 
morphine in the dog is due to release of antidiuretic hormone. 
However, many of the studies on the antidiuretic effect of 
morphine are contradictory, depending on the species and 
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dosage employed, route of administration, presence or absence 
of anesthetic agents, and the development of tolerance. Stu-
dies showing convincing antidiuretic hormone release by mor-
phine were performed in the dog (Fujimoto, 1971; de Bodo, 
1944; Duke et al. 1951; Handley and Keller, 1950), rat (George 
and Way, 1959) and monkey (Hayward, 1974) but studies in man 
show either a primary change in renal hemodynamics (Papper 
and Papper, 1964; Habif et al., 1951) or a diuretic effect 
(Fujimoto, 1971). 
Neuroleptics have been found to induce antidiuretic as 
well as diuretic effects, and their action on antidiuretic 
hormone release are not clear (Gaunt et al., 1963; de Wied, 
1967). 
A dose response relationship has been reported for the 
antidiuretic action of chlorpromazine (Meier et al., 1955; 
Supek et al., 1960). In addition, in rats anesthetized with 
alcohol a very low dose of chlorpromazine elicited a marked 
antidiuresis while in rats with diabetes insipidus the anti-
diuretic effect of chlorpromazine was no longer demonstrable. 
This observation suggests that the antidiuretic effect of 
chlorpromazine is due to increased release of antidiuretic 
hormone (de Wied, 1967). High doses of chlorpromazine given 
over a several-day period may depress synthesis of anti-
di uretic hormone (de Wied, 1967) and in lower dose levels may 
inhibit antidiuretic hormone release in response to hyper-
tonic salt loading or to painful stimuli (Shibusawa et al., 
1955; de Wied and Jinks, 1958). 
c. Gonadotropins 
Morphine administration has been shown to ef-
fect the secretion of gonadotropins (George and Lomax, 1972; 
Barraclough and Sawyer, 1955). One of the earlier sugges-
tions that morphine can alter pituitary gonadotropic hormone 
secretion was from a survey in which it was found that human 
female addicts exhibited decreased libido, amenor.theaand 
sterility during a period of morphine addiction. In many of 
these cases, even though the menstrual cycles returned to 
normal after withdrawal from the drug, sterility persisted 
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(Menninger-Lerchenthal, 1934). Barraclough and Sawyer (1955) 
found that administration of morphine between 12 and 2 P.M. 
on the day of proestrus in rats prevents ovulation. Chroni-
cally injected morphine daily between 12 and 2 P.M. inhibits 
ovulation for a considerable period of time. Tolerance to 
the drug results in the recurrence of ovulation, although 
cycles remain irregular. The site of the morphine effect is 
near the medial eminence. Electrical stimulation in the 
medial eminence, but not in the posterior tuberal region, 
overcomes the morphine blockade of ovulation (Sawyer, 1963). 
Addicts have irregular menstrual cycles and decreased gonad-
otropin secretion as reflected by a diminished urinay ex-
cretion of 17-ketosteroids, while the response to exogenous 
gonadotropins is enhanced (Eisenmann et al., 1958; Hollister, 
1973; Stoffer, 1968). Chronic administration of morphine to 
male rats has been shown to produce atrophic changes in 
their seminal vesicles and prostates (George and Lomax, 1972). 
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Although these data are indicative of a luteinizing hormone 
suppressing effect of morphine, there is also some evidence 
in favor of a follicle-stimulating hormone inhibiting action 
of morphine. Rennels (1961 ) found that two weeks of morphine 
administration produced changes in pituitary cytology and 
gonadotropin content which were indicative of follicle-
stimulation hormone suppression and without effect on lu-
teinizing hormone secretion. In summary, it is apparent that 
morphine administration, either acute or chronic, inhi bits 
gonadotropin secretion. Although there is evidence for a 
morphine inhibitory effect on both follicle-stimulating hor-
mone and luteinizing hormone secretion, most of the evidence 
points to an interference with luteinizing hormone release 
{George, 1971; George and Lomax, 1972; de Wied et al., 1974). 
The endocrine system most uniformly affected by the 
-
phenot.~iazines is the pituitary-gonad axis. Numerous investi-
gations in a variety of species have shown that either acute 
or chronic administration of phenothiazines inhibits secre-
tion of pituitary follicle-stimulating hormone and luteiniz-
ing hormone. Phenothiazines have produced some of the follow-
ing effects which are indirect indices of depression of 
follicle-stimulating hormone and luteinizing hormone secretion: 
failure of ovulation, delayed sexual maturation, reduction in 
weight of ovaries, uteri and vaginae, reduction in size of 
sex organs in the male, and inhibition of compensatory ovari-
an hypertrophy {de Wied, 1967). 
While most of the evidence points to an inhibitory 
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effect of chlorpromazine on hypothalamic pituitary function, 
there are data that suggest the possibility of a blocking ac-
tion of chlorpromazine at the target gland. In large doses 
chlorpromazine has been found to block the action of gonado-
tropins on target glands in both sexes (Meidinger, 1954; 
Zarrow and Brown-Grant, 1964). However, data contrary to 
these findings raise doubts regarding the target gland as 
the site of chlorpromazine action (de Wied, 1967; de Wied and 
de Jong, 1974). 
The results reported from animal studies have also been 
observed in the human female. Chlorpromazine administered one 
to three days prior to ovulation delays menstruation for a 
period of 8 to 16 days (Wheklaw, 1956). Also, many reports 
show that chlorpromazine treatment may produce menstrual ir-
regularities and amenonhea (de Wied, 1967). Butyrophenone 
type neuroleptics have many of the same endocrine effects as 
the phenothiazines (Byck, 1975). 
d. Growth Hormone 
Morphine and methadone have been found to dose 
dependently elevate plasma concentrations of growth hormone 
(Howard and Martin, 1971; Wakaboyaski et al., 1971; Kokka 
et al., 1972; 1973; Kokka and George, 1974). Nalorphine, 
which has many of the agonist properties of morphine, also 
produced increases in plasma concentrations of growth hormone 
(Kokka and George, 1974). Naloxone, a pure antagonist, was 
without effect on growth hormone. The morphine increase in 
plasma growth hormone was not blocked by naloxone (Kokka and 
George, 1974). Chronic morphine administration does not re-
sult in tolerance to its effects on growth hormone (Kokka et 
al., 1973; Kokka and George, 1974). Bilateral electrolytic 
lesions of the ventromedial nucleus did not affect morphine-
induced stimulation of growth hormone secretion. These re-
sults suggest that morphine stimulation of growth hormone 
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secretion may be due to a direct effect on the anterior pitui-
tary, but it is also possible that morphine acts at the level 
of the median eminence to inhibit release of growth hormone-
inhibiting factor (Kokka and George, 1974). 
The secretion of growth hormone is under the control 
of sornatotropin release-inhibiting hormone (Brazeau et al., 
1973) and growth hormone releasing hormone (Deuben and 
Meites, 1964). The influence of dopaminergic neurons on 
growth hormone release is unclear. Pimozide, a dopamine re-
ceptor blocker, elevates plasma growth hormone in rats 
(Mue.lih.ex et .al.,1973). While plasma growth hormone in rats 
is dramatically reduced by haloperidol, with a dose of 0.3 
mg/kg causing levels to fall below 20 percent of control 
values (Muller et al., 1976). Haloperidol also blocked the 
apomorphine-induced stimulation of growth hormone secretion 
(Mueller et al., 1976). Chlorprornazine has also been found 
to inhibit secretion of growth hormone (Byck, 1975) and to 
block the L-DOPA-induced stimulation of growth hormone in 
man (Mims et al., 1975). Chronic chlorprornazine administra-
tion has been reported to have no effect on body growth in 
rats (Meidinger, 1954) or to inhibit growth in mice (Cranston 
and Segal, 1958). 
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e. Prolactin 
Prolactin is a hormone produced by the anterior 
lobe of the pituitary gland. It is capable of initiating 
and sustaining lactation, but only when other essential hor-
mones such as estrogen, progesterone and oxytocin are pre-
sent. The effect of morphine and related compounds on pro-
lactin release has not been studied extensively. Several 
years ago, Meites (1966) reported that acute administration 
of morphine stimulates lactation in the rat, indicating an 
increase in the discharge of prolactin. Recently, increased 
circulating levels of prolactin have been observed in rats 
following systemic (Zimmermann et al., 1974) or intraven-
tricular (Mccann et al., 1974) administration of morphine. 
The effects of neuroleptics on prolactin levels have 
been more extensively studied. The administration of tran-
quilizers to some patients has long been known to cause 
breast enlargement and galactorrhea (MacLeod, 1976). Pheno-
thiazine derivatives, especially perphenazine, have long 
been known to induce mammary development and initiate milk 
secretion in many species. Injection of perphenazine causes 
a prompt increase in serum prolactin levels (Ben-David et 
al., 1970); Lu et al., 1970; MacLeod and Lehmeyer, 1974) 
and increases synthesis of the hor mone (MacLeod and Lehmeyer, 
1972). Dickerman et al. (1972) showed that as little as 
10 ug haloperidol per 100 grams body weight increased serum 
prolactin levels. Th e inhibition produced by dopamine of 
the in vitro secretion of both 3H-prolactin and of radio-
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imrnunoassayable prolactin was reversed by coincubation with 
-9 5 x 10 M haloperidol {MacLeod, 1976). The neuroleptic drug 
pimozide has also been found to be a potent stimulator of 
prolactin secretion. Injecting the drug into rats signifi-
cantly increases the circulating level of prolactin and the 
in vitro capacity of the pituitary to synthesize the labeled 
hormone {MacLeod, 1976). Pimozide also rendered the rat 
pituitary gland refractory to the usual inhibitory in vitro 
action of dopamine {MacLeod and Lehmeyer, 1973; 1974) and 
thus has a pharmacological action similar to perphenazine 
and haloperidol. 
Chronic morphine treatment has been found to decrease 
the release of prolactin {de Weid et al., 1974). However, 
prolactin levels in methadone-treated males have been found 
to be within normal limits {Cushman and Kosek, 1974). With-
drawal from chronic treatment with morphine has been found 
to result in lower circulating levels of serum prolactin in 
male rats {Lal et al., 1977). 
Rats receiving chronic daily injections of perphena-
zine demonstrate an increase in prolactin synthesis, and in 
male rats the drug caused a fivefold increase in in vitro 
prolactin secretion {MacLeod, 1976). The pituitary glands 
from these perphenaz·ine-treated rats when incubated with 
dopamine, failed to exhibit the usual prolactin inhibiting 
action of dopamine {MacLeod, 1976). An implant of pimozide 
in the pituitary gland or in the median eminence-arcuate 
region produces a gradual increase in serum prolactin {Ojeda 
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et al., 1974). Withdrawal from chronic haloperidol treatment 
has been found to result in lower circulating levels of serum 
prolactin in male rats (Lal et al., 1977). These results 
suggest hyperactivity of the tubero-infundibular dopamine sys-
tem (Lal et al., 1977). The tubero-infundibular dopamine 
neurons are responsible for a tonic inhibitory effect on the 
release of prolactin (de Wied and de Jong, 1974; Kamberi, 
1973; Collu et al., 1973). 
f. Thyroid Hormone 
Nearly all of the studies regarding the effects 
of narcotic analgesics on pituitary-thyroid function indicate 
that these agents inhibit basal thyroid secretion (George 
and Lomax, 1972). Single intravenous injections of morphine, 
meperidine, levorphanal, dextrorphan and dihydromorphinone, 
have been reported to stimulate thyrotropin (TSH) release as 
measured by the release of thyroidal 131 1 (George and Lomax, 
1972). The chronic injection of all of these compounds for a 
period of five-day inhibited thyroid activity (Redding et 
al., 1966). Codeine administered to rats for 14 days has 
been found to lower basal thyroid function; however, codeine 
did not prevent hypersecretion of TSH since it did not block 
the thyroid hypertrophy induced by methylthiouracil 
(Schreiber, 1968). 
Chronic morphine administration for three weeks de-
creased pituitary TSH content (Hohlweg et al., 1961}. In-
jection of morphine for periods of three or five days in-
hibits release of 131r-labeled thyroid hormone (George and 
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Lomax, 1965), depresses 131 r uptake by the thyroid and reduces 
thyroid and pituitary weights (Samel, 1958). These data show 
that morphine may have a dual action on the pituitary-thyroid 
axis (George and Lomax, 1972). A single injection of mor-
phine accelerates the release of 131 r-labeled thyroid hormone 
in mice, whereas administration of morphine for a period of 
three days or longer inhibits several parameters of thyroid 
activity in rats (George and Lomax, 1972). 
Although the mechanism through which this inhibition 
occurs is not known, there are several lines of evidence 
which implicate hypothalamo-hypophysial involvement. Hypo-
thalamic control of TSH is well established. Anterior hypo-
thalamic lesions block the goitrogenic effects of propyl-
thiouracil (Greer, 1952) whereas electrical stimulation of 
this area enhances TSH secretion (Harris and Woods, 1958). 
On the basis of these findings, Lomax and George (1966) stu-
died the effect of morphine on thyroid activity in rats with 
hypothalamic lesions. They found that lesions in the caudal 
region of the hypothalamus completely blocked the morphine-
induced thyroidal inhibition, but animals with lesions in 
the anterior hypothalamus displayed normal 131 r thyroidal re-
lease rates. Lomax and George (1966) suggest that morphine 
might be activating an inhibitory hypothalamic area rather 
than depressing a facilitatory one for the secretion of TSH. 
In a subsequent study Lomax et al. (1970) found that intra-
hypothalamic administration of microquantities of morphine 
(5 pg) produced inhibition of thyroid activity when the drug 
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was injected into both rostal and caudal regions of the hypo-
thalamus. The extent of inhibition was found to vary with 
the injection site. Injections of morphine into the caudal 
hypothalamus inhibited release of 1311-labeled thyroid hor-
mone throughout the period of drug administration, while 
injection of morphine into the rostal site produced a tran-
sient inhibition, suggesting the development of tolerance in 
this area. Since there is some evidence that electrical 
stimulation of the caudal hypothalamus may inhibit TSH secre-
tion (Vertes et al., 1965) and since injection of morphine 
into the caudal hypothalamus produces hyperactivity and hyper-
therrnia (Lotti et al., 1965), Lomax et al. (1970) suggested 
that morphine was producing its thyroid inhibiting effect 
primarily via stimulation of inhibitory neurons in the 
caudal hypothalamus. 
Conclusions drawn from experiments on the effect of 
neuroleptics on thyroid function vary considerably. This is 
caused by the various measures used to determine thyroid ac-
tivity, the different dosages and the duration of the treat-
ment employed, and differences i n experimental circumstances, 
especially with regard to environmental temperature. Using 
1311-uptake by the thyroid as a measure of pituitary-thyroid 
activity, several workers observed a decrease in uptake after 
a relatively high dose of chlorpromazine (Arvay et al., 1960; 
Wiseman, 1962; Ksycki and Lockett, 1965; de Wied, 1967). 
Doses of 10 mg of chlorpromazine per kg and lower generally 
do not depress 1311-uptake by the thyroid (Wiseman, 1962; 
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Wright, 1958), but Milcou et al., (1955) found a depression 
with about 6 mg/kg. 
131 Inhibitory effects on I-uptake may be the result 
of a central effect or of a direct action of chlorpromazine 
either on iodine trapping or on peripheral mechanisms. Di-
rect effects of chlorpromazine on synthesis of thyroid hor-
mone in a dose of about 10 mg/kg have been observed by 
Ksychki and Lockett (1965). They found that incubation of 
thyroids from mice treated with chlorpromazine exhibited re-
duced organic binding of 131I. Evidence for a direct action 
of chlorpromazine on the thyroid has been also derived from 
studies by Mayer et al. (1956). Incubation of chlorpromazine 
with thyroid slices depressed 131I trapping by the gland, 
while later stages of the iodine cycle proceeded abnormally 
only if high doses were used. 
The rate of release of 131 I by the thyroid has for 
some time been regarded as the most reliable indirect para-
meter of pituitary-thyroid activity (Brown-Grant et al., 1954; 
de Wied, 1967). It has been employed by a few investigators 
for the study of chlorpromazine on thyroid function (Foldes 
et al., 1959; George and Lomax, 1965; Milcou et al., 1955; 
Wright, 1958). George and Lomax (1965) found that 5 mg/kg 
of chlorpromazine decreased 131I-release by the thyroid in 
intact as well as adrenalectomized rats. Since TSH acceler-
131 
ated I-release in chlorpromazinet:reated animals, it seemed 
likely that thyroid activity was not directly blocked by the 
drug (de Wied, 1967). 
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The effects of chronic treatment with chlorpromazine 
on thyroid function have been studied with a variety of func-
tional and morphological parameters. A reduction in 131I-
uptake by the thyroid in rats chronically treated with chlor-
promazine (2 to 100 mg/kg/day) has been demonstrated (Arvay 
et al., 1960; Reiss, 1958; Wiseman, 1962; Wright, 1958). The 
release of 131 I from the thyroid is similarly depressed by 
chronic treatment (Foldes et al., 1959; Samuel, 1958; Wright, 
1958). These results suggest that thyroid function is blocked 
in animals on long-term basis with chlorpromazine. However, 
other studies (de Wied, 1967; Arvay et al., 1960; von Brau-
131 
chitsch, 1961) have shown a biphasic effect on I-uptake by 
the thyroid after long-term administration of high doses of 
chlorpromazine. Initially, during the first two to three 
d h . . h f d . h'b' . f 131 ays, t ese investigators ave oun an in i ition o I-
uptake which is then followed 9 to 10 days later by an in-
creased uptake of 131I. Long-term administration of chlor-
promazine also has been noted to produce goiter in the rat 
(Sulman, 1959), although chlorpromazine paradoxically partly 
inhibits the goitrogenic effect of thiouracil derivatives 
(Aleshin and Us, 1960; Meidinger, 1954). The effects of 
chronic chlorpromazine administration in man are difficult 
to interpret since most patients receiving chlorpromazine 
have psychiatric disorders. Most of the studies in man have 
failed to show changes in thyroid activity (de Wied, 1967), 
although it has been reported that chlorpromazine may in-
crease thyroidal 131 I-uptake without interfering with other 
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parameters of thyroid functions (Blumberg and Kelin, 1969); 
George and Lomax, 1972). Although the mechanism by which chlor-
promazine interferes with the action of TSH on thyroid tissue 
has not clearly been established, there is some evidence 
which favors an interference at the adenyl cyclase - cyclic 
AMP level (Yamashita et al., 1970; Wolff and Jones, 1970) as 
well as the lysosomal membrane level (Onaya, 1969; Williams 
and Wolff, 1971). 
In summary, there is evidence that acute administration 
of the phenothiazines may inhibit both the uptake and release 
of thyroid 131 I, indicative of reduced TSH secretion, but that 
chronic administration reverses these effects. In vitro ex-
periments suggest that chloropromazine interferes with thy-
roid function by interfering with the action of TSH on the 
thyroid. 
F. Methods for the Production of Physical Dependence 
A large number of methods have been devised for induc-
ing narcotic tolerance and dependence in laboratory animals. 
These different techniques may be distinguished by the route, 
frequency and method of drug delivery to the animal. The ob-
jectives of these experimental maneuvers are to minimize 
acute toxicity while effecting a sufficiently high narcotic 
intake so that a high degree of tolerance and dependence will 
rapidly develop. Some of the more extensively and thoroughly 
investigated models for producing narcotic dependence are 
daily parenteral injections, oral intake via water or food, 
implantation of pellets and infusion. 
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1. Parenteral Injections 
Laboratory animals have traditionally been made de-
pendent on morphine through intraperitoneal or subcutaneous 
injections of the drug on a regular basis for relatively long 
periods of time {Himmelsbach et al., 1935; Martin et al., 
1963; Akera and Brody, 1968; Buckett, 1964; Hynes et al., 
1976). The procedure of Martin et al. (1963) is a typical 
example of the intraperitoneal method, which is the most com-
mon of the injection regimens for addicting rats. The initial 
dose of morphine was 5 mg/kg administered intraperitoneally 
twice daily at 8 A.M. and 3 P.M. The dose was increased bi-
weekly until the rats were receiving 320 mg/kg/day by the 
thirty-fifth day of addiction. The rats were stabilized at 
this dose level for a week and the morphine was withdrawn 
abruptly. Other investigators have employed one daily dose 
of narcotic {Wikler et al., 1963) while others have employed 
three {Akera and Brody, 1968 ; Hynes et al., 1976) and even 
four daily narcotic injections {Puri and Lal, 1973). Ava-
riety of terminal morphine doses have also been employed. 
Terminal morphine doses have ranged from 30 mg/kg/day {Akera 
and Brody, 1968) to over 400 mg/kg/day {Buckett, 1964; Puri 
and Lal, 1973; Hynes et al., 1976). Although many investi-
gators administer the narcotic by the intraperitoneal route 
{Martin et al., 1963; Buckett et al., 1964; Puri and Lal, 
1973; Hynes et al., 1976) others have used subcutaneous in-
jections {Akera and Brody, 1968). 
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Mice have also been rendered tolerant to and physically 
dependent on morphine by daily subcutaneous injections of in-
creasing doses of morphine {Loh et al., 1969; Marshall and 
Grahame-Smith, 1971). Morphine has been injected three times 
a day in these procedures. Loh et al. (1969) used a starting 
dose of 10 mg/kg which was gradually increased over a three-
week period until 200 mg/kg was given every 8 hours, while a 
maximum of only four days of morphine administration was em-
ployed by Marshall and Grahame-Smith (1971). 
Both abrupt withdrawal and precipitated withdrawal have 
been employed after the chronic injection of morphine. Dur-
ing abrupt withdrawal loss of body weight, body shakes, hypo-
thermia, piloerection, ptosis, loose stools and aggression 
have been noted {for review see Granutsos et al., 1975). After 
the precipitation of withdrawal by a narcotic antagonist, 
loss of body weight, jumping, diarrhea, piloerection and body 
shakes have been observed {Marshall and Grahame-Smith, 1971; 
Blasig et al., 1976). 
The administration of narcotics by daily injection is 
a reliable method for the induction of physical dependence 
that is widely employed. There are, however, several draw-
backs to this technique. For example, it requires that the 
researcher spend part of his time injecting animals on a 
regular basis. There is also a possibility of producing skin 
inflammation, injury and infection. Large amounts of nar-
cotics are needed to establish dependence according to this 
method. 
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2. Oral Consumption 
The oral route of narcotic administration is another 
method which has been employed by several investigators to in-
duce dependence in laboratory rats (Risner and Khavari, 1973; 
Stolerman and Kumar, 1970; Shuster et al., 1963; Wikler et 
al., 1963). Although the oral ingestion method is simple and 
economical, there are some difficulties associated with it. 
The amount of morphine solution ingested by rats is apparently 
limited by at least two factors. First, the highly bitter 
taste of the opium alkaloid appears to be aversive to animals 
~ 
even at low concentrations. Secondly, the animals consume 
relatively constant quantities of water to satisfy bodily 
fluid requirements (Khavari and Risner, 1973). 
One method used to overcome these problems has been to 
force animals to drink narcotic solutions in order to relieve 
their thirst. Wikler et al., (1960) found that normal rats 
deprived of water for twenty-two hours drank an aqueous so-
lution of etonitazene methane sulfonate avidly. Within seven 
minutes after starting to drink this potent narcotic the rats 
exhibited exophthalmos, tail rigidity and periods of stupor 
and/or hyperactivity (Wikler et al., 1960). After twenty-
four hours of abstinence similarly water-deprived addicted 
rats (maintained on a single subcutaneous dose of morphine, 
200 mg/kg/daily) also drank a solution of etonitazene avidly. 
These rats showed not only morphine-like effects but also the 
disappearance of withdrawal body shakes (Wikler et al., 1960; 
Wikler et al., 1963). Further investigation revealed that 
rats drink an aqueous solution of etonitazene in substantial 
quantities even without prior water-deprivation (Wikler et 
al., 1963). When only the etonitazene solution is available 
for drinking during abstinence, morphine-addicted rats con-
sume significantly greater quantities of the etonitazene so-
lution than they do of water during the same period and at 
79 
the end of etonitazene consumption period body shakes are re-
duced (Wikler et al., 1963). Stolerman and Kuman (1970) also 
forced rats to drink morphine solutions in order to relieve 
their thirst. They found that these rats overcame their aver-
sion for morphine solutions and eventually preferred them to 
water. 
Narcotics have been administered in milk or sucrose 
solutions in order to reduce the adversive taste of the opiates. 
Mice have been reported to become tolerant and dependent by 
drinking large quantities of dilute evaporated milk contain-
ing dihydromorphinone (Shuster et al., 1963). When these 
mice were withdrawn they lost body weight indicating that 
physical dependence had been established. The addicted mice 
showed no clear preference for milk containing the narcotic 
when allowed a choice between plain milk and dihydromorphi-
none milk (Shuster et al., 1963). A procedure for a highly 
effective and reliable method for oral morphine administra-
tion has been developed by Khavari and Risner (1972; 1973). 
Specifically, they found that rats would ingest large quan-
tities of morphine when the drug was presented in a sucrose 
medium and that they would prefer sucrose morphine over the 
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sucrose vehicle in subsequent two-bottle choice test (Khavari 
and Risner, 1972). The morphine-sucrose solution was effec-
tive in producing morphine dependence in rats. This conclusion 
was confirmed by the presence of withdrawal signs such as 
body weight loss, anorexia and adipsia when the morphine was 
withheld or nalorphine was administered (Khavari and Risner, 
1973). 
The possibility of adding morphine directly to the ani-
mals food as a method for inducing physical dependence has 
not been extensively investigated. This method was used by 
Sollman (1924) in a limited way but he reported that depend-
ence did not develop as measured by the effects of subsequent 
removal of morphine from the food. Sollman's experiment 
represented the only attempt to induce dependence using mor-
phine-adulterated food until Madinaveitia's (1969) examina-
tion of this method. He also observed that in rats which for 
several weeks had morphine added to their food in concentra-
tions up to 1 mg/g there was no significant changes seen upon 
withdrawal. More recently Khavari and Risner (1973) investi-
gated the ingestion of morphine adulterated food in rats. 
They found that those animals maintained on concentrations 
of 1 mg/g morphine in the food showed a preference for mor-
phine-adulterated food over regular food in a choice test. 
Those rats given concentrations of 3 or 4 mg/g morphine 
showed severe withdrawal signs when they failed to maintain 
their morphine intake in the food choice test. These signs 
varied in intensity as a direct function of the animals' 
81 
prior morphine intake and indicated they were morphine de-
pendent (Khavari and Risner, 1973). Therefore, it seems that 
either morphine dependence or forced treatment seems to be 
essential for the rat to show preference for morphinized food. 
3. Pellet Implantation 
In recent years, a morphine pellet implantation pro-
cedure has been employed to produce tolerance and physical 
dependence in the mouse, rat and guinea pig. The implanta-
tion technique was originated by Maggiolo and Huidobro (1961) 
who made a pellet by compressing 75 mg of morphine base under 
high pressure. Such a pellet proved cumbersome to make and 
its absorption is not rapid enough to produce physical depend-
ence of a magnitude that can be measured by abrupt withdrawal, 
although striking abstinence signs could be precipitated by 
injection of nalorphine (Maggiolo and Huidobro, 1961). Gibson 
and Tingstad (1970) made improvements in this pellet and this 
new formulation has been widely used for the quantitative as-
sessment of tolerance and physical dependence (Way et al., 
1969; Ho et al., 1972; Wei et al., 1973; Wei, 1973). Theim-
plantation procedure has gained considerable popularity be-
cause of its ease and suitability for rapidly inducing toler-
ance and physical dependence. The pellets are implanted 
under light anesthesia subcutaneously in the back or in the 
lower abdominal wall (Wei and Way, 1975). Between twenty-five 
and fifty percent of the morphine in the pellet is absorbed 
in the first two days after implantation, after which the 
rate of absorption of morphine plateaus (Way et al., 1969; 
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Blasig et al., 1973; Goldstein and Schultz, 1973). After im-
plantation of the morphine pellet, animals exhibit the charac-
teristic signs of acute morphine effects (Wei and Way, 1975). 
The acute effects of the morphine pellet largely subside with-
i n twenty-four hours, while the optimum time for obtaining a 
tolerant and dependent state after implanting a morphine 
pellet is three days (Wei and Way, 1975). In the mouse, tol-
erance and dependence were noted to be maximum three to four 
days after implanting the pellet, after which there is a de-
crease in these parameters because the pellet becomes encap-
sulated with fibrous tissue (Way et al., 1969). Similarly, 
in the rat tolerance and precipitated withdrawal signs be-
came maximal three to five days after a single pellet implant 
(Wei, 1973; Cicero and Meyer, 1973). Dependence was maximal 
three days after morphine implantation in the guinea pig 
(Goldstein and Schultz, 1973). 
The withdrawal syndrome is represented by a constel-
lation of behavioral signs after pellet implantation. The 
following withdrawal signs have been observed in the rodent, 
body weight loss, jumping, wet shakes, vocalizations, fight-
ing behavior and piloerection (Wei and Way, 1975). Most 
investigators have found the abrupt withdrawal syndrome dif-
ficult to quantify because the protracted course of abstinence 
requires extended periods of continuous observation after 
pellet removal (Ho et al., 1972). The delayed onset and pro-
tracted course of abrupt morphine withdrawal have led to the 
increasing use of antagonist-precipitated withdrawal for the 
assessment of physical dependence. The withdrawal syndrome 
precipitated by opiate antagonists is a rapid event that ap-
pears to condense, in a short period, the abstinence signs 
of abrupt withdrawal (Wei and Way, 1975). 
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The pellet implantation technique provides a simple 
and rapid method for inducing morphine tolerance and depend-
ence in a wide variety of laboratory animals. However, after 
a pellet is in place the daily dose of morphine cannot be 
controlled directly. Abrupt morphine withdrawal may require 
surgical intervention or may not be possible. The effective-
ness of the pellet method for inducing primary physical de-
pendence on narcotics other than morphine has not been re-
ported. 
4. Infusion 
Recently, several investigators have demonstrated 
that physical dependence on narcotics can be rapidly induced 
in the rat by either continuous or discontinuous injections 
of morphine solutions (Coussens et al., 1973; Teiger, 1974; 
Numan et al., 1975). A high degree of physical dependence 
on morphine has been produced in the rat with two to six 
days of continuous intraperitoneal infusion (Teiger, 1974). 
In this model, rats are prepared with an indwelling intra-
peritoneal catheter, which is led out through a stab wound 
in the back. They are then fitted with a harness and al-
lowed to roam freely within their home cage by use of a 
spring and swivel arrangement. The catheter is attached to 
a Harvard pump, and morphine or other drugs are infused 
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continuously at a slow rate (Teiger, 1974; Harris, 1976). On 
abrupt withdrawal or administration of an antagonist, the 
typical signs of abstinence are seen. After two days of mor-
phine infusion (100 mg/kg/day) as little as 0.1 mg/kg of 
naloxone or 1 mg/kg of nalorphine precipitated abstinence, 
while after six days of morphine infusion, abrupt withdrawal 
tests showed a high degree of physical dependence. Weight 
loss and hyperirritability were the signs used to follow the 
time course and severity of the withdrawal syndrome (Teiger, 
1974; Harris, 1976). This method also allowed Teiger (1974) 
to demonstrate physical dependence on codeine and merperidine 
by abrupt withdrawal as well as precipitated withdrawal. 
Harris (1976) has used this technique to study the concomi-
tant administration of narcotics and narcotic antagonists. 
Intermittent injections of morphine sulfate in increas-
ing doses has been found to produce reliable narcotic depend-
ence in rats (Coussens et al., 1973; Numan et al., 1975; 
Smith and Davis, 1975). In this model rats are implanted 
with an indwelling jugular catheter and fitted with a harness. 
The catheter is connected by way of a swivel to an injection 
system located outside the chamber (Smith and Davis, 1973; 
1975; Numan et al., 1975). Discontinuation of injections re-
sulted in the appearance of a withdrawal syndrome character-
ized by ptosis, piloerection, writing, body shakes, hypo-
thermia and weight loss (Coussens et al., 1973; Numan et al., 
1975). Rats withdrawn from these injections acquired high 
rates of operant responding for morphine self-administration 
(Numan et al., 1975). 
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The short duration of time needed for infusion methods 
to induce physical dependence on morphine as well as other 
narcotics makes it a useful method. However, surgery is re-
quired along with expensive infusion equipment. 
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III 
METHODS AND MATERIALS 
A. Animals 
Male hooded rats of the Long-Evans strain, random-bred, 
weighing 250-350 grams were obtained from Charles River Breed-
ing Farms, Wilmington, Massachusetts. Prior to their use in 
this investigation the rats were housed in colony cages and 
allowed free access to food and water at all times. 
B. Drugs 
Azaperone, benperidol, haloperidol, spiramide, oxiper-
mide, spiperone, pipamperone, pimozide, fentanyl, and dexeti-
mide were obtained through the courtesy of McNeil Laboratories, 
Inc., Fort Washington, Pennsylvania and Janssen Pharmaceutica, 
Beerse, Belgium. Chlorpromazine, trifluoperazine, phenoxy-
benzamine, tranylcypromine and amphetamine were obtained 
from Smith Kline and French Laboratories of Philadelphia, 
Pennsylvania. Eli Lilly and Company of Indianapolis, Indiana 
supplied the methadone, propoxyphene, apomorphine and fluoxe-
tine. The naloxone was provided by the Endo Laboratories, Inc. 
of Garden City, New York. Pilocarpine, dihydroxyphenyl-1-
alanine, atropine, scopolamine, oxotremorine, and DL-5-
hydroxytryptophan were purchased from the Aldrich Chemical 
Company, Inc., Milwaukee, Wisconsin. Chlordiazepoxide, fluro-
zepam, diazepam, Ro4-4602/l and physostigmine were generously 
supplied by Hoffmann-La Roche, Inc., Nutley, New Jersey. 
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The Merck Sharp and Dohme Company of West Point, Pennsylvania 
supplied the methysergide, benztropine and amitriptyline. 
The d and 1 isomers of butaclarool were supplied by the Ayerst 
Laboratories of Montreal, Canada. Loxapine was supplied by 
Lederle Laboratories of Pearl River, New York. The morphine 
sulfate was purchased from the Merck Chemical Company, Rahway, 
New Jersey. Winthrop Laboratories provided the pentazorine. 
Deanol was provided by the Riker Laboratories of Northridge, 
California. The Eastman Kodak Company of Rochester, New 
York provided the choline chloride. Desmethylirnipramine was 
obtained from the Geigy Pharmaceutical Company of Ardsley, 
New York. The alpha-methyl-p-tyrosine was purchased from 
the Sigma Chemical Company, St. Louis, Missouri. Boehringer 
Ingelheim, Ltd. of Elmsford, New York provided the clonidine. 
Sodium pentabarbital was obtained from the Mallinckrodt 
Chemical Works, St. Louis, Missouri. 
Azaperone, benperidol, haloperidol, spiramide, oxi-
perrnide, pipamperone, spiperone and pimozide were dissolved 
in 0.3% tartaric acid. Alpha-methyl-p-tyrosine, L-DOPA and 
DL-5-hydroxytryptophan were suspended in 0.5% carboxymethyl 
cellulose. All other drugs were dissolved in physiological 
saline. 
C. Chronic Intravenous Morphine Administration 
1. Cannula Construction 
The cannulas employed for chroni c intravenous in-
fusion were constructed from polyethylene and silicone tub-
ing. The intramedic polyethylene tubing, I.D. 0.023 in. x 
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O.D. 0.0 38 in., was obtained from Clay Adams, Parsippany, 
New Jersey. Silastic brand medical grade silicone tubing, 
I.D. 0.020 in. x O.D. 0.037 in., was obtained from the Dow 
Corning Corporation, Midland, Michigan. The polyethylene tub-
ing was cut into 1.5 ft segments while the silicone tubing 
was cut into either 0.75 in. or 1.5 in. pieces. The two 
pieces of silicone tubing were then placed in ether for 15 
seconds resulting in expansion of the tubing. The polyethyl-
ene was first inserted through the 0.75 in. silicone tubing 
until it was about 1 in. from the end of the polyethylene 
tubing. Secondly, the 1.5 in. segment of silicone tubing was 
placed about 0.25 in. over the end of polyethylene tubing 
closest to the 0.75 in. silas tic piece. The tip of the sili-
cone tubing not overlapping the polyethylene tubing was 
sealed with Silastic brand medical adhesive made by the Dow 
Corning Corporation, Midland, Michigan. A small amount of 
silicone adhesive was also placed around the junction between 
the polyethylene and silicone tubing. The cannula was then 
bent to form a U-shape in a hot water bath. The bend was 
made at the middle of the 0. 75 in . . piece of silicone tubing. 
The cannulas were allowed 24 hours to dry prior to use. Many 
small holes made by needle pricks were placed in the 1.5 in. 
segment of silicone tubing for the drug solution to flow 
through before being implanted in the jugular vein. The 
cannula is shown in Figure 1. 
FIGURE 1. Diagram of the Cannula Employed for Chronic 
Intravenous Morphine Administration 
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2. Cannula Implantation 
The rats were anesthetized with 50 mg/kg of sodium 
pentobarbital administered intraperitoneally. 
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As soon as the rat was unconscious, the back of the 
neck behind the ears, the upper chest and lower neck were 
shaved with small animal clippers. As much hair as possible 
was removed from these sites. These areas were then wiped 
with gauze soaked in 70% alcohol solution. 
An incision was made through the skin above the right 
jugular vein which is approximately 1-2 cm from the midline. 
The right external jugular vein was exposed by using blunt 
dissection. 
A small cut was then placed in the vein through which 
the cannula was inserted. The cannula was filled with 0.9% 
saline and attached to a 3 ml syringe also filled with saline. 
The silicone tip of the cannula was inserted into the vein 
as far as the polyethylene tubing, so that the entire 1.5 in. 
segment of silicone tubing was in the vein. The cannula was 
then tied in the vein with silk suture. Additional sutures 
were employed to sew the cannula to the neck muscles. 
A 10 cm sterile piece of 15 gauge stainless steel tub-
ing with a sharpened point at one end was inserted beneath 
the skin at the site of the incision. The tubing was pushed 
carefully underneath the skin until the sharpened end was 
brought through the shaved skin on the rat's back. The 
cannula was then inserted into the stainless steel tubing 
until it came out the other end. The entire length of can-
nula was pulled through the tubing prior to its removal. 
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The incision was then sutured closed. The muscle was 
sutured back together with absorbable sutures while silk 
suture was employed to close the skin. Following surgery 
75,000 units of procaine penicillin G was injected intramus-
cularly in the hind paw. The rat was then placed in a saddle. 
The saddle was constructed from a small square of brass shim 
stock to which a curved piece of 13 gauge hypodermic needle 
tubing was soldered for the purpose of attaching a metal 
spring leash. A copper wire collar for the rat's neck was 
also soldered to the brass square. A piece of VelcroR nylon 
closure was cemented to the top of the saddle and a mating 
R Velcro strap was employed to pass around the rat's thorax 
just behind the forelegs. The inner parts of both the saddle 
and the strap were padded with 1/4-inch polyurethane foam. 
Each rat was placed individually in plexiglass chambers for 
the duration of the experiment. The plexiglass chambers were 
located in air-conditioned rooms thermostatically maintained 
at 20-22° with room lighting turned off between 8 P.M. and 
7 A.M. The cannula was passed from the rat's saddle through 
a long metal spring to the top of the plexiglass chamber 
where it was connected to an injection system located out-
side the chamber. This apparatus is shown in Figure 2. 
3. Injection System 
The injection system consisted of a Harvard Appa-
ratus Compact Infusion Pump Model 975 which was modified to 
hold 4 or 8 syringes having a 10-ml capacity. The syringes 
FIGURE 2. Rat Housed in Plexiglass Chamber Fitted 
with Cannula and Saddle for Chronic 
Intravenous Morphine Administration 
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were then filled with either a solution of morphine sulfate 
or normal saline which was infused according to the addiction 
schedule. 
D. Addiction Procedure 
The syringes in the infusion pumps were filled with 
morphine sulfate and infused according to the schedule shown 
in Table 1. The starting dose of 36 mg/kg/day morphine sul-
fate was gradually increased until a terminal dose of 100 
mg/kg/day was reached. A minimum of five days on the terminal 
dose of morphine was allowed before the infusion pumps were 
turned off to produce withdrawal. 
E. Measurement of Withdrawal Body Shakes 
Morphine withdrawal body shakes were measured 8 to 12 
hours after the morphine infusion was discontinued. The in-
fusion pumps were stopped at midnight so that the pretreat-
ment withdrawal observation could be made at 8 A.M. the fol-
lowing morning. To observe withdrawal body shakes the doors 
of the plexiglass chambers were opened and food cups removed. 
Each rat was observed for a period of 30 min during which 
the occurrence of withdrawal body shakes were counted. Body 
shakes were defined as violent shaking movements of the head 
and/or trunk of the rat which resemble the action of an ani-
mal that has been drenched with water (for a description and 
review, see Gianutsos et al., 1975a). The test drug was then 
injected, food cup replaced, cage door closed, and a prede-
Table 1. Morphine Concentration and Infusion Schedule to Establish 
Morphine Dependence in the Rat 
Infusion Flow Ratel Morphine I nfusion/Day 
Pump 2 Total Day Setting ml/day mg mg/kg 
1 30 1.08 12 36 
2 29 1. 51 17 50 
3 28 2.16 24 71 
4-10 27 3.02 33 100 
l.Harvard Apparatus Infusion Pump Model No. 975. Syringes with a 10-ml 
capacity. 
2~Morphine sulfate dissolved in saline at a concentration of 11 mg/ml. 
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determined period for onset of drug action was allowed. Fol-
lowing this treatment the rats were observed again for 30 
min for the occurrence of body shakes, as before the cage door 
was opened and food cup rennved. 
After the post-drug observation the infusion pump was 
turned on again to continue infusion of morphine solution un-
til the next withdrawal. 
F. Statistical Analysis 
The effectiveness of the test drug was determined by 
comparing the withdrawal body shakes observed on the same day 
before and after the drug treatment. Therefore, the pre-drug 
shakes served as a ~ign of withdrawal against which the ef-
fectiveness of the test drug was evaluated. This was accom-
plished by calculating the average number of body shakes ex-
hibited during the pre-drug observation period by those with-
drawn rats reaching criteria. Withdrawn rats had to show a 
minimum of 8 withdrawal body shakes in the 30 min. observa-
tion period to be employed for drug testing. Criteria was 
established at 8 body shakes since 97 percent of the rats 
withdrawn from morphine showed this number of shakes while 
only 13 percent of the rats infused chronically with saline 
exhibited 8 or more body shakes. The average number of body 
shakes occurring during the pre-drug observation was then 
divided into the number of withdrawal shakes observed for 
each individual subject after the test drug administration. 
A mean and standard error was then calculated from these 
individual percentage values. 
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Regression analysis was employed to test for the ex-
istence of a dose response relationship. The Student's 't' 
test was employed to establish significant differences be-
tween treatment groups, with the level of statistical signif-
icance defined as a P value of less than 0.05. The dose of 
test drug that reduced withdrawal body shakes by 50 percent 
(Io 50 ) was calculated from the regression equation Y=MX+b. 
Where the slope is M and the Y intercept is b. The equation 
was then solved for X where Y was designated as 50 percent 
inhibition. 
IV 
RESULTS 
A. The Occurrence of Morphine Withdrawal Body Shakes 
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Rats implanted with indwelling cannula and perfused with 
saline showed only negligible withdrawal body shakes (Table 
2). These results are in agreement with previous reports 
(Numan et al., 1975; Lal and Numan, 1976). However, termina-
tion of morphine infusion in rats who had been continuously 
perfused with morphine for several days resulted in the re-
liable and frequent occurrence of withdrawal body shakes as 
can be seen in Table 2. These dependent rats showed an aver-
age of 25 withdrawal body shakes in a 30-min observation 
period which was significantly (p~0.001) greater than the 
number of body shakes observed in saline infused rats. The 
frequency distribution for the occurrence of withdrawal body 
shakes upon the cessation of morphine or saline infusion i s 
shown in Table 3. Rats withdrawn from morphine exhibit nnre 
than 8 withdrawal body shakes 97 percent of the time while 
sal~ne controls show less than 7 shakes 87 percent of the 
time in a 30-min observation period. Fifty-two percent of 
the time withdrawn rats show between 8 and 21 body shakes 
while only 13 percent of saline infused rats exhibited shakes 
at this frequency. More than 21 shakes were observed in the 
remaining 45 percent of withdrawn rats while saline infused 
rats show no shakes at this frequency • 
Table 2. The Incidence of Withdrawal Body Shakes in Depend-
ent and Non-Dependent Rats 
Withdrawal 
Chronic 1 N2 
Body Shakes 3 
Treatment (Mean + S. E.) 
Saline 54 2.6 + 0.5 
-
Morphine 54 25.1 + 1.7* 
-
1. Intravenously infused for several days as described in 
the text. 
2. The number of rats observed after specified chronic 
treatment. 
3. Pretreatment withdrawal shakes were observed for a 30 
min period 8 hours after the termination of morphine 
or saline infusion. 
* Significantly (p J:. 0. 001) different from saline group 
according to Student's "t" test, two-tailed. 
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Table 3. The Incidence of Withdrawal Body Shakes in the Rat 
Percent of Rats Showing Shakes 
of Stated Frequencyl 
Number of Morphine Saline 
Withdrawal Shakes Withdrawal 2 Controls 3 
0 0 44 
1-7 3 43 
8-14 30 9 
15-21 22 4 
22-28 14 0 
29-35 14 0 
36-42 8 0 
43-49 4 0 
.L.. 50 5 0 
1. Withdrawal shakes were observed for a 30-min period 
8 hours after the termination of morphine or saline 
infusion. 
2. Based upon 505 withdrawal observations of morphine 
dependent rats. 
3. Based upon 54 withdrawal observations of saline 
perfused rats. 
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Before initiating the drug studies it was first estab-
lished that rats once made dependent upon morphine exhibited 
a fairly consistent number of shakes even upon repeated with-
drawal. This information was obtained by withdrawing depend-
ent rats 12 consecutive times and observing the occurrence of 
withdrawal body shakes after 8 hours of withdrawal. At least 
14 hours of morphine infusion was instituted between with-
drawal observations. The data given in Table 4 show that an 
average of 18 body shakes occurred during the first withdraw-
al session after 5 days of maintenance at the terminal con-
centration of morphine. The number of shakes was significant-
ly greater than those observed before withdrawal {p L0.0001) 
or those observed in rats withdrawn from saline infusion 
{pL'.0.001). The rate of withdrawal body shakes was somewhat 
higher on day 3 and then remained fairly constant throughout 
the period of consecutive withdrawal trials until the exper-
iment was terminated after completion of 12 withdrawal obser-
vations. 
B. The Effect of Narcotics on Morphine Withdrawal Body 
Shakes 
1. The Effect of Narcotic Agonists 
Upon the termination of morphine infusion, withdraw-
al body shakes began to occur within 3 hours but were not 
fully developed until 6 hours after which time they remained 
constant for up to 24 hours if the morphine infusion was not 
reinstated. The administration of morphine, methadone or 
fentanyl, potent narcotic agonists, reliably abolished the 
Table 4. The Frequency of Withdrawn Body Shakes During 
Twelve Consecutive Withdrawal Sessions 
Withdrawal1 Withdrawal Shakes 
Sessions N2 (Mean + S. E.) 
1 36 18.3 + 1.4 
-
2 29 20.0 + 1.5 
3 22 24.7 + 3.1 
-
4 18 25.3 + 4.6 
-
5 16 27.9 + 4.3 
6 15 24.5 + 3.2 
7 12 26.8 + 4.7 
-
8 13 25.7 + 3.1 
-
9 12 24. 6 + 3.5 
-
10 11 32.2 + 3.6 
-
11 10 27.4 + 3.3 
-
12 8 25.3 + 4.5 
3 
1. Dependent rats were withdrawn on 12 consecutive days. 
Withdrawa l shakes were counted after 8 hours of with-
drawal . At least 14 hours of morphine infusion were 
instituted between withdrawal observation sessions. 
2. The number of rats observed during each withdrawal 
session. 
3. Withdrawal shakes were observed for a 30-min period 
8 hours after the termination of morphine infusion. 
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occurrence of withdrawal body shakes 8 hours after the termi-
nation of morphine infusion. These results are summarized in 
Table 5 which shows that the regression coefficient for each 
of these narcotics was significant (p L. 0. 05) . Calculation of 
ID 50 concentrations on a mg/kg basis revealed fentanyl to be 
the most potent with methadone being the next most potent and 
morphine having the lowest potency for those narcotics tested. 
2. The Effect of Narcotic Antagonist 
The injection of either naloxone or pentazocine 8 
hours after the cessation of morphine infusion did not cause 
any further increase in the rate of withdrawal shakes as is 
shown in Table 5. There was a slight tendency towards an in-
crease in the number of withdrawal body shakes, however, this 
increase was not significant. 
3. The Interaction Between Narcotics and Naloxone 
Morphine (40 mg/kg) administration reduced with-
drawal body shakes by about 90 percent. Naloxone antagonizes 
this morphine-induced blockade of withdrawal shakes in a dose 
dependent manner (Table 6). A naloxone dose of 1.25 mg/kg 
completely reversed the blockade produced by morphine given 
at a dose of 40 mg/kg. Increasing the naloxone dose to 5 
mg/kg did not increase the withdrawal shakes beyond those 
seen before morphine injection. 
C. The Effect of Dopaminergic Agents on Morphine Withdrawal 
Body Shakes 
1. The Effect of Dopaminergic Antagonists 
The effect of the various dopaminergic antagonists 
Table 5. The Effect of Narcotic Agonist and Antagonist on Morphine Withdrawal Body Shakes 
1 Treatment 
Saline 
Fentanyl 
Methadone 
Morphine 
Naloxone 
Pentazocine 
Dose 
(mg/kg) 
0.04 
0.16 
0.64 
2.5 
2.5 
10 
40 
10 
40 
0.16 
0.64 
1.25 
5.00 
10 
40 
N2 
64 
5 
16 
6 
6 
7 
8 
5 
14 
10 
5 
8 
11 
8 
6 
5 
Withdrawal Shakes 
ID50 
.% Pretreatment Correlation 
(Mean ~ S.E.) 3 (m~j/kg) Coefficient 
110.2 + 9.6 
-
116.4 + 70.0 
107.0 + 22.7 
4.8 + 4.8 
0 + 0 0.3 -0.88* 
-
53.4 + 14.4 
14.7 + 9.4 
0 + 0 4.1 -0.96* 
-
67.6 + 21.7 
11.6 + 5.0 14.4 -0.99* 
-
169.8 + 43.9 
112.4 + 26.5 
128.6 + 11.4 
105.1 + 14.5 - -0.33 
-
111.5 + 36.9 
133.4 + 52.1 - +0.88 
l."All drugs were administered i.p. 30 min prior to observation with the exception of fen-
tanyl and naloxone which were given 10 mins prior to post treatment observation. 
2.The number of rats employed per dose. 
3.Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of morphine 
abs tinence. 
* Significant (p..L.0.05) regression coefficient. 
I-' 
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Table 6. Reversal of Morphine Induced Blockade of With-
drawal Body Shakes by Naloxone 
Withdrawal Shakes 1 Naloxone % Pretreatment Correlation 
N2 (mg/kg) (Mean+ S.E.)3 Coefficient 
1. 
2. 
3. 
* 
0 10 11.6 + 5.0 
-
0.04 7 23.8 + 11.7 
-
0.16 7 65.0 + 13. 9 
0.64 8 49.3 + 17.5 
1.25 8 86.3 + 13. 4 
-
5.00 8 97.8 + 32.0 +0.93* 
-
Morphine sulfate (40 mg/kg) was administered i.p. to all 
rats 30 min prior to post treatmenu observation. 
Naloxone was then injected i.p. 20 min after the morphine 
administration which was 10 min prior to observation. 
The number of rats employed per dose. 
Pretreatment withdrawal body shakes were observed for 
a 30 min period after 8 hours of morphine abstinence. 
Significant regression coefficient (P.L0.05). 
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test on withdrawal shakes are shown in Tab le 7. Benperidol 
dose dependently reduced withdrawal shakes and this effect 
was significant (r = 0.93, p.L...0.05) by regression analysis. 
A dose of 0.01 mg/kg of benperidol was without effect but in-
creasing the dose to 0.64 mg/kg reduced withdrawal body shakes 
by 95 percent. (+)Butaclamol produced a dose dependent re-
duction in body shakes with a dose of 0.64 mg/kg reducing 
shakes b y approximately 80 percent. The correlation coef-
ficient for the relationship between the log dose of (+)buta-
clamol and percent reduction in body shakes was (r = 0.98, 
p~0.05). (-)Butaclamol did not reduce withdrawal shakes. 
The phenothiazine neuroleptic, chlorpromazine, at a dose of 
0.16 mg/kg reduced shakes to 50 percent of pretreatment. The 
degree of reduction remained at approximately 50 percent even 
when the dose of chlorpromazine was increased to 0.64 or 
2.5 mg/kg. However, further increasing the dose to 10 mg/kg 
did completely reduce the occurrence of withdrawal shakes. 
The correlation coefficient for chlorpromazine (r = 0.83) was 
not significant suggesting that the effect was not dose de-
pendent. Haloperidol reduced withdrawal shakes in a dose 
dependent manner. A reduction of 80 percent was achieved by 
the administration of haloperidol at a dose of 0.64 mg/kg. 
Regression analysis demonstrated a significant (r = 0.98, 
p~0.05) dose effect relationship. The dopamine antagonist 
loxapine produced a similar reduction in withdrawal body 
shakes. A near total blockade of withdrawal shakes was 
achieved by the administration of 2.5 mg/kg of loxapine. 
Table 7. The Effect of Various Neuroleptics on Morphine Withdrawal Body Shakes 
Withdrawal Shakes 
ro5o 
Treatment1 
Dose 
N2 
% Pretreatment Correlation 
(mg/kg) (Mean + S • E. ) 3 (mg/kg) Coefficient 
--
Saline - 64 110.2 + 9.5 
-
Benperidol 0.01 15 116.1 + 15.7 
0.04 8 48.5 + 13.2 
0 .16 12 50.8 + 6.8 
0.64 5 4.8 + 3.7 0.08 -0.93* 
-
+Butaclamol 0.04 4 66.2 + 18.6 
0.16 7 40.2 + 10.8 
0.64 7 21.1 + 7.7 0.12 -0.98* 
-
-Butaclamol 0.64 9 128.4 + 14.2 
-
Chlorpromazine 0.16 12 45.7 + 10.5 
0.64 4 25.2 + 20.0 
2.50 5 50.4 + 15. 7 
10.00 2 0 + 0 0.49 -0.83 
Haloperidol 0.04 9 83.4 + 14.8 
0.16 8 41.5 + 9.5 
0.64 13 19 . 4 + 5.3 0.17 -0.98* 
-
Loxapine 0.04 6 53.8 + 7.2 
0.16 9 38.8 + 13.6 
0.64 7 44.7 + 17.9 
2.50 9 0. 8 + 0.5 0.16 -0.92* 
-
Oxiperomide 0.14 7 90.0 + 19.l 
...... 
0 
0.16 9 30. 0 + 7.7 00 
0.64 9 18. 2 + 6.1 
2.50 10 3.8 + 2.2 0.16 -0.96* 
Table 7 (continued) 
Pimozide 0.04 7 55.5 + 16.4 
0.16 7 68.1 + 23.4 
0.64 12 82.7 + 18.7 
2.50 13 35.8 + 12.2 1.64 -0.68 
-
Pipamperone 2.50 6 38.6 + 13.2 
10.00 5 79.8 + 14.4 
40.00 4 22.2 + 14.5 11.02 -0.71 
-
Spiperone 0.01 10 72.0 + 14.3 
0.04 9 50.2 + 16.9 
0.16 7 22.0 + 11.3 
0.64 15 14.7 + 5.2 0.04 -0.97* 
-
Spiramide 0.04 6 82.6 + 22.5 
0.16 7 43.5 + 9.3 
0.64 9 34.5 + 16.8 
2.50 6 0. 6 + 0.6 0.19 -0.98* 
-
Trifluoperazine 0.16 3 80.3 + 15.1 
0.64 6 36.3 + 14.6 
2.50 4 38.7 + 29.6 
10.00 5 0 + 0 0.74 -0.97* 
l.All drugs were administered i.p. 30 min prior to observation with the exception of 
haloperidol and pirnozide which were given 120 min prior to post-treatment observation. 
2.The number of rats employed per dose. 
3.pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
morphine abstinence. 
*Significant regression coefficient (p.O:::: 0.05). 
...... 
0 
\0 
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Dose effect analysis demonstrated a significant (r = 0.92, 
p~0.05) correlation coefficient. A dose dependent reduction 
in withdrawal body shakes was also produced by the administra-
tion of oxiperomide. Withdrawal shakes were reduced by 95 
percent by the administration of oxiperomide at a dose of 
2.5 mg/kg. Regression analysis revealed a significant 
(r = 0.96, p.L 0.05) correlation coefficient. Pimozide did 
not reduce withdrawal body shakes in a dose dependent manner. 
Even with highest dose employed, 2.5 mg/kg, withdrawal shakes 
were only reduced by approximately 65 percent. Pipamperone 
failed to reduce withdrawal body shakes in a dose dependent 
manner (r = 0.71). A dose of 2.5 mg/kg reduced shakes by 60 
percent; however, when the dose was increased to 10 mg/kg 
the reduction was only 20 percent. Withdrawal shakes were re-
duced by 80 percent when a 40 mg/kg dose of pipamerone was 
employed. Spiperone did reduce the frequency of withdrawal 
shakes in a dose related fashion. At a dose of 0.04 mg/kg 
spiperone reduced shakes by about 50 percent while increasing 
the dose to 0.64 mg/kg reduced shakes by 85 percent. The 
correlation coefficient for the relationship between the 
log dose of spiperone and percent reduction in body shakes 
was significant (r = 0.97, p..L 0.05). A similar dose related 
decrease in the frequency of withdrawal shakes was produced 
by the administration of the neuroleptic spiramide. A total 
reduction in shakes was achieved when sipramide was adminis-
tered at a dose of 2.5 mg/kg. Regression analysis show a 
significant (r = 0.98, p~0.05) correlation coefficient. 
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Trifluoperazine, a phenothiozine neuroleptic, also reduced 
withdrawal shakes but only at relatively high doses. A 10 
mg/kg dose of trifluoperazine was needed to completely abol-
ish the occurrence of withdrawal body shakes. The dose de-
pendent effect was found to be significant (r = 0.97, pL0.05) 
by regression analysis. Consideration of the ID values for 
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these neuroleptics showed that on a mg/kg basis the order 
of potency for those neuroleptics tested to be as follows: 
spiperone, benperidol, +butaclamol, loxapine, oxiperomide, 
haloperidol, spiraimide, chlorpromazine, trifluoperazine, 
pimozide and pipamperone. 
2. The Effect of Dopaminergic Agonists. 
The dopaminergic agonists tested for their effects 
on withdrawal shakes all reduced shakes as can be seen in 
Table 8. Amphetamine produced a dose-related decrease in 
the frequency of withdrawal shakes which was significant 
(r = 0.96, p.L0.05) by regression analysis. When a 2.5 
mg/kg dose of amphetamine was employed shakes were reduced 
by 85 percent. In a similar fashion withdrawal shakes were 
dose dependently reduced by the dopaminergic agonist, apo-
morphine. A 95 percent reduction was demonstrated when 
apomorphine was given at a dose of 0.64 mg/kg. The corre-
lation coefficient for the dose-effect relationship was 
(r = 0.99, pL0.05). The administration of L-DOPA also pro-
duced a dose dependent reduction in withdrawal shakes. Ana-
lysis of the L-DOPA effect demonstrated a significant 
1 Treatment 
Saline 
Amphetamine 
Apomorphine 
L-DOPA4 
Table 8. Reduction of Morphine Withdrawal Body Shakes Induced by 
Dopamine Receptor Stimulants 
Dose 
(mg/kg) 
0.04 
0.16 
0.64 
2.50 
0.01 
0.04 
0.16 
0.64 
10.0 
40.0 
160.0 
N2 
-
64 
7 
8 
8 
9 
3 
5 
7 
8 
9 
6 
5 
Withdrawal Shakes 
% Pretreatment3 (Mean + S. E. ) 
110.2 + 9.6 
106.3 + 24.4 
53.6 + 11.9 
20.7 + 4.6 
13. 0 + 6.0 
-
86.6 + 28.1 
49.2 + 13.9 
35.3 + 8.7 
5.0 + 2.5 
-
66.6 + 17.3 
41.0 + 20.9 
23.2 + 14.4 
ID50 
(mg/kg) 
0.26 
0.06 
32.47 
Correlation 
Coefficient 
-0.96* 
-0.99* 
-0.97* 
l.All drugs were administered i.p. 30 mins prior to observation with the exception of apo-
morphine which was given 10 mins prior to post-treatment observation. 
2.The number of rats employed per dose. 
).Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of morphine 
abstinence. 
4. These rats were injected with 25 mg/kg of R04-4602/l 30 mins prior to L-DOPA administration. 
*significant regression coefficient (pL.0.05). 
f--' 
f--' 
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(r = 0.97; p.L0.05) correlation coefficient. The ro50 values 
for amphetamine, apomorphine and L-DOPA were 0.26, 0.06 and 
32.47 mg/kg, respectively. 
3. The Interaction Between Dopaminergic Agents and 
Naloxone 
When administered after a large dose of haloperidol, 
naloxone caused a considerable reversal of the haloperidol 
effect in blocking withdrawal shakes as can be seen in Tables 
9 and 10. Haloperidol in a dose of 0.64 mg/kg reduced body 
shakes to 20 percent of pretreatment but when administered in 
conjunction with naloxone body shakes were reduced to only 
about 50 percent of pretreatment. Naloxone, at a dose of 
0.64 mg/kg produced a maximum effect which could not be fur-
ther potentiated by increasing the naloxone dose to 5 mg/kg. 
However, only the 5 mg/kg dose of naloxone produced an ef-
fect which was significantly (p~ 0.05) different from halo-
peridol alone (Table 10). 
The data summarized in Table 10 show the interaction 
between the various neuroleptics found to reduce withdrawal 
body shakes and naloxone. The maximum effect dose of each 
neuroleptic was combined with a 5 mg/kg dose of naloxone. 
Benperidol, oxipermide, haloperidol and trifluoperazine were 
the only neuroleptics to have their effects significantly 
(p..oi::0.05) antagonized by the administration of naloxone 
(5 mg/kg). The interaction between benperidol and naloxone 
proved to be significant (p~0.002) in that benperidol 
alone (0.64 mg/kg) reduced withdrawal shakes by 95 percent 
Table 9. The Effect of Naloxone on the Haloperidol 
Induced Reduction in Morphine Withdrawal 
Body Shakes 
1 Withdrawal Shakes
3 
Naloxone % Pretreatment Correlation 
(mg/kg) N2 (Mean + S • E. ) Coefficient 
0 13 19.4 + 5.3 
-
0.64 9 45.5 + 11.5 
-
1.25 9 35.5 + 9.7 
-
5.00 8 45.0 + 9.7 +0.77 
-
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1. Haloperidol (0.64 mg/kg) was administered i.p. to all rats 
120 mins prior to post treatment observation. Naloxone 
was then injected i.p. 10 mins prior to observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal shakes were observed for a 30 
min period after 8 hours of morphine abstinence. 
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Table 10. The Interaction Between Neuroleptics and Naloxone 
on Morphine Withdrawal Body Shake s 
1 Treatment 
Saline 
Benperidol 
+Butaclamol 
Chlorpromazine 
Haloperidol 
Loxapine 
Oxiperomide 
Spiperone 
Spiramide 
Dose 
(mg/kg) 
0.64 
0.64 
10.00 
0.64 
2.50 
2.50 
0.64 
0.64 
Trifluoperazine 10.00 
Withdrawal Shakes 2 
% Pretreamtnet 
(Mean + S. E. ) 
Saline3 Naloxone3 
110.2 + 9.6 (64) 105.1 + 14.5 (8) 
4.8 + 3.7 (5) 
21 . 2 + 7. 7 ( 7) 
0 + 0 ( 2) 
19.4 + 5.3 (13) 
0.8 + 0.5 (9) 
3.8 + 2.2 (10) 
14.7+ 5.2 (15) 
34.5 + 16.8 (9) 
0.3 + 0.3 (5) 
60.0 + 7.9 (8)* 
29.4 + 5.2 (5) 
5.3 + 5.3 (3) 
45.0 + 9.7 (8)* 
8.3 + 4.9 (6) 
18.9 + 6.8 (10)* 
28.1 + 8.4 (10) 
48.8 + 8.2 (10) 
19.6 + 7.3 (16)* 
1. All drugs were a dministered i.p. 30 mins prior to observa-
tion with the exception of haloperidol which was given 120 
mins prior to post treatment observation. 
2. 
3. 
4. 
* 
Pretreatment withdrawal shakes were observed for a 30 min 
period after 8 hours of morphine abstinence. 
Saline or naloxone (5 mg/kg) was administered 10 mins prior 
to observation. 
The number of rats employed per dose is indicated in 
parentheses. 
Significantly (p.L0.05) different from saline by Student's 
't' test. 
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but when administered in conjunction with naloxone (5 mg/kg) 
body shakes were reduced by only 40 percent. Naloxone 
failed to antagonize the effects of spiperone, spiramide, 
loxapine, chlorpromazine and +butaclamol to any significant 
extent. 
The data obtained when naloxone was administered in 
conjunction with dopaminergic agonist is shown in Table 11. 
The effect of apomorphine was significantly (p...t!.0.05) antag-
onized by the administration of naloxone (5 mg/kg). However, 
the administration of naloxone in conjunction with amphet-
amine failed to produce any significant antagonism of the 
amphetamine effect. 
D. The Effect of Adrenergic Agents on Morphine Withdrawal 
Body Shakes 
1. The Effect of Adrenergic Antagonist 
The data in Table 12 demonstrates a blockade of 
withdrawal shakes by azaperone, a butyrophenone neuroleptic 
possessing high alpha noradrenergic potency. The effect of 
azaperone was significantly (r = 0.96, pL0.05) dose depend-
ent by regression analysis with a dose of 0.64 mg/kg reduc-
ing body shakes by about 95 percent. The alpha noradrenergic 
blocker phenoxybenzamine failed to produce any significant 
effect on withdrawal body shakes. Similarly, the beta 
blocker propronalol also failed to reduce withdrawal shakes 
to any significant extent. A dose of 10 mg/kg of propronalol 
only reduced shakes by about 30 percent. 
Table 11. The Interaction Between Dopamine Receptor 
Stimulants and Naloxone on Morphine Withdrawal 
Body Shakes 
Withdrawal Shakes 2 
% Pretreatment 
(Mean + S. E.) 
1 Dose 3 Naloxone 3 Treatment (mg/kg) Saline 
Saline 110.2 + 9.6 (64) 105.1 + 14.5 
Amphetamine 2.50 13.0 + 6.0 (9) 2.5 + 1.6 
Apomorphine 0.64 5.0 + 2.5 (8) 43.3 + 17.1 
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( 8) 
(8) 
( 6) * 
1. All drugs were administered i.p. 30 mins prior to observa-
tion with the exception of apomorphine which was given 10 
mins prior to post treatment observation. 
2. Pretreatment withdrawal shakes were observed for a 30 min 
period after 8 hours of morphine abstinence. 
3. Saline or naloxone (5 mg/kg) was administered 10 mins 
prior to observation. 
4. The number of rats employed per dose is indicated in 
parentheses. 
* Significantly (pL0.05) different from saline by Student's 
't' test. 
Table 12. The Effect of Adrenergic Blockers on Morphine Withdrawal Body Shakes 
Dose 
N2 (mg/kg) Treatment1 
--
Saline 64 
Azaperone 0.01 4 
0.04 7 
0.16 6 
0.64 13 
Phenoxybenzamine 0.64 7 
2.5 20 
10.0 9 
Propranolol 2.5 10 
10.0 6 
Withdrawal Shakes 
% Pretreatment3 (Mean + S. E. ) 
--
110.2 + 9.6 
78.7 + 15.3 
33.1 + 15.9 
10.6 + 8.9 
7.8 + 3.2 
-
74.4 + 14.8 
51.9 + 11.2 
68.5 + 16.1 
-
89.2 + 11.8 
70.0 + 13.1 
ID50 
(mg/kg) 
0.04 
8.66 
38.45 
Correlation 
Coefficient 
-0.96* 
-0.76 
-0.99* 
1. 
2. 
3. 
All drugs were administered i.p. 30 mins prior to post treatment observation. 
The number of rats employed per dose. 
* 
Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
morphine abstinence. 
Significant regression coefficient (pL..0.05). 
I-' 
I-' 
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2. The Effect of Adrenergic Agonist 
The adrenergic agonist amitriptyline, clonidine, des-
methylimipramine and tranylcypromine were tested for their ef-
fects on withdrawal body shakes. The effect of these agents 
on body shakes are shown in Table 13. Desmethylimipramine 
(r = 0.98, p.L0.05) and clonidine (r = 0.95, p~.05) pro-
duced dose dependent decreases in morphine withdrawal body 
shakes which were significant. Clonidine proved to be very 
effective in that a dose of 0.16 mg/kg completely abolished 
the occurrence of withdrawal body shakes. Amitriptyline and 
tranylcypromine also reduced body shakes to a limited extent, 
regress~on analysis show no significant correlations between 
dose and effect. Clonidine had an ro50 value of 0.02 mg/kg 
while the value for desmethylimipramine was considerably 
higher, 1.74 mg/kg. 
3. The Interaction Between Adrenergic Agents and Naloxone 
The administration of naloxone after azaperone 
(0.64 mg/kg) caused a considerable reversal of the azaperone 
effect in reducing withdrawal shakes as can be seen in Tables 
14 and 15. Azaperone when administered at a dose of 0.64 
mg/kg reduced body shakes by 95 percent but when administered 
in conjunction with naloxone body shakes were reduced by only 
about 40 percent. A dose of 0.64 mg/kg of naloxone produced 
a maximum effect which could not be further potentiated by 
increasing the naloxone dose to 5 mg/kg (Table 14). The ef-
fects of azaperone were significantly (p-'0.01) antagonized 
by the administration of naloxone at a dose of 5.0 mg/kg 
Table 13. The Effect of Adrenergic Agonists on Morphine Withdrawal Body Shakes 
Treatment1 
Dose 
N2 (mg/kg) 
--
Saline - 64 
Amitriptyline 2.5 4 
10.0 6 
Clonidine 0.01 10 
0.04 6 
0.16 6 
Desmethylimiprarnine 0.64 8 
2.5 8 
10.0 7 
Tranylcypromine 2.5 9 
10.0 8 
Withdrawal Shakes 
% Pret reatment 
(Mean + s . E . ) 3 
110.2 + 9.6 
-
50.3 + 14.4 
49.6 + 13.9 
-
44.1 + 8.6 
22.3 + 8.1 
0 + 0 
78.7 + 13.8 
30.2 + 11.2 
13. 7 + 4.7 
-
40.0 + 9.9 
22. 0 + 8.0 
1050 
(mg/kg) 
6.13 
0.02 
1.74 
3.16 
Correlation 
Coefficient 
-0.87 
-0.95* 
-0.98* 
-0.94 
1. All drugs were administered i.p. 30 mins prior to post treatment observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
morphine abstinence. 
* Significant regression coefficient (p40.05). 
....... 
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Table 14. Reversal of Azaperone Induced Blockade of With-
drawal Body Shakes by Naloxone 
Withdrawal Shakes 
1 N2 
% Pretreatment Correlation 
Naloxone (Mean + S .E.} 3 Coefficient 
0 13 7.8 + 3.2 
-
0.64 7 61.2 + 16.3 
-
1.25 8 52.5 + 25.9 
-
5.00 8 71.6 + 21.3 +0.88 
-
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1. Azaperone (0.64 mg/kg} was administered i.p. to all rats 
30 mins prior to post treatment observation. Naloxone 
was then injected i.p. 20 mins after the azaperone ad-
ministration which was 10 mins prior to observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal body shakes were observed for a 
30 min period after 8 hours of morphine abstinence. 
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Table 15. The Interaction Between the Adrenergic Agonist : 
Clonidine and the Narcotic Antagonist Naloxone 
on Morphine Withdrawal Body Shakes 
Withdrawal Shakes 
% Pretreatment 
(Mean+ S.E.)2 
Dose 
Treatment 1 (m9/kg) Saline 3 Naloxone 3 
Saline 110.2 + 9.6 (64) 4 105.1 + 14.5 (8) 
- -
Azaperone 0.64 7.8 + 3.2 (13) 81.6 + 21.3 (8) * 
-
Clonidine 0.16 o.o + o.o (6) 12.3 + 4.1 (11) 
1. 
2. 
3. 
4. 
* 
- -
All drugs were administered i.p . 30 mins prior to post 
treatment observation. 
Pretreatment withdrawal shakes were observed for a 30 
min period after 8 hours of morphine abstinence. 
Saline or naloxone (5 mg/kg) was given 10 mins prior 
to post treatment observation. 
The number of rats employed per dose is indicated in 
parentheses. 
Significantly (p.£0.01) different from saline by Student's 
't' test. 
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(Table 15). The antiwithdrawal effect of clonidine was also 
reduced by the administration of naloxone at a dose of 5 mg/kg. 
These data are shown in Table 15. The naloxone antagonism of 
the clonidine effect was not nearly as large as the naloxone 
antagonism of azaperone. 
E. The Effect of Agents that Influence the Synthesis and 
Storage of Catecholamines on Morphine Withdrawal Body Shakes 
The results achieved with alpha-methyl-p-tyrosine and 
reserpine are given in Table 16. Alpha-methyl-p-tyrosine, an 
inhibitor of catecholamine synthesis, reduced withdrawal 
shakes only when a dose of 160 mg/kg was employed. Regres-
sion analysis failed to reach significance for this effect. 
Reserpine, which interferes with the storage of catecholamines, 
dose-dependently reduced withdrawal body shakes. A dose of 
10 mg/kg of reserpine reduced shakes by approximately 60 per-
cent. Regression analysis show a significant (r = 0.96, 
pL.0.05) dose effect relationship for reserpine. 
F. The Effect of Serotoninergic Agents on Morphine Withdraw-
al Body Shakes 
The data for the effect of serotoninergic agents on 
withdrawal body shakes is shown in Table 17. Fluoxetine, 
which increases the concentration of serotonin at its recep-
tor site by blocking its uptake,reduced body shakes by 50 
percent at a dose of 0.64 mg/kg. This effect could not be 
further intensified by increasing the dose to 2.5 mg/kg. The 
administration of 5-HTP was similarly without significant 
Table 16. The Effect of Agents that Influence the Synthesis and Storage of 
Catecholamines on Morphine Withdrawal Body Shakes 
Treatment1 
Dose 
N2 (mg/kg) 
--
Saline 64 
Alpha-methyl-p-Tyrosine 40 6 
160 5 
Reserpine 0.16 8 
0.64 8 
2.50 10 
10.0 10 
Withdrawal Shakes 
% Pretreatment 
(Mean ~ S • E. ) 
110.2 + 9.6 
-
91.3 + 16.9 
50.6 + 19.7 
-
84.5 + 16.5 
53.0 + 12.6 
48. 5 + 9.0 
37.7 + 12.4 
ro5o 
(mg/kg) 
189.6 
2.2 
Correlation 
Coefficient 
-0.97 
-0.96* 
1. All drugs were administered i.p. 60 mins prior to observation with the exception of 
alpha-methyl-p-tyrosine which was given 120 mins prior to post treatment observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
morphine abstinence. 
* Significant regression coefficient (p..:..0.05). 
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Table 17. The Effect of Serotoninergic Agents on Morphine Withdrawal Body Shakes 
1 Treatment 
Saline 
Fluoxetine 
5-HTP4 
Methysergide 
Dose 
(mg/kg} 
0.64 
2.50 
2.50 
10 
40 
0.64 
2.50 
N2 
-
64 
6 
7 
6 
7 
8 
4 
6 
Withdrawal Shakes 
% Pretreatment 
(Mean+ S.E.)3 
110.2 + 9.6 
-
51.8 + 7.1 
63.0 + 17.7 
-
153.2 + 25.5 
128.0 + 24.9 
88.6 + 37.5 
-
105.2 + 32.1 
81.6 + 27.1 
Correlation 
Coefficient 
-0.76 
-0.43 
-0.93 
1. All drugs were administered i.p. 30 mins prior to post treatment observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
roorphine abstinence. 
4. These rats were injected with 25 mg/kg of R04-4602/l 30 mins prior to 5-HTP administration . 
....... 
l\.J 
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effect on the frequency of withdrawal body shakes. At a dose 
of either 2.5 or 10 mg/kg of 5-HTP there was a slight in-
crease in withdrawal body shakes. Methysergide, a serotonin 
antagonist, was without effect on the occurrence of withdraw-
al body shakes at the doses tested. 
G. The Effect of Cholinergic Agents on Morphine Withdrawal 
Body Shakes 
1. The Effect of Anticholinergic Agents 
Atropine, benztropine, dexetimide and scopolamine, 
all well established anticholinergic drugs, were tested for 
their effects on morphine withdrawal body shakes. The data 
for these anticholinergic agents are summarized in Table 18. 
Atropine at a dose of 2.5 mg/kg had no effect on body shakes, 
however, increasing the dose to 10 mg/kg resulted in a slight 
but nonsignificant increase in the intensity of withdrawal 
shakes. Benztropine was without significant effect on with-
drawal body shakes at those doses tested. No significant 
result was achieved for the effect of dexetimide on withdraw-
al shakes. However, there was a slight increase in shake 
frequency at a dexetimide dose of 0.64 mg/kg. Similarly, 
scopQlamine was without significant effect on withdrawal 
body shakes. Although at a dose of 0.64 mg/kg scopolamine 
did increase withdrawal shakes to 169 percent of pretreat-
ment, this effect failed to achieve significance. 
2. The Effect of Cholinergic Agonist 
A number of cholinergic agonist were studied for 
Table 18. The Effect of Anticholinergics on Morphine Withdrawal Body Shakes 
Treatment1 
Saline 
Atropine 
Benztropine 
Dexetimide 
Scopolamine 
Dose 
(mg/kg) 
2.5 
10.0 
2.5 
10.0 
0.04 
0.16 
0.64 
2.50 
0.16 
0.64 
N2 
--
64 
15 
9 
8 
8 
7 
7 
5 
6 
7 
8 
Withdrawal Shakes 
% Pretreatment 
(Mean + S . E. ) 3 
110.2 + 9.6 
-
97.8 + 20.0 
132.1 + 23.7 
109.6 + 12.7 
90. 0· + 19 .1 
-
93.6 + 15.6 
96.6 + 20.3 
140.6 + 8.0 
118.3 + 12.8 
-
75.4 + 30.8 
169.1 + 36.8 
Correla tion 
Coefficient 
-0.63 
-0.88 
+0.52 
+0.62 
1. All drugs were administered i.p. 30 mins prior to post treatment observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
morphine abstinence. 
...... 
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their effect on body shakes and the results from these studies 
are summarized in Table 19. Deanol and choline chloride pro-
duced decreases in withdrawal body shakes, however, regression 
analysis failed to show significance. The calculated rn50 
values for deanol and choline chloride were 1,016 and 86 mg/kg 
respectively. Oxotremorine failed to have any significant 
effect on the occurrence of withdrawal shakes. The rn50 for 
oxotremorine was calculated from the regression line to be 
23 mg/kg which is well above the lethal dose for this drug. 
A significant dose-effect relationship was established by 
regression analysis for physostigmine (r = 0.99, p.L0.05) and 
pilocarpine (r = 0.99, p~0.05). The rn50 values for physo-
stigmine and pilocarpine, 0.1 and 3.8 mg/kg, respectively, 
were well within the pharmacological range of these drugs. 
Pilocarpine at a dose of 10 mg/kg reduced withdrawal shakes 
by 90 percent; this was the largest reduction in body shakes 
produced by any of the cholinergic agonists. 
3. The Interaction Between Cholinergic Agents and 
Naloxone 
A 10 mg/kg dose of pilocarpine which reduced with-
drawal shakes by 90 percent was i n teracted with a 5 mg/kg 
dose of naloxone. The results of this interaction are given 
in Table 20 . Naloxone failed to antagonize the pilocarpine 
induced decrease in withdrawal body shakes. This is evi-
denced by the fact that withdrawal body shakes were still 
reduced by 90 percent after the administration of both pilo-
carpine and naloxone. 
Table 19. The Effect of Cholinergic Agonists on Morphine Withdrawal Body Shakes 
1 Treatment 
Saline 
Deanol 
Choline Chloride 
Oxotremorine 
Physostigmine 
Pilocarpine 
Dose 
{mg/kg) 
640 
2560 
10 
40 
160 
0.04 
0.16 
0.64 
0.04 
0.16 
2.5 
10.0 
N2 
-
64 
4 
5 
6 
6 
7 
5 
5 
14 
6 
5 
5 
7 
Withdrawal Shakes 
% Pretreatment 
{Mean + S. E.) 3 
110.2 + 9.6 
-
57.7 + 16.5 
25.2 + 11.4 
-
82.2 + 17.6 
42.3 + 7.6 
54.7 + 12.3 
-
93.0 + 43.l 
101. 4 + 21. 3 
75.l + 24.2 
-
72.6 + 7.7 
39.6 + 11.3 
-
76.2 + 15.7 
9.7 + 4.8 
ID50 
{mg/kg) 
1,016.6 
86.7 
23.3 
0.10 
3.87 
Correlation 
Coefficient 
-0.98 
-0.88 
-0.84 
-0.99* 
-0.99* 
1. All drugs were administered i.p. 30 mins prior to observation with the exception of 
oxotremorine and physostigmine which were given 10 mins prior to post treatment 
observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
morphine abstinence. 
* Significant regression coefficient {p.£0.05). 
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Table 20. The Interaction Between Pilocarpine and Naloxone 
on Withdrawal Body Shakes 
Treatment1 
Dose 
(mg/kg) 
Withdrawal Shakes 2 
% Pretreatment 
(Mean + S. E. ) 
Saline ~ Naloxone 
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Saline 110.2 + 9.6 (64) 105.1 + 14.5 (8) 
Pilocarpine 10 9.7 + 4.7 (7) 9.1 + 4.5 (7) 
1. All drugs were administered i.p. 30 mins prior to post 
treatment observation. 
2. Pretreatment withdrawal shakes were observed for a 30 
min period after 8 hours of morphine abstinence. 
3. Saline or naloxone (5 mg/kg) was administered 10 rnins 
prior to observation. 
4. The number of rats employed per dose is indicated in 
parentheses. 
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H. The Effect of Gabaminergic Agents on Morphine Withdrawal 
Body Shakes 
The effectsof bicuculline, depakene and picrotoxin, on 
morphine withdrawal body shakes are shown in Table 21. Bi-
cuculline tested at doses of 0.16 and 0.64 mg/kg was without 
effect on withdrawal body shakes. A biphasic effect was ob-
served on withdrawal shakes after the administrat ion of depa-
kene. A slight reduction in shakes was observed when depakene 
was administered in doses between 2.5 and 40 mg/kg; however, 
as the dose was further increased to 160 or 320 mg/kg, with-
drawal shakes increased in frequency. The highest dose em-
ployed, 640 mg/kg, yielded a 60 percent decrease in with-
drawal shakes. Picrotoxin, a blocker of J" -arninobutyric 
acid (GABA) at post-synaptic receptors, reduced the frequency 
of body shakes by about 70 percent at a dose of 0.64 mg/kg. 
Further increasing the dose of picrotoxin to 2.5 mg/kg was 
lethal in those rats tested. 
I. The Effect of Sedative-Hypnotic Agents on Morphine 
Withdrawal Body Shakes 
The data sununarized in Table 22 show the effect of the 
sedative-hypnotic agents tested on withdrawal body shakes. 
Chlordiazepoxide had no effect on withdrawal shakes at either 
2.5 or 10 mg/kg. When the dose was increased to 40 mg/kg 
there was a near total reduction in body shakes. The results 
achieved with flurazepam were similar. A dose of 40 mg/kg 
of flurazepam was necessary to reduce withdrawal body shakes 
Table 21. The Effect of Gabaminergic Agents on Morphine Withdrawal Body Shakes 
1 Treatment 
Saline 
Bicuculline 
Depakene 
Picrotoxin 
Dose 
(mg/kg) 
0.16 
0.64 
2.5 
10.0 
40.0 
160.0 
320.0 
640.0 
0.64 
2.50 
N2 
-
64 
7 
6 
8 
19 
8 
5 
9 
6 
8 
2 
Withdrawal Shakes 
% Pretreatment 
(Mean .:!:_ S . E. ) 3 
110.2 + 9.6 
-
99.8 + 41.0 
124.8 + 57.3 
-
66.4 + 19.2 
42 .2 + 9.2 
76.6 + 17.4 
113.0 + 31.4 
280.2 + 64.7 
39. 8 + 34. 7 
-
33.4 + 12.6 
lethal 
Correlation 
Coefficient 
+0.55 
+0.28 
1. All drugs were administered i.p. 30 mins prior to observation with the exception of 
picrotoxin which was given 15 mins prior to post treatment observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
morphine abstinence. 
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Table 22. The Effect o f Sedative-Hypnotic Agents on Morphine Withdrawal Body Shakes 
Withdrawal Shakes 
rn5o 
1 Dose N2 
% Pretreatinent Correlation 
Treatment (mg/kg) (Mean + S. E.) 3 (mg/kg) Coefficient 
--
Saline 64 110.2 + 9.6 
-
Chlordiazepoxide 2.5 5 106.4 + 21.0 
10.0 6 80.0 + 24.6 
40.0 4 6 + 6 14.2 -0.91 
Flurazepam 2.5 7 76.7 + 16.9 
10.0 5 124.0 + 49.2 
40.0 6 42.0 + 22.6 144.8 -0.54 
-
Pentobarbital 0.64 6 74.5 + 17.9 
2.50 5 96.4 + 16.6 
10.00 6 50.0 + 23.3 21.4 -0.77 
-
1. All drugs were administered i.p. 30 mins prior to post treatment observation. 
2. The number of rats employed per dose. 
3. Pretreatment withdrawal shakes were observed for a 30 min period after 8 hours of 
morphine abstinence. 
I-' 
w 
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by about 60 percent. Pentobarbital was without effect on 
withdrawal shakes until a dose of 10 mg/kg was administered. 
Withdrawal shakes were reduced to 50 percent of pretreatment 
when a 10 mg/kg dose of pentobarbital was administered. The 
highest dose of each sedative hypnotic employed produced a 
substantial degree of sedation. Regression analysis showed 
no significant correlation between dose and effect for these 
drugs. 
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V. DISCUSSION 
A. Morphine Withdrawal Body Shakes 
Morphine withdrawal body shakes were reliably observed 
upon the termination of continuous morphine infusion. These 
shakes were similar to those previously described by several 
authors (for review see Gianutsos et al., 1975) in rats with-
drawn from periodic injections of narcotic drugs. However, 
their rate of occurrence in the continuously infused rats was 
higher than that usually seen in rats made dependent by in-
traperi toneal (Gianutsos et al., 1975) subdermal (Herz et al., 
1974) or oral (Lal et al., 1975) administration of narcotics. 
Body shakes are related to narcotic withdrawal because they 
are not seen in rats similarly infused with saline or in 
morphine-infused rats which were not withdrawn (Table 2). 
Additionally, these shakes were abolished by narcotic drugs 
and the reinstatement of narcotic infusion (Table 5). This 
shake reducing action of narcotic drugs was antagonized by 
the administration of the narcotic antagonist naloxone 
(Table 6). Recently, it has been demonstrated that many mor-
phine effects may be brought under stimulus control through 
various procedures of conditioning (Lal et al., 1976). Like 
many of the other effects of morphine, the shake mitigating 
action of this narcotic could be elicited by conditional 
stimuli previously paired with morphine injections (Numan 
et al., 1975). 
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Withdrawal body shakes were selected as a sign of ab-
stinence since they are a consistent, reliable and objective 
measure. Rats withdrawn from morphine for an eight-hour 
period emitted an average of 25 body shakes in a 30 min ob-
servation period. The frequency of withdrawal shakes remained 
constant over many withdrawal sessions (Table 3). These vi-
olent shaking movements were easily detectable. The reli-
ability for detection of these body shakes was very high be-
tween independent observers. For the purpose of establishing 
inter-observer reliability two trained observers recorded 
withdrawal body shakes during the same withdrawal session. 
While observing the same withdrawal session these independent 
observers recorded essentially the same number of body shakes. 
In fact they were always within 2 percent of each other for 
the total number of shakes occurring during the withdrawal 
session. The intense and violent nature of these shaking 
movements make them an objective measure of withdrawal that 
is easily distinguishable from body tremors or jerking type 
movements. 
Withdrawal observation was always started 8 hours 
after the termination of morphine infusion. There were sever-
al reasons for selecting 8 hours of withdrawal as the time 
interval to start the withdrawal observation. By the eighth 
hour of withdrawal the shaking movements were fully developed 
and occurring at a high rate. Body shakes were found to start 
to occur 3 hours after the morphine infusion was terminated 
and to have reached a fairly constant frequency by 6 to 7 
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hours of withdrawal. Once the withdrawal shakes were fully 
developed they remained at a fairly constant frequency for up 
to 24 hours if the morphine infusion was not reinstated. Thus 
the pretreatment shakes could be observed 8 hours after the 
termination of morphine infusion, a test drug could then be 
injected and given sufficie nt time to exert its action with 
a high degree of certainty that the rate of occurrences of 
withdrawal shakes would remain unchanged except for drug ac-
tion. The fact that withdrawal shakes remained at a constant 
intensity following 8 hours of abstinence is demonstrated by 
the failure of a saline injection to influence the occurrence 
of this withdrawal sign. 
Morphine, methadone and fentanyl, potent narcotics, 
blocked the occurrence o f withdrawal shakes (Table 5). The 
narcotic antagonist naloxone and pentazocine increased the 
rate of withdrawal shakes slightly but not significantly 
(Table 5). However, naloxone effectively antagonized the 
morphine induced blockade of withdrawal s h akes in a dose de-
pendent manner (Table 6). 
In addition to the blockade of withdrawal shakes pro-
duced by the narcotic agonist all the dopamine receptor 
blockers investigated were found to mitigate the rate of 
shaking with the exception of pimozide and pipamperone (Table 
7). These results are in agreement with previous findings 
(Lal et al., 1971; Lal and Numan, 1976). However there a p -
peared to be dramatic potency differences between those neuro-
leptics employed. The butyrophenone neuroleptics, benperidol, 
138 
haloperidol, oxiperomide, spiperone and spiramide, were spe-
cific in blocking withdrawal shakes in that they reduced them 
at low doses which are well within the range of those produc-
ing the usual pharmacological actions of these drugs. (+}Buta-
clamol, a derivative of benzocycloheptapyridoisoquinolinol, 
exerted its antiwithdrawal effect at a low dose, that is, in 
the dose range within which it produces its other psycho-
pharmacological activities (Voith and Herr, 1975 ) . Similarly, 
the member of the dibenzoxazepine series employed, loxapine, 
also mitigated withdrawal shake behavior at dos es within its 
pharmacological range for antidopamine activity (Coupet et 
al., 1976). The two phenothiazine neuro l ept ics e mployed in 
this study were only effective in blocking withdrawal shakes 
at very high doses which also produce hypotonia and nonspecif-
ic sedation, while pimozide, of the diphenylbutylpiperidine 
series, and pipamperone did not totally block wi thdrawal 
shakes even at the highest dose tested. From this comparison 
it is clear that the butyrophenone, benzocycloheptapyrido-
isoquinolinol and dibenzoxazepine type neuroleptics are more 
potent and specific in blocking withdrawal body shakes than 
are the phenothiazines and diphenylbutylpiperidine type neuro-
leptics. 
The dopamine receptor agonists tested for antiwithdrawal 
potency also reduced the rate of withdrawal body shakes 
(Table 8). Amphetamine, a drug which causes the release of 
dopamine (McKenzie and Szerb, 1968; Carr and Moore, 1970) dose 
dependently reduced body shakes as did the direct acting 
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dopamine receptor agonist apomorphine (Ernst, 1967; Anden et 
al., 1967). L-DOPA, which is converted centrally into dop-
amine (Carlsson, 1971) reduced body shakes in a similar fash-
ion. 
With the exception of a2aperone, all the adrenergic 
blockers tested for anti-abstinence properties were without 
effect (Table 12). Azaperone is a sedative neuroleptic of 
the butyrophenone series which is a potent alpha-noradrenergic 
blocking drug (Niemegeers et al., 1974). The adrenergic ago-
nists also seem to mitigate the occurrence of withdrawal 
shakes. However, only desmethylimipramine and clonidine ex-
hibited a significant dose dependent decrease in the occur-
rence of this withdrawal sign (Table 13). Inhibition of cat-
echolamine synthesis by alpha-methyl-p-tyrosine (Nagatsu et 
al., 1964) or storage by reserpine (Haggendal and Dahlstrom, 
1972) decreased occurrence of withdrawal body shakes (Table 
16) . 
Agents that affect serotonergic mechanisms by either 
increasing or decreasing the concentration of tra nsmitter 
present at its receptor site were without significant effect 
on the occurrence of withdrawal body shakes (Table 17). Man-
ipulation of gabaminergic mechanism also failed to influence 
this withdrawal sign to any significant extent (Table 21). 
The results achieved with the utilization of choliner-
gic agents provided a more consistent picture. A cursory 
examination of the data indicates that anticholinergics in-
crease withdrawal shakes while cholinergic decrease. Although 
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the anticholinergics used, atropine, benztropine, dexetimide 
and scopolamine, did tend to increase body shakes, these in-
creases failed to achieve significance (Table 18). With the 
exception of oxotremorine, all the cholinergics employed de-
creased body shakes (Table 19). This effect achieved dose 
related significance for only physostigrnine and pilocarpine. 
The reduction in body shakes induced by pilocarpine is in 
agreement with previous results (Hynes et al., 1976). 
The involvement of nonspecific sedation in the reduc-
tion of withdrawal shakes was investigated by studying the 
effect of several hypnotic drugs on this index of withdrawal. 
Regression analysis revealed no significant correlation be-
tween the dose of chlordiazepoxide, flurazepam or pentobarbi-
tal and their effects on withdrawal shakes (Table 22). How-
ever, a 40 mg/kg dose of chlordiazepoxide did completely re-
duce the occurrence of this withdrawal sign. 
Body shakes measured here as an index of withdrawal 
originate within the central nervous system. There are 
several lines of evidence which point to that conclusion. 
Naloxone when injected into the brain of morphine dependent 
animals elicits body shakes (Way et al., 1973; Laschka et al., 
1976a). Narcotic withdrawal has also been attenuated by 
lesion of the central nervous system (Pouzolo and Kerr, 1972). 
Pilocarpine, a cholinergic agonist, is known to reduce both 
withdrawal aggression and body shakes (Hynes et al., 1976). 
The antiwithdrawal effect of pilocarpine is centrally medi-
ated. Its antiwithdrawal effects are not blocked by methyl-
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scopolamine, a peripherally active anticholinergic which does 
not penetrate into the brain (Hynes et al., 1976). These 
lines of evidence clearly point to the central origins of 
withdrawal body shakes. It is therefore assumed that the 
drugs which reduce body shakes are acting on the central ner-
vous system. All drugs employed in this study have we11 
established central mechanisms of action. However, it is 
possible that they could have peripheral actions which might 
influence the expression of withdrawal body shakes. It is 
conceivable that a drug could inhibit withdrawal by prevent-
ing the muscular expression of withdrawal. That is to say, 
a drug could prevent the expression of a withdrawal sign 
without having any effect on the underlying pathology. D-
tubocurare would be an example of a drug that would produce 
this type of effect, since it would produce muscular para-
lysis and thereby prevent the expression of withdrawal with 
little or no effect on the underlying neuropathology. None 
of the drugs employed in this study are known to act in this 
fashion, thus it can be reasonably assumed that they are ex-
erting their antiwithdrawal effects on the central nervous 
system. 
B. The Neurotransmitter Hypothesis of Antiwithdrawal Activity 
Neuroleptics have many important and well demonstrated 
effects on neurotransmitters such as dopamine, norepinephrine, 
serotonin, (f' aminobutyric acid and acetylcholine. The anti-
withdrawal actions of neuroleptics may be mediated by their 
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effects on the aforementioned neurotransmitters. 
Previously, it was hypothesized that the antiwithdrawal 
effectiveness of butyrophenones was the result of their dop-
amine receptor blocking action. This hypothesis was based 
upon the supersensitivity of dopamine-receptors seen during 
morphine withdrawal (for review see Lal, 1975; Lal et al., 
1976) and the effectiveness of haloperidol in reducing nar-
cotic withdrawal in laboratory animals (Lal et al., 1971; 
1971; Puri and Lal, 1973; Gianutsos et al., 1974; Lal and 
Numan, 1976; Martin et al., 1974) and human patients (Karkalas 
and Lal, 1973; Lal and Hynes, 1977). The antiwithdrawal po-
tencies of the additional butyrophenone type neuroleptics 
tested support this hypothesis. The effective doses of those 
neuroleptics with antiwithdrawal potency in producing other 
pharmacological actions are given in Table 23. As can be 
seen from this table there is a correlation between the dose 
of these drugs which antagonize the effect of apomorphine and 
the antiwithdrawal dose. Generally, those neuroleptics which 
inhibit the effects of apomorphine at low concentrations also 
reduced withdrawal body shakes at low doses. There are sev-
eral exceptions, however; azaperone which is the most potent 
neuroleptic in terms of its antiwithdrawal effect is the 
least potent apomorphine antagonist. Pimozide is another 
exception in that it is a very poor inhibitor of withdrawal 
body shakes but is a relatively potent apomorphine antagonist. 
Even with these exceptions there appears to be a relationship 
between antiwithdrawal and anti-apomorphine activity. 
Table 23. A Comparison of the Various Properties of Those Neuroleptics Tested for 
Anti-Withdrawal Potency 
ID50 (mg/kg) En50 Values in the Rat (mg/kg)l 
Ampetamine Norepinephrine Apomorphine 
Anti-Withdrawal Antagonism Antagonism Catalepsy Ptosis Anta9:onism 
Azaperone 0.03 2.5 0.33 8.0 1.5 0.98 
Spiperone 0.04 0.02 1. 2 0.036 0.27 0.0002 
Benperidol 0.08 0.012 0.30 0.18 1.2 0.0005 
+Butaclamol 0.12 6.31 10. 0 - - .052 
Loxapine 0.16 0.12 1.25 0.25 - 0.3 
Oxiperomide 0.16 0.03 5.0 40.0 2.5 0.014 
Haloperidol 0.17 0.038 2.1 0.18 1.0 0.018 
Spiramide 0.19 0.016 9.5 0.34 1.5 0.0021 
Chlopromazine 0.49 0.60 0.60 2.3 2.3 0.71 
Trifluoperazine 0.74 0.08 7.2 0.6 2.5 0.034 
Pimozide 1.64 0.1 40.0 0.18 4.5 0.011 
Pipamperone 11.02 2.5 3.0 16.5 2.7 0.97 
1values were derived from Janssen and Van Bever (1975). 
I-' 
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Apomorphine antagonism is a well established index of the abil-
ity of a drug to block brain dopamine receptors. The antiwith-
drawal activity of neuroleptics may result from the inhibition 
of brain dopamine receptors. However, this hypothesis is not 
supported by the fact that agents which stimulate dopamine 
receptors also reduce withdrawal wet shakes. The three dop-
amine receptor stimulants employed in this study all dose de-
pendently reduce withdrawal body shakes. Although both dop-
amine receptor agonist and antagonist have the same effect on 
body shakes, they differ with respect to their effects on 
other withdrawal signs. Butyrophenones, for example, have 
previously been shown to block many other signs of narcotic 
withdrawal. These include hypothermia (Lal et al., 1971; 
Cox et al., 1975) aggression (Puri and Lal, 1973; Gianutsos 
et al., 1974; Lal, 1975); jumping (Takemori et al., 1976) and 
responding for self-administration of narcotics (Hanson and 
Cimini-Venema, 1972; Lal and Hynes, 1977). Whereas dopa-
minergic agonists have been found to intensify many other 
signs of narcotic withdrawal, pretreatment with L-DOPA, am-
phetamine or apomorphine enhances morphine withdrawal aggres-
sion (Lal et al., 1971; Lal, 1974) and withdrawal jumping 
(Gunne, 1965; Herz, 1975). Thus it is conceivable that the 
action of dopaminergic agonists on withdrawal body shakes are 
not related to dopaminergic activity. Drugs that stimulate 
dopamine receptors are known to induce stereotyped behaviors 
which consist of sniffing, licking and biting movements 
(Ernst, 1967; Gianutsos et al., 1974). The possibility 
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exists that the induction of these stereotyped behaviors and 
the occurrence of withdrawal shakes are not compatible. Thus 
the withdrawn rat treated with a dopamine receptor agonist 
would only be able to emit stereotyped movement and not body 
shakes. 
The marked potency of azaperone in blocking shakes 
does not support this hypothesis. Azaperone is one of the 
least potent anti-dopamine drugs tested yet the most potent 
butyrophenone in blocking withdrawal shakes {Table 12). How-
ever, azaperone is a potent alpha-noradrenergic blocking 
drug {Niemegeers et al., 1974). It is thus possible that the 
antiwithdrawal action of neuroleptics may be the result of 
antinoradrenergic activity. However, chlorpromazine which 
is approximately an equally potent blocker of alpha adrener-
gic receptors {Janssen and Van Bever, 1975), is one of the 
weakest blockers of withdrawal shakes {Table 7). Addition-
ally, the alpha blocker phenoxybenzamine {Nickerson and Grump, 
1949) failed to reduce body shakes as did the beta adrenergic 
blocker propranolol {Nickerson and Collier, 1975). The data 
summarized in Table 23 do not support the hypothesis that 
the antiwithdrawal activity of neuroleptics is the result of 
antiadrenergic activity. As can be seen from this table 
there is no correlation between the antiwithdrawal activity 
of neuroleptics and antiadrenergic potency. Further evidence 
against this particular hypothesis comes from the data on 
adrenergic agonist drug. One of the nost potent drugs in re-
ducing withdrawal body shakes is clonidine, an alpha receptor 
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stimulant (Anden et al., 1970). The tricyclic antidepressant 
agents amitriptyline and desmethylirnipramine, which block 
the re-uptake of norepinephrine into adrenergic nerve termi-
nals (Byck, 1975), also decreases the occurrence of with-
drawal body shakes (Table 13). 
Since the discovery that the symptoms of Parkinsonism 
could be relieved by drugs which act on either the choliner-
gic or the dopaminergic neuronal system, considerable evi-
dence has suggested a possible reciprocal cholinergic-dopa-
minergic interaction in the central nervous system. Neuro-
leptic drugs have been found to increase the release of 
acetylcholine (Stadler et al., 1973; 1974; Lloyd et al., 
1973). The possibility arises that neuroleptic drugs may be 
exerting their antiwithdrawal effects through cholinergic 
mechanisms. If this is true then cholinergic drugs should 
reduce withdrawal body shakes. The results achieved here 
indicate that cholinergic agonists tend to reduce withdrawal 
shakes (Table 19). However, this effect was significant for 
only two of the five cholinergics studied. Cholinergic ago-
nist do possess some of the other antiwithdrawal effects seen 
after the administration of neuroleptics. They decrease with-
drawal aggression (Hynes et al., 1976) and inhibit antagonist 
precipitated morphine withdrawal jumping (Grumbach, 1969; 
Bhargava and Way, 1972; Brase et al., 1974). Thus it is con-
ceivable that the antiwithdrawal effects of neuroleptics are in 
part mediated by cholinergic mechanisms. However, if stimula-
tion of cholinergic receptors is responsible for inhibition of 
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certain withdrawal signs then anticholinergics would be ex-
pected to increase withdrawal intensity or have no effect. 
The results obtained in general conform with this expecta-
tion. Those anticholinergic drugs tested produced some in-
crease in withdrawal shakes but this effect failed to achieve 
significance (Table 18). The possibility exists that these 
withdrawn rats were showing the near maximum number of shakes 
physiologically possible, thus it may not have been possible 
to significantly increase their rate of occurrence by the 
administration of anticholinergics. This hypothesis does not 
explain the antiwithdrawal body shake effect produced by the 
administration of dopaminergic agonist. Apomorphine, amphet-
amine and L-DOPA have been found to increase acetylcholine 
levels in the caudate (Sethyl and Van Woert, 1974) which sug-
gests a decreasedlevel of acetylcholine at its receptor site. 
In line with the above hypothesis, these agents would be ex-
pected to increase or have no effect on withdrawal shakes 
which is the direct opposite of what was found. Thus a dop-
amine-acetylcholine hypothesis of withdrawal shakes is not 
totally sufficient to explain all of the results. 
In addition to the interaction between dopamine and 
acetylcholine, it has also been postulated that dopamine in-
teracts with serotonin (Cools, 1974) and GABA (Ladinsky et 
al., 1976) in the central nervous system. The results ob-
tained here do not support a role for either serotonin or 
GABA in morphine withdrawal body shakes. The administration 
of serotonin receptor agonist or antagonist were without 
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significant effect on the occurrence of body shakes observed 
in morphine withdrawal (Table 17). Similarly, those agents 
employed to modify GABA activity had no significant effect 
on this index of withdrawal (Table 21). Picrotoxin, a blocker 
of GABA receptors (Galindo, 1969), however, did reduce body 
shakes by about 70 percent at a dose of 0.64 mg/kg. 
Neuroleptics in addition to their complex effects on 
the various neurotransmitters, also produce a considerable 
degree of sedation when given initially. Sedation then may 
be responsible for the antiwithdrawal activity of neuroleptic 
drugs. To test this possibility, several drugs of the seda-
tive hypnotic type were administered to withdrawn rats. 
Neither chlordiazepoxide, flurazepam or pentobarbital had 
any significant dose related effects on withdrawal body shakes 
(Table 22). The highest dose of these drugs employ ed did re-
duce body shakes. The reduction was accompanied with a con-
siderable degree of sedation much greater than observed with 
the various neuroleptics. The degree of sedation produced 
by the various neuroleptics does not correlate with the abil-
ity to reduce withdrawal body shakes. For example, haloperidol 
has less of a sedative effect than chlorpromazine (Byck, 1975) 
but is a more potent inhibitor of withdrawal shakes. Seda-
tion does not appear to be an important factor in the reduc-
tion of withdrawal shakes produced by neuroleptics. 
Of the neurotransmitters effected by neuroleptic drugs 
it appears that effects on dopamine systems are the rrost im-
portant in terms of antiwithdrawal activity. A relatively 
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good correlation exists between antiwithdrawal activity and 
antagonism of brain dopamine receptors for those neuroleptics 
tested. However, the antiwithdrawal effect of neuroleptics 
may be mediated at least in part through cholinergic mecha-
nisms. This possibility arises because neuroleptics are 
known to effect cholinergic mechanisms and the manipulation 
of cholinergic systems was found to alter the occurrence of 
withdrawal body shakes. Administration of cholinergic ago-
nists was found to decrease withdrawal body shakes and neuro-
leptics, which cause the release of acetylcholine (Stadler 
et al., 1973; 1974) similarly reduce this index of withdraw-
al. 
c. The Opiate Receptor Hypothesis of Antiwithdrawal Activity 
It has been recently recognized (Clay and Brougham, 
1975; Creese et al., 1975; Leysen et al., 1976) that buty-
rophenone type neuroleptics are among many non-narcotic drugs 
which show binding affinity with opiate-binding sites in the 
central nervous system. It is possible t .t the withdrawal 
blocking action of butyrophenones is related to this binding 
ability. Besides the availability of actual binding data, 
support for this hypothesis comes from studies with naloxone. 
The administration of naloxone after the maximally effective 
dose of azaperone, benperidol, oxipermide, haloperidol and 
trifluoperazine in reducing withdrawal shakes produced a sig-
nificant reversal of the antiwithdrawal effect of these 
neuroleptics (Table 10). Unlike the complete antagonism of 
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morphine's action produced by naloxone, the only neuroleptic 
to be completely antagonized by naloxone was azaperone (Table 
15). Naloxone antagonism in the case of benperidol, oxiper-
mide, haloperidol and trifluoper~zine although significant, 
was far from complete. Naloxone failed to antagonize the 
antiwithdrawal body shake effect of spiperone, spiramide, l ox-
apine, chlorpromazine and +butaclamol to any significant ex-
tent (Table 10). These results do not support the idea that 
the binding of neuroleptics to the opiate receptor is respon-
sible for their antiwithdrawal effects. Further evidence 
against this theory comes from the fact that pimozide which 
shows affinity for the opiate receptor (Creese et al., 1975) 
does not block withdrawal wet shakes. 
Opiate receptor binding is believed to be responsible 
for many opiate actions, such as analgesia. We have been un-
able to detect any activity of these compounds in prolonging 
tail-withdrawal latency, a reliable and sensitive test for 
analgesia (Janssen et al., 1963; Niemegeers et al., 1976). 
However, it has not yet been established that binding with 
opiate receptor sites necessarily correlates with analgesia 
in the case of nonnarcotic drugs. It is possible that there 
are different opiate receptors responsible for different ac-
tions of narcotic and nonnarcotic drugs. 
Of the other drugs found to have antiwithdrawal potency 
only one was antagonized to a significant extent by naloxone. 
The reduction in withdrawal shakes produced by apomorphine 
was reversed by the administration of naloxone (Table 11). 
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This result is not unexpected in light of the fact that apo-
morphine is a narcotic. However, the antiwithdrawal effects 
of clonidine, amphetamine or pilocarpine were not signifi-
cantly antagonized by naloxone. 
These results suggest that some neuroleptics, but not 
all, exert their antiwithdrawal effects to some extent by 
binding with opiate receptors. Although this explanation is 
highly speculative, the resemblance between butyrophenones 
with opiates in many other pharmacological actions (for re-
view see Lal et al., 1975; 1976) provides some support for 
this hypothesis. It is difficult then to explain why some 
butyrophenone neuroleptics which reduce withdrawal shakes are 
not antagonized by naloxone. The naloxone effect may be the 
result of an increas e in the severity of the withdrawal syn-
drome and not a real antagonism of the neuroleptic. Those 
neuroleptics which are seemingly antagonized by naloxone may 
not be able to reduce this withdrawal syndrome of increased 
intensity. The fact that the dose of naloxone, 5 mg/kg, em-
ployed in these experiments, does not produce an increase in 
the number of body shakes fails to support this explanation 
of the results. It thus appears that naloxone is able to an-
tagonize the antiwithdrawal activity of some neuroleptics in 
a specific manner. However, even for those neuroleptics that 
were significantly antagonized by naloxone that antagonism 
was well below the total reversal level. This fact would in-
dicate that in addition to the binding of these neumleptics 
with the opiate receptor that they also reduce shakes by an 
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additional mechanism that is not antagonized by naloxone. It 
appears that the binding of neuroleptics to opiate receptors 
is in part responsible for the antiwithdrawal activity of 
neuroleptics; however, this mechanism is not totally suffi-
cient to explain the antiwithdrawal activity of these drugs. 
Although the binding of nonnarcotic drugs to the opiate 
receptor does not totally explain the antiwithdrawal activity 
of these compounds, a role for the opiate receptor cannot be 
ruled out. It is possible that morphine or opiate-like com-
pounds present in the body could react with the opiate re-
ceptor to reduce withdrawal after nonnarcotic drug administra-
tion. 
Withdrawal body shakes were observed eight hours after 
the termination of morphine infusion which may be insufficient 
time for the complete metabolism of all morphine present in 
the system. This concentration of morphine is insufficient to 
exert any significant pharmacological effects by itself. 
Since neuroleptics are known to potentiate some of the effects 
of morphine (Yelnosky and Gardocki, 1964; Edmonds-Seal and 
Prys-Roberts, 1970) it is possible that those neuroleptics 
with antiwithdrawal activity potentiate the morphine remain-
ing in the system after eight hours of withdrawal. This po-
tentiation of previously ineffective concentrations of mor-
phine by the administration of neuroleptics may be responsible 
for the reduction in withdrawal intensity. If t~is mechanism 
is operating to reduce withdrawal then naloxone would be ex-
pected to antagonize the reduction in body shakes. The neuro-
leptic induced reduction in body shakes is, however, only 
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partially antagonized in some cases, while in others unaffected 
by naloxone administration, indicating that this mechanism does 
not fully account for the neuroleptic induced reduction in 
body shakes, although it may operate to a limited extent in 
the antiwithdrawal activity of certain neuroleptics. A simi-
lar mechanism may also be proposed to explain the amphetamine 
induced reduction in body shakes. Amphetamine has been found 
to augment the analgesia induced by morphine (Forrest et al., 
1977). Administration of amphetamine to withdrawn rats could 
potentiate the morphine still present after eight hours of 
withdrawal. Again it would seem logical to expect naloxone to 
antagonize the antiwithdrawal effect of this combination; how-
ever, no such antagonism was observed, suggesting that amphet-
amine's reduction in body shakes is mediated by another mech-
anism. Although the actions of morphine can be potentiated 
by a variety of drugs such as neuroleptics and amphetamines, 
this potentiation does not appear to be responsible for the 
antiwithdrawal activity of these drugs. 
Much recent evidence has suggested that the body con-
tains endogenous morphine-like compounds having many proper-
ties similar to those of narcotic drugs (Hughes, 1975; Gold-
stein, 1976). These endogenous morphine-like compounds could 
be responsible for the antiwithdrawal activity of those non-
narcotic drugs tested. For example, neuroleptics may cause 
the body to release these endogenous morphine-like substances 
which in turn reduce withdrawal intensity. The activity of 
these endogenous morphine-like substances (endorphins) is 
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reversed by the narcotic antagonist naloxone (Hughes, 1975; 
Goldstein, 1976). If the endorphins are mediating the reduc-
tion in withdrawal intensity induced by neuroleptics then 
naloxone would be expected to antagonize this effect. Since 
naloxone is not able to antagonize the antiwithdrawal effect 
of all neuroleptics this explanation is not very tenable. 
This hypothesis is also not supported by the fact that neuro-
leptics do not produce analgesia which would be expected upon 
endorphin release (Belluzzi et al., 1976; Hill et al ., 1976; 
Unca et al., 1977). This data fails to establish a role for 
endorphins in the neuroleptic induced reduction of withdraw-
al body shakes. 
D. The Multiple Receptor Site Hypothesis of Antiwithdrawal 
Activity 
The probability exists that there is no single mecha-
nism by which neuroleptic drugs inhibit the expression of 
morphine withdrawal body shakes. Neuroleptics are known to 
have many complex effects on the central nervous system and 
any combination of these effects may be responsible for the 
reduction in this withdrawal sign. It is conceivable that 
the reduction in body shakes induced by neuroleptics is the 
result of an effect on several different neurotransmitters 
and opiate receptors. From the data presented here the most 
likely combination of neurotransmitters are dopamine and 
acetylcholine. Naloxone was able to reverse that portion of 
antiwithdrawal activity that was the result of opiate 
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receptor binding but not that which was the result of neuro-
transmitter receptor binding. It is also possible that in 
addition to affecting opiate, dopamine and cholinergic mecha-
nisms neuroleptics also bind with additional neurotransmitter 
receptor sites to reduce narcotic withdrawal body shakes. 
Many of the drugs that reduced withdrawal body shakes 
have very different mechanisms of action suggesting that they 
may share a common structural feature which is responsible 
for antiwithdrawal activity. The chemical structures of all 
those compounds employed in this study are shown in Figure 3. 
A cursory examination of these structures to ascertain a com-
mon structural feature in those drugs that inhibited with-
drawal failed to show any apparent similarity. This does not 
rule out the existence of any structural similarity between 
antiwithdrawal agent. To demonstrate the presence of a 
common feature would necessitate an in-depth computer analysis 
for structure activity relationship. 
The data obtained in this study suggest that neurolep-
tics reduce morphine withdrawal body shakes through activity 
on several different receptor sites in the central nervous 
system. Both narcotic and neurotransmitter receptor sites ap-
pear to be involved. The neurotransmitter receptor sites 
which appear to be the most important are those for dopamine 
and acetylcholine. The blockade of dopamine receptors and 
the release of acetylcholine resulting from the administration 
of a neuroleptic is one possible mechanism to explain anti-
wi thdrawal activity. Other transmitters influenced by neuro-
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leptics can not be totally ruled out at this time but from 
the data achieved in these experiments it is not highly prob-
able that they are involved to any major extent . 
In addition to the effects of neuroleptics on the various 
neurotransmitters it is conceivable that an action on opiate 
receptors is in part responsible for the reduction in with-
drawal body shakes. Neuroleptics may red uce withdrawal by 
binding with both the dopamine and opiate receptor. This 
could explain why naloxone did not fully antagonize the ef-
fect of any neuroleptic. 
FIGURE 3 Chemical Structures of Those Drugs 
Investigated for Antiwithdrawal 
Potency 
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SUMMARY AND CONCLUSIONS 
Termination of continuous morphine infusion resulted in 
the relabile occurrence of withdrawal body shakes (Table 2). 
These body shakes were abolished by the administration of nar-
cotic drugs (Table 5). Morphine withdrawal body shakes were 
also dose dependently reduced by the administration of a 
variety of neuroleptics (Table 7). This reduction appears to 
be related to inhibition of brain dopamine receptors. Manip-
ulation of other transmitter systems affected by neuroleptics 
points to a role for some of these neurotransmitters in the 
reduction of body shakes. Acetylcholine may play an import-
ant role in the antiwithdrawal activity of neuroleptics. The 
administration of cholinergic agents was found to produce 
dose related decreases in withdrawal body shakes (Table 19). 
It is highly possible that neuroleptics reduce withdrawal by 
acting on both dopaminergic and cholinergic mechanisms. The 
reversal of the antiwithdrawal activity of some neuroleptics 
by naloxone suggest a role for narcotic receptors (Table 10) . 
The possibility that neuroleptics bind with narcotic recep-
tors thereby reducing withdrawal is not totally consistent 
with all of the available data. Naloxone was not able to 
antagonize the antiwithdrawal activity of all neuroleptics 
and even for those neuroleptics which were antagonized by 
naloxone that antagonism was not complete, suggesting that 
narcotic receptors are involved to a limited extent in the 
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antiwithdrawal effects of some neuroleptics. It is possible 
that neuroleptic binding with both dopamine and narcotic re-
ceptor sites mediates the reduction in withdrawal body shakes, 
with some neuroleptics having more of an effect on the dopa-
mine receptor rather than narcotic receptors thus being less 
likely to be reversed by naloxone. Neuroleptic effects on 
other neurotransmitters and receptor sites in conjunction with 
narcotic receptors can not be totally discounted. 
The data suggest neuroleptics reduce withdrawal body 
shakes by complex effects on several different mechanisms 
within the central nervous system. Dopaminergic, cholinergic 
and narcotic mechanisms, appear to be the most relevant. 
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